

Medicinski fakultet Univerziteta u Beogradu  
Izbornom veću Medicinskog fakulteta u Beogradu

### **Komisija za pripremu referata u sastavu:**

1. **Prof. dr Biljana Mihaljević**, redovni profesor Univerziteta u Beogradu - Medicinskog fakulteta, predsedavajući
2. **Prof. dr Nada Suvajdžić Vuković**, redovni profesor Univerziteta u Beogradu - Medicinskog fakulteta, član
3. **Prof. dr Ivana Urošević**, redovni profesor Univerziteta u Novom Sadu - Medicinskog fakulteta, član

određena na sednici Izbornog veća Medicinskog fakulteta u Beogradu održanoj 17.06.2020. godine, analizirala je prijave na konkurs raspisan u oglasnim novinama Poslovi, objavljenom 08.07.2020. godine za izbor dva nastavnika u zvanje redovnog profesora, za užu naučnu oblast Interna medicina (hematologija) i podnosi sledeći

## **R E F E R A T**

Na raspisani konkurs prijavila su se dva kandidata:

1. **dr Ana Vidović**, dosadašnji vanredni profesor za užu naučnu oblast Interna medicina (hematologija), specijalista interne medicine, subspecijalista hematolog,
2. **dr Milena Todorović Balint**, dosadašnji vanredni profesor za užu naučnu oblast Interna medicina (hematologija), specijalista interne medicine, subspecijalista hematolog,

### **Kandidat br. 1. dr ANA (Dragoljub) VIDOVIĆ**

#### **A. OSNOVNI BIOGRAFSKI PODACI**

Ana (Dragoljuba) Vidović, rođena je 10.03.1962.god. u Beogradu, zaposlena na Klinici za hematologiju KCS, kao vanredni profesor Medicinskog fakulteta Univerziteta u Beogradu, za užu naučnu oblast Interna medicina (hematologija). Načelnik je odeljenja Akutne leukemije 2, na Klinici za Hematologiju KCS.

#### **B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

##### **Osnovne studije**

Dr Ana Vidović, školske 1981/1982 godine upisuje Medicinski fakultet u Beogradu a diplomirala je 1987. god. sa prosečnom ocenom 9,82 (devet osamdeset dva)

##### **Magisterijum**

Dr Ana Vidović je 1995.odbranila magistarsku tezu pod nazivom "Uticaj fibroze koštane srži na citološke promene periferne krvi i veličinu slezine u primarnoj mijelofibrozi" na Medicinskom fakultetu Univerziteta u Beogradu pred komisijom usastavu: Prof.dr Milica Čolović- mentor, Prof.dr Gradimir Janković, Prof dr Pavle Milenković.

##### **Doktorat**

Doktorsku tezu pod nazivom «Značaj aktivnosti onkogeni i antionkogeni u evoluciji hronične mijeloidne leukemije» je odbranila 28.11. 2005. pred komisijom u sastavu: Prof dr Darinka Bošković, Prof. dr Milica Čolović, Prof. dr Pavle Milenković, mentor Prof. dr Gradimir Janković) na Medicinskom fakultetu Univerziteta u Beogradu.

##### **Specijalizacija**

Specijalistički ispit iz interne medicine položila je 26.06. 1996. sa odličnim uspehom.

##### **Uža specijalizacija**

Rad iz uže specijalizacije iz hematologije pod nazivom "Kliničke, imunofenotipske i citogenetske karakteristike blastne krize hronične mijeloidne leukemije", odbranila je 28.12.2007. godine, pred komisijom u sastavu: Prof.dr Dragica Tomin, Prof dr Biljana Mihaljević, Prof.dr Gradimir Janković, mentor.

##### **Dosadašnji izbori u nastavna i naučna zvanja**

1998.god. odlukom Izbornog Veća Medicinskog fakulteta u izabrana je u zvanje asistenta za užu naučnu oblast Interna medicina (hematologija), a reizabrana u isto zvanje 25.12.2002 i 22.11. 2006. godine. Od 20.12.2007. god u radnom odnosu na poslovima nastavnika u zvanju Docenta za užu naučnu oblast Interna medicina (hematologija), a reizabrana u isto zvanje 15.01.2013.godine. U zvanje vanrednog profesora za predmet interna medicina je izabrana 03.12.2013.a reizabrana 2018.godine.

## **OBABVEZNI USLOVI ZA IZBOR U ZVANJE REDOVNOG PROFESORA**

#### **C. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

Od izbora u zvanje asistenta na predmetu Interna medicina (1998. godina) redovno obavlja kako praktičnu tako i teorijsku nastavu sa punim fondom časova predviđenim planom i programom nastave za studente 3.i 4. godine osnovnih studija medicine.

Predavanja u osnovnoj i posleddiplomskoj nastavi (za lekare na specijalizaciji, specijalističkim akademskim studijama i subspecijalističkim studijama) i to: u osnovnoj studentskoj nastavi na srpskom i engleskom jeziku i u

poslediplomskoj nastavi (specijalizantima iz interne medicine, lekarima na SAS iz hematologije, užoj specijalizaciji iz hematologije, imunologije i transplanatologije)

Od 2008. godine učestvuje u ispitima studenata OAS iz predmeta interna propedeutika, a od 2014. ispituje studente iz predmeta interna medicina. Od 2014. godine ispituje lekare na specijalizaciji interne medicine kolokvijum iz hematologije. Od 2015. godine član je komisije za polaganje subspecijalističkog ispita iz hematologije. Od 2018. je član komisije za polaganje specijalističkog ispita iz predmeta interna medicina.

Takođe, predavanjima je uključena u sprovođenje specijalističke nastave iz: Interne medicine (6 časova (god), kao, iz Opšte medicine (2 časa/god), Urgentne medicine (1 čas/god); kao i iz uže specijalizacije- Hematologija (4 časa/god) i studijama na Engleskom jeziku iz predmeta Interna Medicina (2 čas/god).

Dr Ana Vidović je pokazala posvećenost, odgovornost i originalnost u radu sa studentima, što je rezultovalo maksimalnom ocenom (odličan 5- za 2018. godinu), i 4,69 za 2019. godinu. njenog pedagoškog rada.

#### **D. OCENA REZULTATA U OBEZBEĐIVANJU NAUČNO-NASTAVNOG PODMLATKA MENTORSTVO**

##### ***Diplomski radovi***

1. "Diferencijalna dijagnoza pancitopenija"- Žarković Dušan, 10.10.2017.
2. "Akutne leukemije"- Ilić Ivana, septembar 2017. godine
3. "Febrilne neutropenije"- Tojić Petar, 03.10.2017.

##### ***Poslediplomski radovi - Rad iz uže specijalizacije:***

1. "Difuzni B ćelijski limfom bogat T ćelijama, desetogodišnje iskustvo", dr Jelica Gligorić, jul 2010. godine
2. «Kliničke i laboratorijske karakteristike akutizacije Filadelfija negativnih mijeloproliferativnih bolesti», dr Zoran Mirković, 30.11.2011. godine
3. "Akutna limfoblastna leukemija, Filadelfija pozitivna: kliničke, hematološke osobine i procena terapijskog odgovora", dr. Rada Marković, jul 2020.

##### ***Doktorska disertacija:***

1. "Udruženost infektivnih komplikacija sa metaboličkim poremećajima kod bolesnika sa malignim hemopatijama: kliničke, laboratorijske i molekularne karakteristike", kandidat Dragišić Tatjana, odobren od strane Univerziteta u Beogradu i Naučno nastavnog veća Medicinskog fakulteta Univerziteta u Beogradu.

#### **UČEŠĆE U KOMISIJAMA ZA ODBRANU RADOVA**

##### ***Diplomski radovi***

1. «Ciroza jetre», Milijana Svilar, jul 2010. godine
2. «Etiopatogeneza ciroze jetre», Sanja Jelić, jun 2011. godine
3. «Oboljenja hepatobilijarnog sistema u graviditetu», Marija Jašić, 2011. godine
4. «Ciroza jetre», Tanasković Milena, 2011. godine
5. «Lečenje ulceroznog kolitisa», Nikola Trbojević, januar 2012. godine
6. "Ciroza jetre", Miloš Mledenović, septembar 2012. godine.
7. "Dijagnoza i diferencijalna dijagnoza ulkusa želuca i duodenuma", Ivana Mitrović, april 2012. godine.
8. "Savremeno lečenje Hočkinovog limfoma", Stanimirović Milena, 23.05.2013.
9. "Kliničko-laboratorijske karakteristike bolesnika sa imunoproliferativnim bolestima", Darko Marinković, 07.11. 2017. godine

##### ***Poslediplomski radovi-Rad iz uže specijalizacije:***

1. „Značaj određivanja scoring sistema u prognozi preživljavanja bolesnika sa osteomijelofibrozaom“, dr Jelena Ljubičić, 23.10.2009. godine
2. „Hemolizna anemija kao autoimuni fenomen u limfoproliferativnim oboljenjima“, dr Petrović Zorica, 12.07.2010. godine
3. «Analiza kliničkih i laboratorijskih rezultata lečenja bolesnika sa Waldenstrom makroglobulinemijom u odnosu na grupu rizika pri dijagnozi», dr Slavica Milićević Rašić, 28.11. 2011. godine
4. "Udruženi maligniteti sa hroničnom limfocitnom leukemijom", dr Vladimir Kecman, 26.11. 2013. godine.

##### ***Doktorska disertacija:***

1. "Uticaj reaktivnih vrsta kiseonika na aktivnost mTOR signalnog puta kod pacijenata sa mijeloproliferativnim neoplazmama", dr. Dragoslava A. Đikić, 07.09.2018.

#### **E. NAUČNI I STRUČNI RAD**

##### ***a) Spisak objavljenih radova***

##### **Originalni radovi in extenso u časopisima sa JCR liste**

1. Čolović M., Janković G., Elezović I., Vidović A., Bila J., Novak A and Babić D: "Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukemia". Med Oncol, 1997; 14(2): 66-72. **M23, IF- 0,29**
2. Janković G, Čolović M, Wiernik PH, Antić N, Rajić Z, Vidović A, Pantić M and Čolović R. Multiple karyotypic aberrations in a polymorphous variant of Waldenström macroglobulinemia. Cancer Genet Cytogenet 1999; 111: 77-80. **M22; IF- 1,756**

3. Čolović M, Wiernik PH, Janković G, Vidović A, Janošević S and Basara N. Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis relation to collagen and reticulin fibrosis. *Eur J Haematol* 1999; 61:1-5. **M22; IF-1,478**
4. Milena P, Angelina N, Marisavljević D, Djordjević V, Elezović I, Vidović A, Colović M. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence, *Med Oncol* 2000;17(4): 307-313. **M23; IF-1,281**
5. Vidović A, Čemerikić V, Suvajdžić N, Petrović M and Čolović M. T-cell-rich B-cell lymphoma: a clinicopathologic study of eight cases. *Haematologia* 2001; 31:17-24. **M23; IF-0,400**
6. Rajić Z, Janković G, Vidović A, Milić N, Škorić D, Pavlović M, Lazarević V. Size of protein-coding genome and rate of molecular evolution. *J Hum Genet* 2005; 50: 217-29. **M23; IF-1,978**
7. Vidović A, Janković, G., Čolović, M., Tomin, D, Peruničić M., Bila J., Marković O, Bošković, D. The proto-oncogene expression varies over the course of chronic myeloid leukemia. *Hematology* 2008;13 (1):34-40. **M23; IF-1,425**
8. Marković O, Marisavljević, D., Čemerikić, V., Vidović A, Peruničić M., Todorović, M., Elezović I., Čolović M. Expression of VEGF and microvessel density in patients with multiple myeloma: Clinical and prognostic significance. *Med Oncol* 2008; 25 (4): 451-457. **M23; IF-1,134**
9. Djunic I, Tomin D, Perunicic M, Vidović A, Cemerikic V, Djurasinovic V, Jakovic Lj, Jankovic G. Diagnosis and the treatment of primary amyloidosis, *Vojnosanit Pregl* 2010; 67 (9):781-785. **M23; IF-0,199**
10. Čolović N., Bubaširević Lj, Palibrk V, Vidović A, Čolović M. Neuroborreliosis in patient with aplastic anaemia secondary to therapy with ticlopidine. *Srp Arh Celok Lek* 2010; 138 (9-10):632-634. **M23; IF-0,194**
11. Čolović N, Bogdanović A., Vidović A, Perunčić-Jovanović M., Čolović M. Granulocytic sarcoma of the femur in a patient with acute megakaryoblastic leukaemia. *Srp Arh Celok Lek* 2011;139(11-12):805-808. **M23; IF-0,190**
12. Čolović N, Terzić, T Radojković, Palibrk V, Vidović A. Progression of nodal marginal zone lymphoma into diffuse large B cell lymphoma in a patient with Sjögren's syndrome. *Srp Arh Celok Lek* 2011; 139 (3-4): 229-232. **M23; IF-0,190**
13. Čolović N, Radovanović N, Vidović A, Čolović M. Primarni Burkittov limfom želuca. *Srp Arh Celok Lek* , 2011;139 (7-8):523-526. **M23, IF- 0,190**
14. Djunic I, Elezovic I, Marinkovic M., Suvajdzic-Vukovic N., Tomin D, Jankovic G, Bila, J, Antic D, Vidovic A, Neskovic, B., Nikolic-Vukosavljevic, D. Osteolytic lesions marker in multiple myeloma. *Med Oncol* 2011; 28 (1):. 237-240. **M23; IF-2,140**
15. Djunic, I., Elezovic I., Ilic V., Tomin D., Suvajdzic-Vukovic N., Bila J., Antic D, Vidovic A, Milosevic-Jovicic N. Acquired von Willebrand syndrome in multiple myeloma. *Hematology* 2011;16(4): 209-212. **M23; IF-1,487**
16. Čolović M, Suvajdžić N, Čolović M, Tomin D, Vidović A, Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. *Platelets* 2011; 22(2):153-6. **M23; IF-1,847**
17. Colovic N, Tomin D, Vidovic A, Suvajdzic N, Jankovic G, Palibrk V, Djunic I, Djurasinovic V, Virijevic M. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia. *Biomed Pharmacother* 2012; 66(8):. 578-582. **M23; IF-2,068**
18. Colovic M, Vidovic A, Colovic N, Perunicic-Jovanovic M, Tomin D. Primary cutaneous large B-cell non-Hodgkin lymphoma in first-degree relatives. *Biomed Pharmacother* 2012; 66(6): 425-427. **M23; IF- 2,068**
19. Suvajdzic N, Cvetkovic Z, Djordjevic V, Kraguljac-Kurtovic N, Stanisavljevic D, Bogdanovic A, Djunic I, Colovic N, Vidovic A, Elezovic I, Tomin D. Prognostic factors for therapy-related acute myeloid leukaemia (t-AML) - A single centre experience. *Biomed Pharmacother* 2012; 66(4): 285-292. **M23; IF- 2,068**
20. Kuzmanovic M B, Tosic N M, Colovic N R, Karan-Djurasevic T Z, Spasovski V, Radmilovic M M, Nikcevic G T, Suvajdzic-Vukovic N, D, Tomin D S, Vidovic A D, Virijevic M, Pavlovic S T, Colovic M D. Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia, *Acta Haematol* 2012;128( 4): 203-12, IF **M23, IF-0,894**
21. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. *Med Oncol*. 2012; 29(2):1077-81. **M23; IF-2,140**
22. Colovic N, Tomin D, Vidovic A, Tosic N, Atkinson H.D, Colovic M. Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia. *Med Oncol* 2012; 29: 260-262. **M23; IF-2,140**
23. Djunic I, Virijevic M, Djurasinovic V, Novkovic A, Colovic N, Kraguljac-Kurtovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. *Med Oncol*. 2012; 29 (3): 2077-82. **M23; IF-2,140**
24. Colovic M., Colovic N., Jankovic G., Kraguljac Kurtovic N, Vidovic A, Djordjevic, V, Bogdanovic A. Mixed phenotype acute leukemia of T/myeloid type with a prominent cellular heterogeneity and unique karyotypic aberration 45,XY, dic(11;17). *Int J Lab Hematol* 2012; 34 (3):290-294. **M23; IF-1,176**
25. Ratkov E, Vidovic A, Minic P, Janic D, Sipetic-Grujicic S, Dzamic A, Arsic-Arsenijevic V. Detection of Laboratory Biomarkers in Haematological and Pulmonology Patients at High Risk for Aspergillosis. *Srp Arh Celok Lek*. 2012;140(5-6):290-8. **M23, IF-0,190**
26. Colovic N, Suvajdzic N, Kraguljac Kurtovic N, Djordjevic V, Dencic Fekete M., Drulovic J, Vidovic A, Tomin D. Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. *Biomed Pharmacother* 2012; 66 (3):173-174. **M23; IF- 2,00**

27. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. *Hematology*, 2012; 17:53-8. **M23; IF-1,487**
28. Karan-Djurasevic T, Palibrk V, Kostic T, Spasovski V, Nikcevic G, Srzentic S, Colovic M, Colovic N, Vidovic A, Antic D, Mihaljevic B, Pavlovic S, Tosic N. Mutational Status and Gene Repertoire of IGHV-IGHD-IGHJ Rearrangements in Serbian Patients With Chronic Lymphocytic Leukemia. *Clin Lymphoma Myeloma Leuk*. 2012;12 (4):252-60. **M23; IF- 1,880**
29. Čolović M, Čolović N, Radojkovic M, Stanisavljevic D, Kraguljac N, Jankovic G, Tomin D, Suvajdzic N, Vidovic A, Atkinson HD. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients. *Ann Hematol* 2012; 91(1): 1363-1370. **M22; IF-2,866**
30. Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M, Djunic I, Mitrovic M, Tomin D. Is there a "gold" standard treatment for patients with isolated myeloid sarcoma?, *Biomed Pharmacother* 2013; 67(1): 72-77. **M23; IF-2,068**
31. Djunic I, Suvajdzic-Vukovic N, Virijevic M, Novkovic A, Colovic N, Vidovic A, Tomin D. Prognostic risk score for the survival of elderly patients with acute myeloid leukaemia comprising comorbidities. *Med Oncol* 2013; 30 (1): 394- 398. **M23; IF- 2,147**
32. Matic I Z, Djordjevic M, Djordjic M J, Grozdanic N Dj, Damjanovic A B, Kolundzija B S, Vidovic A D, Bila J, Ristic S, Mihaljevic B S, Tomin D S, Milanovic N, Ristic D J, Puric M, Gavrilovic D, Cordero O J, Juranic Z D. Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies, *Leuk & Lymph* 2013;54(12):2701-6: **M22, IF-2,605**
33. Bila J, Andjelic B, Bodrozic J, Jakovic Lj R, Perunicic-Jovanovic M D, Vidovic A D, Todorovic M R, Mihaljevic B S. Extramedullary plasmacytoma of the tongue base: A rare presentation of head and neck plasmacytoma, *Vojnosanit Pregl* 2013;70 (10): 972-5. **M23, IF- 0,269**
34. Mijoljevic V, Markovic-Denic Lj N, Vidovic A D, Jovanovic M M, Tosic T O, Tomin D S. Risk factors for vancomycin-resistant *Enterococcus* colonization in hematologic patients, *Vojnosanit Pregl*, 2013;70(12):1109-1116 **M23, IF- 0,269**
35. Đunić I, Elezović I, Vučić M, Srdić- Rajić T, Konić- Ristić A, Ilić V, Milić N, Bila J, Suvajdžić- Vuković N, Virijević M, Antić D, Vidović A, Tomin D. Specific Binding of Paraprotein to Platelet Receptors as a Cause of Platelet Dysfunction in Monoclonal Gammopathies. *Acta Haematol* 2013; 130: 101-107. **M23; IF-0,994**,
36. Colovic M D, Vidovic A D, Jankovic M, Colovic N R, Perunicic-Jovanovic M D. Myeloid Sarcoma of the Testis and Skin With Osteolytic Bone Lesions in Blastic Transformation of Primary Myelofibrosis, *Labmed* 2013; 44(3):258-61. **M23, IF- 0,489**
37. Djunic I, Elezovic I V, Ilic V Lj, Milosevic-Jovcic N, Bila J, Suvajdzic-Vukovic N D, Antic D A, Vidovic A D, Tomin D S. The Effect of Paraprotein on Platelet Aggregation, *J Clin Labor Anal* 2014;28( 2):141-6; **M23, IF 1,038**
38. Lekovic D R, Gotic M D, Perunicic-Jovanovic M D, Vidovic A D, Bogdanovic A D, Jankovic G M, Cokic V P, Milic N M. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis, *Med Oncol* 2014;31(3): 869. doi: 10.1007/s12032-014-0869-8 **M22, IF- 2,634**
39. Mitrovic M, Suvajdzic D, Elezovic I V, Bogdanovic A D, Djordjevic V J, Miljic P S, Djunic I, Gvozdenov M, Colovic N R, Virijevic M, Lekovic D R, Vidovic A D, Tomin D S. Thrombotic events in acute promyelocytic leukemia, *Thromb Res* 2015;135 (4): 588-93 **M23, IF- 2,320**
40. Colovic N R, Bogdanovic D, Virijevic M, Vidovic A D, Tomin D S. Acute Myocardial Infarction during Induction Chemotherapy for Acute MLL t(4;11) Leukemia with Lineage Switch and Extreme Leukocytosis, *Srp Arh Celok Lek* 2015;143(11-12): 734-8 **M23 IF 0,277**
41. Colovic N R, Seferovic P M, Plecic M, Vidovic A D, Suvajdzic N D, Tomin D S. Peripartum cardiomyopathy in a patient treated for acute myeloid leukemia, *Srp Arh Celok Lek* 2016;144(1-2):77-80 **M23 IF 0,253**
42. Virijevic M, Vidovic A D, Colovic N R, Djunic I, Mitrovic M, Suvajdzic-Vukovic N D, Tomin D S. Hypercalcemia with multiple osteolytic lesions and increased circulating tumor necrosis factor in an adult patient with B-cell acute lymphoblastic leukemia, *Srp Arh Celok Lek* 2016; 144(3-4): 207-10: **M23 IF 0,253**
43. Virijevic M, Karan-Djurasevic T Z, Marjanovic I, Tosic N M, Mitrovic M, Djunic I, Colovic N R, Vidovic A D, Suvajdzic-Vukovic N D, Tomin D S, Pavlovic S T. Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype, *Radiol Oncol* 2016;50(4): 385-93; **M23, IF- 1,681**
44. Marjanovic I, Karan-Djurasevic T Z, Ugrin M, Virijevic M, Vidovic A D, Tomin D S, Suvajdzic-Vukovic N D, Pavlovic S T, Tosic N M.) Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients, *Clin Lymph Myeloma & Leuk* 2017;7( 5): 312-9; **M22, IF 2,494**

#### **Ostali radovi sa JCR liste**

1. Čolović M, Janković G, Jovanović J, Vidović A. Acute myelocytic leukemia (M4) with t(2;4)(q22;q31) and review of the literature. *Cancer Genet Cytogenet* 2004, 153: 181-2. **M23; IF- 1,577**
2. Suvajdzic N D, Zivkovic R, Djunic I, Vidovic A D, Markovic O, Marisavljevic D Z, Tomin D S, Elezovic I V, Pekmezovic T D (2014) Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia, *Platelets* 2014; 25 (4): 467-9; **M22; IF 2,982 (IF 1,491)**

### Ceo rad indeksiranom Science Citation Index (SCI) Expanded

1. Vidović A., Janković G., Tomin D, Peruničić-Jovanović M, Djunić I., Djurašinović V, Čolović M. Prognostic significance of cellular vascular endothelial growth factor (vegf) expression in the course of chronic myeloid leukaemia. *Srp Arh Celok Lek*, 2009, 137 (7-8) : 379-383.
2. Đunić I, Tomin D, Antonijević N, Siniša G, Mirjana K, Vidović A., Đurašinović V, Elezović I. Dijagnostikovanje i lečenje trombocitopenije izazvane heparinom posle operacije atrijalnog miksoma - prikaz bolesnika. *Srp Arh Celok Lek* , 2009, 137 ( 9-10): 540-544.
3. Vidović A., Arsić Arsenijević Valentina, Tomin D, Đunić I, Jaković R, Lončar Z, Barać A. Proven invasive pulmonary mucormycosis successfullz terated with amphotericin B and surgery in patient with acute myeloblastic leukemia: a case report. *J Med Case report*, 2013;7:263
4. Vidović A., Janković G, Suvajdzic Vukovic N, Radisavljević Z, Jovanović J, Denčić Fekete M, Todorović Živanović B, Đunić I, Virijević M, Čolović N, Tomin D.5q-Syndrome in Transformation to the Philadelphia Chromosome Positive Acute Myeloblastic Leukemia.Carcinogenesis & Mutagenesis, 2014;8:2.
5. Čolović N, Suvajdzic Vuković N, Kosanović Janković N, Miljić P, Đunić I, Vidović A., Tomin D. Central Retinal Vein Occlusion in Acute Promyelocytic Leukemia and Heterozygosis for Factor V Leiden and Methylenetetrahydrofolate Reductase (MTHFR) Gene Mutations. *Austin Journal of Clin Case Reports* 2014;1:1.
6. Janic D, Paric J, Karan-Djurasevic T, Kostic T, Marjanović I, Stanić B, Pejanović N, Dokmanović L, Lazić J, Krstovski N, Virijevuć M, Tomin D, Vidović A., Suvajdzic-Vuković N, Pavlović S. Application of target next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia. *J Med Biochem* 2020; 39:72-82.

### Radovi u časopisu koji je uključen u bazu podataka MEDLINE

1. Vidović A., Janković G., Suvajdžić N., Čolović M: "Ekstramedulski blastni preobražaj u hroničnoj granulocitnoj leukemiji". *Srp Arh Celok Lek*, 1993, 121 : 48-9
2. Vidović A., Suvajdžić N., Jovanović V, Janković G, Čolović M., Rolović Z: "Leukemijska faza intermedijarnog ("Mantle zone") limfoma". *Srp Arh Celok Lek*, 1994, 122: 113-5.
3. Rolović Z., Čolović M., Elezović I., Vidović A., Bošković D, Radošević N, Novak A., Basara N: "Lečenje akutne promijelocitne leukemije retinoičnom kiselinom ol-trans, primenom evropskog protokola za lečenje akutne promijelocitne leukemije". *Srp Arh Celok Lek*, 1995, 123 :279-85.
4. Vidović A., Jovanović V, Novak A., Basara N., Janković G, Čolović M.: "Agnogena mijeloidna metaplazija sa eozinofilijom". *Srp Arh Celok Lek*, 1996, 124: 314-7.
5. Vidović A. D. Tomin, V. Čemerikić, G. Milivojević and M. Čolović. Limfom ćelija B bogat ćelijama T. *Srp Arh Cel Lek* 2000, 128:116-9.
6. O. Marković, D. Marisavljević V. Čemerikić, A Vidović, Bakrač M, Peruničić M Suvajdžić, Čolović M. ,, Proliferativna aktivnost mijelomskih ćelija merena antitelom Ki-67: biološki i klinički značaj".*Vojnosanit Pregl* 2005, 62: 33-8.

### Ceo rad u časopisu koji nije indeksiran u gore navednim bazama podataka

1. Čolović M, Janković G, Vidović A., Bila J, Novak A. Babić D.Rezultati lečenja bolesnika sa akutnom promijelocitnom leukemijom primenom ATRA-e i hemioterapije. *Acta Fac Med Naiss* 1998, 15 (2): 101-8.
2. Vidović A. N. Suvajdžić. Hipereozinofilni sindrom-pregledni članak. *Acta Fac Med Naiss* 2002, 19(2):135-9.
3. Vidović A., Peruničić-Jovanović M. T ćelijama i histiocitima bogat B ćelijski limfom - difrencijalno dijagnostičke dileme. *Acta clinica* 2010; 10(3): 81-96.
4. A. Vidović. Invazivne gljivične infekcije kod hematookoloških bolesnika. *Medicinska istraživanja* 2011; 45 (5):61.

### Ceo radu u zborniku međunarodnog skupa

1. Vidović A., Čolović R, Janković G. Splenectomy in the treatment of chronic lymphocytic leukemia. 17th International Cancer Congress, Rio de Janeiro, August 24-28, 1998, p 1385-9.

### Ceo rad u zborniku nacionalnog skupa

1. Rolović Z., Čolović M., Elezović I., Vidović A., Bošković D, Radošević N., Novak A., Basara N: "Naša iskustva u lečenju 15 bolesnika sa akutnom promijelocitnom leukemijom sa Vesanoidom (ATRA) primenom evropskog protokola APL 91. Bilten za hematologiju, 1994, 22:38-9.
2. Vidović A., Bakrač M, Janković G, Tomin D, Đunić I, Antić A, Čemerikić V, Peruničić M, Đordjević V, Milić N, Bošković D. Korelacija nivoa ekspresije VEGF i p53 sa kliničkim karakteristikama bolesnika u blastnoj krizi hronične granulocitne leukemije. *Bilten za hematologiju*, 2004, 32: 175-8.
3. Vidović A. Kako dijagnostikovati i lečiti bolesnike sa akutnom mijeloblastnom leukemijom u molekularnoj eri. *Knjiga Sažetaka, 3. Kongres Hematologa Srbije, Kragujevac, 2015, 26-28.*

### Izvod u zborniku međunarodnog skupa

1. Čolović M., Janković G., Suvajdžić N, Janković S, Jančić-Nedeljkov R., Vidović A and Milošević R: Plasma cell leukemia - a report on 10 cases". 24th Congres of International society of haematology, London, 23-27 august 1992, abstract 474,p 122.

2. Suvajdžić N., Bogdanović A., Milošević R., Vidović A., Nedeljković N., Bogdanović G, Tomašević R., Janković G et Čolović M: "Effets thérapeutiques des dérivés sanguins chez des patients adultes atteints des leucémies aiguës et traités suivant les protocoles français 01 AM86 (LMA) et LALA 87 (LLA) dans les périodes de 1988-1990 (A) et de 1991-1993 (B)." Ier Congrès de la société Française de Transfusion Sanguine, Angers, 8-10 Juin, 1994, P- 8-5 str. 125.
3. Kalezić V, Čolović R., Čolović M., Vidović A., Janković G: "Splenectomy in treatment of Agnogenic myeloid metaplasia". XXV Congress of the International Society of Hematology, Mexico, April 1994, abstract 379, 282.
4. Elezović I., Bošković D, Čolović M., Mijović A., Marisavljević D, Vidović A., Rolović Z: "Early mortality due to the retinoic syndrome in acute promyelocytic leukemia". XIIIth Meeting of the International society of Haematology, Turkey, September 3-8, 1995, abstract 382.
5. Rolović Z., Elezović I., Vidović A.: "Effect of all-trans retinoic acid on disseminated intravascular coagulation in newly diagnosed acute promyelocytic leukemia". XIV International Congress on Thrombosis, October 14-19, 1996, Montpellier, France, abstract 401.
6. Čolović M., Jovanović V, Damjanović D, Vidović A., Basara N: "Circulating hematopoietic progenitor in primary and secondary myelofibrosis: relations to collagen and reticulin fibrosis". 26th Congress of the International Society of Hematology, Singapore, August 25-29, 1996, abstract No 279.
7. Pantić M., Novak A., Djordjević V., Elezović I., Vidović A., Čolović M: "Additional chromosome abnormalities in acute promyelocytic leukaemia". Cytogenetics and Cell Genetics. Abstracts of the 1th European Cytogenetics Conference, Athens, Greece, June 22-25, 1997. abstract 336.
8. Marisavljević D., Radošević N, Ludoški M., Vidović A., Čolović M: Chronic myelomonocytic leukaemia: Clinical and hematopathological features of 27 patients. Leukemia Research, Clinical and Laboratory studies, Fourth International symposium on Myelodysplastic syndromes. Barcelona, Spain, April 24-27, 1997, abstract 28
9. Vidović A., Sefer D, Jovanović V, Čolović M: "Circulating hematopoietic progenitor in primary osteomyelofibrosis: correlation to collagen and reticulin fibrosis and hepatosplenomegaly". XIVth Meeting of ISH, Stockholm, Sweden, Aug 30 - Sep 4, 1997, abstract 295.
10. Elezović I., Čolović M., Bošković D., Vidović A., Bila J., Suvajdžić N., Miljić P., Radošević N., Novak N., Rolović Z: "Disseminated intravascular coagulation in acute promyelocytic leukaemia during treatment with all-trans retinoic acid." XIVth Meeting of International society of Haematology, Stockholm, Sweden, aug 30-sept 4, 1997, abstract 046.
11. Čolović M, Janković G, Elezović I., Vidović A., Bila J., Novak A., Babić D: "Effect of all-trans-retinoic (ATRA) alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukemia (APL). XIV th Meeting of International Society of Haematology, Stockholm, Sweden, Aug 30-4 Sept, 1997, abstract 075.
12. Čolović R, Čolović M, Janković G, Vidović A., Vulović V. Splenectomy for chronic lymphocytic leukemia and low grade lymphoma. 17th International Cancer Congress, Rio de Janeiro, August 24-28, 1998, abstract No 587.
13. Čolović R, Bilanović D, Čolović M., Vidović A., Suvajdžić N, Janković G: "Splenectomy in treatment of Agnogenic myeloid metaplasia." XIVth Meeting of International Society of Haematology, Stockholm, Sweden, Aug 30 -Sept 4, 1997, abstract 309.
14. M. Čolović, N. Suvajdžić M., G. Janković, N. Kraguljac, A. Vidović, A. Novak and M. Pantić. Cytogenetic aberration in primary plasma cell leukemia. Br J Haematol 1998, 102, abstract No 1397.
15. A Vidović, R. Čolović., G. Janković, M. Čolović. and V. Vulović. Splenectomy in the treatment of chronic lymphocytic leukemia. Br J Haematol 1998, 102, abstract No 0874.
16. A Vidović, N. Kraguljac, V. Lazarević, G. Janković and M. Čolović. Karyotypic and immunophenotypic characteristics of blast crisis in chronic myeloid leukemia. 4th Meeting European Hematology Association, Barcelona 1999. Hematologica 1999, 84 abs No 0720.
17. Bogdanović A, Janković G, Donfrid M, Bogunović M, Suvajdžić N, Rajić Z , Vidović A., Čemerikić V, Tomašević R, Bogdanović, Nedeljković N, Čolović M. Do elderly patients with acute myeloid leukemia have benefits from standard intensive induction chemotherapy? 4th Meeting European Hematology Association, Barcelona 1999. Hematologica 1999; 84: abs No 0611.
18. Vidović A., Čemerikić V, Tomin D, Petrović M and Čolović M. T-cell-rich B-cell lymphoma- a clinicopathologic study of eight cases. VII International Conference of Malignant Lymphoma, 2-5 June 1999, Lugano, Switzerland, Annals of Oncology, Vol 10, abstract No 313.
19. Vidović A., Čemerikić V, M. Petrović and M. Čolović. T-cell-rich B-cell lymphoma- a clinical pathologic study of eleven cases. The Haematology Journal, Vol 1, Suppl. 1, 5th Annual Meeting of the Haematologic Association, Birmingham, 2000; abstract No 693.
20. Bošković D, Elezović I, Čolović M, Tomin D, Suvajdžić N, Vidović A., Bila J. "Long term survival in acute promyelocytic leukemia treated with ATRA by protocol APL-91 joint". International Congress on APL and Differentiation therapy, Rome, Italy, 4-7 October, 2001; abstract No 7.9.
21. Elezović I, Bošković D, Čolović M, Miljić P, Tomin D, Suvajdžić N, Vidović A. "All-trans retinoic acid activity on DIC in acute promyelocytic leukemia". International Congress on APL and Differentiation therapy, Rome, Italy, 4-7 October, 2001; abstract No 7.21.
22. Bila J, Elezović I, Tomin D, Vidović A., Gotić M and Bošković D. "Clinico-biological characteristics and outcome of Waldenström macroglobulinemia". The Haematology Journal, Vol 3, Suppl. 1, 7th Annual Meeting of the Haematologic Association, Florence, Italy, 6-9 June, 2002; abstract No 0865.

23. Vidović A, Mihaljević B, Antić D, Lazarević V, Jančić-Nedeljkov R, Tomin D, Bošković D, Čolović M. "Long lasting remission in solitary CNS plasmocytoma". 8th Annual Congress of the European Hematology Association, Lyon, France, 12-15 June, 2003; abstract No 0550.
24. Vidović A, Janković G, Čolović M, Tomin D, Lazarević V, Antić D, Kraguljac N, Čemerikić V, Đorđević V, Milić N, Bošković D. "Karyotypic and immunophenotypic characteristics of blast crisis in chronic myeloid leukemia". 8th Annual Congress of the European Hematology Association, Lyon, France, 12-15 June, 2003; abstract No 0580.
25. Tomin D, Čemerikić-Martinović V, Antić D, Vidović A, Peruničić M, Janković G, Bošković D. "An unusual course of myeloblastoma: a case report". 8th Annual Congress of the European Hematology Association, Lyon, France, 12-15 June, 2003; abstract No 1037.
26. Antić D, Jaković Lj, Tomin D, Čemerikić-Martinović V, Vidović A, Milivojević G, Suvajdžić N, Lazarević V, Bogdanović A, Sretenović M, Milić N, Bošković D. "Clinical, hematological and laboratory findings in patients with solid tumour metastasis in bone marrow". 8th Annual Congress of the European Hematology Association, Lyon, France, 12-15 June, 2003; abstract No 0125.
27. Marković O, Marisavljević D, Čemerikić V, Peruničić M, Vidović A, Suvajdžić N, Čolović M. "Clinical significance of p53 expression in multiple myeloma". 9th Congress of the European Hematology Association, Geneva Palexpo, Switzerland, 10-13 June, 2004, abstract 800.
28. Tomin D, Čemerikić-Martinović V, Peruničić-Jovanović M, Vidović A, Janković G, Lazarević V, Kuzmanović M, Bošković D. "Myeloblastoma as initial manifestation of acute myeloid leukemia". 9th Congress of the European Hematology Association, Geneva Palexpo, Switzerland, 10-13 June, 2004, abstract 813.
29. Bakrač M, Peruničić-Jovanović M, Vidović A, Petrović M, Elezović I, Čolović M, Bošković D. "Expression of proliferation and apoptotic antigens in newly diagnosed and relapsed acute lymphoblastic leukemia". 9th Congress of the European Hematology Association, Geneva Palexpo, Switzerland, 10-13 June, 2004, abstract 971.
30. Vidović A, Janković G, Čolović M, Čemerikić V, Tomin D, Antić D, Đunić I, Đorđević V, Bošković D. "Prognostic significance of cellular vascular endothelial growth factor expression in chronic myeloid leukemia". 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005; abstract No 1061.
31. Antić D, Tomin D, Čemerikić V, Mihaljević B, Janković G, Vidović A, Đunić I, Bošković D. "Expression of oncogenes and IPS like prognostic factors in Hodgkin's lymphoma- our experience". 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005; abstract No 1186.
32. Marković O, Marisavljević D, Čemerikić V, Peruničić M, Bakrač M, Vidović A, Elezović I, Čolović M. "VEGF expression and microvessel density in patients with multiple myeloma: clinical and prognostic significance". 11th Congress of the European Hematology Association, Amsterdam, the Netherlands, June 15-18, 2006; abstract No 0759.
33. Bila J, Peruničić M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Tomin D, Vidović A, Čemerikić V, Bošković D. "Tumor-host interactions in the bone marrow of multiple myeloma patients: analysis of clinical relevance and prognostic significance". 11th Congress of the European Hematology Association, Amsterdam, the Netherlands, June 15-18, 2006; abstract No 0766.
34. Vidović A, Janković G, Čolović M, Tomin D, Peruničić M, Đunić I, Antić D, Bila J, Bakrač M, Marković O, Čemerikić V, Bošković D. "The expression of proto-oncogenes in the course of chronic myeloid leukemia". 11th Congress of the European Hematology Association, Amsterdam, the Netherlands, June 15-18, 2006; abstract No 0680.
35. Bakrač M, Kraguljac N, Bila J, Mihaljević B, Elezović I, Petrović M, Gotić M, Vidović A, Peruničić M, Čolović N, Suvajdžić N, Marković O, Bošković D. "Evaluation of peripheral blood and bone marrow involvement in mantle cell lymphoma (MCL)- immunophenotypic and morphological findings". 11th Congress of the European Hematology Association, Amsterdam, the Netherlands, June 15-18, 2006; abstract No 1379.
36. Vidović A, Janković G, Čolović N, Tomin D, Đorđević V, Kraguljac N, Bila J, Đurašinović V, Marković O, Bošković D. "Biological profile of blast crisis of chronic myeloid leukemia: analysis of clinical relevance and prognostic significance". 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007; abstract No 1515.
37. Đunić I, Elezović I, Milošević-Jovčić N, Suvajdžić N, Bila J, Antić D, Vidović A, Tomin D. "Haemostasis disorder in monoclonal gammopathies". 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007; abstract No 1361.
38. Marković O, Marisavljević D, Čemerikić V, Peruničić M, Vidović A, Bakrač M, Elezović I, Čolović M. "Different methods for estimation of angiogenesis in patients with multiple myeloma". 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007; abstract No 1104.
39. Bila J, Peruničić M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Mihaljević B, Tomin D, Vidović A, Čemerikić V, Bošković D. "Clinical relevance of regulatory network in the bone marrow compartment of patients with multiple myeloma". 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007; abstract No 1069.
40. Bila J, Peruničić M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Mihaljević B, Vidović A, Tomin D, Čemerikić V, Bošković D. "The relation between proliferation index and angiogenesis in multiple myeloma". 12th Congress of the European Hematology Association, Vienna, Austria, June 7-10, 2007; abstract No 0683.

41. Djunic I, Elezovic I, Milosevic-Jovcic N, Ilic V, Suvajdzic N, Bila J, Vidovic A, Tomin D. Effekt of paraproteins on platelet aggregation. *Journal of Thrombosis and Haemostasis* 2007; 5 Supplement 2: P-S 194.
42. Djunic I, Elezovic I, Milosevic-Jovcic N, Ilic V, Suvajdzic N, Bila J, Antic D, Vidovic A, Tomin D. Haemostasis disorders in monoclonal gammopathies. *Haematologica* 2007; 92Supplement 1: 490.
43. Antic D, Cikota V, Cemerikic V, Tomin D, Jankovic G, Vidovic A, Djunic I, Petrovic M, Mihaljevic B. Analysis of B-cell clonality in composite Hodgkin's disease and non Hodgkin's lymphoma. *Leukemia Research* 2007; 31 Supplement 2:P073.
44. Vidović A, Bila J, Suvajdžić-Vuković N. Invazivne gljivične infekcije kod bolesnika sa hematološkim malignitetima. 6th Congress of Medical Mycrobology 2008; Beograd 11-14 jun 2008; 158-159.
45. Vidović A, Mijoljević V, Jovanović B, Tomin D, Mihaljević B. Epidemiological Characteristics of Nosocomial Infections in Institute of H during Period January-July 2008. 11th International Symposium on Febrile Neutropenia 2009; P-0023.
46. Djunic I, Elezovic I, Milosevic-Jovcic N, Ilic V, Suvajdzic-Vukovic N, Bila J, Vidovic A, Antic D, Tomin D. The role of paraprotein on platelet disfunction. *Haematologica* 2008; 93 Supplement 1:267.
47. Djunic I, Elezovic I, Markovic O, Tadic J, Tomin D, Antic D, Vidovic A, Ljubic A. Diffuse cavernous hemangioma of the left leg, vulva and uterus in a pregnant woman: report of a rare case. 15th International Meeting Danubian League against Thrombosis and Haemorrhagic Disorders, Belgrade, Abstract book, 2009: 86.
48. Djunic I, Tomin D, Antonijevic N, Kovac M, Jankovic G, Vidovic A, Elezovic I. heparin-induced thrombocytopenia occurred after cardiosurgical treatment of atrial mixoma: a case report. 15th International Meeting Danubian League against Thrombosis and Haemorrhagic Disorders, Belgrade Abstract book, 2009: 22.
49. Djunic I, Elezovic I, Milosevic-Jovcic N, Ilic V, Antic D, Vidovic A, Tomin D. Acquired von Willebrand syndrome in patients with multiple myeloma. *Journal of Thrombosis and Haemostasis* 2009; 7 supplement 2: PP-WE-634.
50. Djunic I, Elezovic I, Markovic O, Tadic J, Tomin D, Antic D, Vidovic A, Ljubic A. Diffuse cavernous hemangioma of the left leg, vulva and uterus in a pregnant woman: report of a rare case. *Thrombosis Research* 2009; 123 Supplement 2:S148.
51. Djunic I, Elezovic I, Tomin D, Jankovic G, Antic D, Vidovic A, Bila J, Marinkovic M. Serum concentration of C-terminal collagen telopeptide as an osteolytic lesions marker in patients with multiple myeloma. *Haematologica* 2009; 94 supplement 2: 616.
52. Vidovic A, Jankovic G, Tomin D, Gotic M, Djunic I, Perunicic M, Kraguljac N, Djordjevic V, Colovic M. Leukemic transformation of Philadelphia chromosome-negative chronic myeloproliferative disease – analysis of 10 cases. *Haematologica* 2009; 94 Supplement 2: 589.
53. Mitrovic-Vasiljevic M, Djunic I, Tomin D, Suvajdzic N, Elezovic I, Todorovic M, Jankovic Vidovic A, Antic D. Results of treatment with HyperCVAD in adult acute lymphocytic leukemia: single center experience. *Haematologica* 2009; 94 supplement 2: 565.
54. Antic D, Tomin D, Elezovic I, Perunicic M, Jankovic G, Suvajdzic N, Gotic M, Vidovic A, Bila J, Djunic I, Mitrovic M. Does intensive anti-leukemic therapy really improves the prognosis for patients suffering from isolated myeloid sarcoma?. *Haematologica* 2009; 94 supplement 2: 560.
55. Colovic M, Vidovic A, Tomin D, Elezovic I, Colovic N, Palibrk V. Micophenolat mofetil in the treatment of adult chronic thrombocytopenic purpura. 14th Congress of European Hematology Association. Berlin, Germany, 4-7, June 2009. Abstract 0240.
56. Čolović N, Radovanović N, Palibrk V, Alempijević T, Vidović A. Primary gastric Burkitt's lymphoma presenting with prolonged melena. 11th European Bridging Meeting in gastroenterology. Belgrade, Serbia, 31. Oct/November 1. 2009. Abstract book, page 62.
57. Palibrk V, Vidović A, Čolović N, Sokić A, Čolović M. Neutropenic enterocolitis in a patient with acute myeloid leukemia. 11th European Bridging Meeting in gastroenterology. Belgrade, Serbia, 31. Oct/November 1. 2009. Abstract book, page 50-51.
58. Jovanović J, Đorđević V, Denčić- Fekete M, Vidović A, Tomin D, Bogunović M, Todorčić- Živanović B, Gotić M. Del (5)(q13q33) and Ph chromosome in myelodysplastic syndrome. 8th Balkan meeting on Human Genetics, Cavtat-Dubrovnik, Croatia. May 14-17, 2009. Abstract No 120.
59. Djunic I, Elezovic I, Tomin D, Bila J, Antic D, Vidovic A, Suvajdzic-Vukovic N. The influence of paraprotein on bleeding complications in multiple myeloma. *Thrombosis Research* 2010; 125 Supplent 2: S178-S179.
60. Djunic I, Elezovic I, Milosevic-Jovcic N, Ilic V, Antic D, Vidovic A, Tomin D. Acquired von Willebrand syndrome in patients with multiple myeloma. *Journal of Thrombosis and Haemostasis* 2009; 7 supplement 2: PP-WE-634.
61. Djunic I, Elezovic I, Markovic O, Tadic J, Tomin D, Antic D, Vidovic A, Ljubic A. Diffuse cavernous hemangioma of the left leg, vulva and uterus in a pregnant woman: report of a rare case. *Thrombosis Research* 2009; 123 Supplement 2:S148.
62. Djunic I, Elezovic I, Tomin D, Jankovic G, Antic D, Vidovic A, Bila J, Marinkovic M. Serum concentration of C-terminal collagen telopeptide as an osteolytic lesions marker in patients with multiple myeloma. *Haematologica* 2009; 94 supplement 2: 616.
63. Vidović A, Jankovic G, Tomin D, Gotic M, Djunic I, Perunicic M, Kraguljac N, Djordjevic V, Colovic M. Leukemic transformation of Philadelphia chromosome-negative chronic myeloproliferative disease – analysis of 10 cases. *Haematologica* 2009; 94 Supplement 2: 589.

64. Ratkov E, Vidovic A, Suvajdzic-Vukovic N, Džamić A, Arsić Arsenijević A. Screening for galactomannan and anti-Aspergillus antibodies in hematological patients suspected for developing invasive aspergilosis. Mycoses, 4th Trends in medical Mycology, 18-21 October 2009; Athens, Greece, P154.
65. Ratkov E, Arsić Arsenijević V, Čolović N, Džamić A, Vidović A, Janić D. Detection of Galactomannan and Antibodies in Patients with Invasive Aspergillosis. International Meeting on Emerging Diseases and Surveillance, Vienna, Austria, february 13-16, 2009, P18.157.
66. Mitrovic-Vasiljevic M, Djunic I, Tomin D, Suvajdzic N, Elezovic I, Todorovic M, Jankovic G, Vidovic A, Antic D. Results of treatment with HyperCVAD in adult acute lymphocytic leukemia: single center experience. Haematologica 2009; 94 supplement 2: 565.
67. Antic D, Tomin D, Elezovic I, Perunicic M, Jankovic G, Suvajdzic N, Gotic M, Vidovic A, Bila J, Djunic I, Mitrovic M. Does intensive anti-leukemic therapy really improves the prognosis for patients suffering from isolated myeloid sarcoma?. Haematologica 2009; 94 supplement 2: 560.
68. Colovic M, Colovic N, Vidovic A, Jankovic G, Djordjevic V. Mixed lineage acute leukemia of T-lymphoid and myeloid immunophenotype with a unique karyotype 45XY. DIC(11;17). XXXIII World Congress of the International Society of Hematology. Jerusalem, October 10-13, 2010. Abstr. 23.
69. Colovic N, Jurisic V, Colovic M, Vidovic A, Palibrk V. Systemic sclerosis accompanied with IgG multiple myeloma: a possible connection? XXXIII World Congress of the International Society of Hematology. Jerusalem, October 10-13, 2010. Abstr. 24.
70. Colovic R, Tomin D, Colovic N, Vidovic A, Suvajdzic N, Colovic M. Efficacy and safety of splenectomy in adults with chronic immune thrombocytopenic purpura: single institution study. XXXIII World Congress of the International Society of Hematology. Jerusalem, October 10-13, 2010. Abstr. 35.
71. Djunic I, Elezovic I, Tomin D, Bila J, Antic D, Vidovic A, Suvajdzic-Vukovic N. The influence of paraprotein on bleeding complications in multiple myeloma. Thrombosis Research 2010; 125 Supplement 2: S178-S179.
72. Vidovic A, Ljubicic J, Suvajdzic-Vukovic N, Djunic I, Perunicic-Jovanovic M, Djordjevic V, Colovic N, Pavlovic A, Colovic M. The importance of scoring system in the prognosis of patients with primary myelofibrosis. Haematologica 2010; 95 Supplement 2: 1520.
73. Suvajdzic-Vukovic N, Djurdjevic P, Colovic M, Colovic R, Petrovic M, Elezovic I, Tomin D, Gotic M, Jankovic G, Todorovic M, Vidovic A, Bila J, Djunic I, Perunicic-Jovanovic M, Mihaljevic B. Clinical features of the patients with lymphoproliferative disorders and associated autoimmune rheumatic diseases: single center study. Haematologica 2010; 95 Supplement 2: 1569.
74. Djunic I, Vidovic A, Pavlovic A, Virijevic M, Jankovic G, Elezovic I. Coexistence of inherited and acquired thrombophilia at patient with acute leukemia. Pathophysiology of Haemostasis and Thrombosis 2010; 37 Supplement 1: A172.
75. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Haema, 5th Balkan day 2010; 1(3): 237-238.
76. Mitrovic M, Sretenovic A, Suvajdzic N, Antic D, Todorovic M, Dunic I, Vidovic A, Colovic N, Virijevic M, Durasinovic V, Elezovic I, Tomin D. Efficacy of PETHEMA LPA99 protocol: a single center experience. Haema, 5th Balkan day 2010; 1(3): 258.
77. Suvajdzic N, Cvetkovic Z, Antic D, Dunic I, Vidovic A, Colovic N, Mitrovic M, Virijevic M, Durasinovic V, Pavlovic A, Jankovic G, Elezovic I, Tomin D. Outcome of therapy-related acute myeloid leukemia (t-AML): a single center experience. Haema, 5th Balkan day 2010; 1(3): 258-259.
78. Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic N, Antic D, Bila J, Vidovic A, Milosevic-Jovcic N. Acquired von Willebrand syndrome in woman with monoclonal gammopathy. Thrombosis Research 2011; 127(Suppl.3): p S141.
79. Vidović A, Miodjević V, Tošić T, Jovanović S, Jovanović B, Tomin D, Mihaljević M. Bacterial epidemiology and susceptibility patterns among 127 febrile Neutropenic adult patients with the acute Leukemia. 12th International Symposium on febrile Neutropenia, 12- 13 March 2010, Luxembourg, P-0018.
80. Vidović A, Ljubičić J, Suvajdzic- Vuković N, Đunić I, Peruničić- Jovanović M, Đorđević V, Čolović N, Pavlović A, Čolović M. The importance of scoring system defining in the prognosis of patients with primary myelofibrosis. 15th Congress of the European Hematology Association, Spain, Barcelona, June 10-13, 2010, P1640.
81. Bila J, Leković D, Smiljanić M, Sretenović A, Anđelić B, Vidović A, Todorović M, Elezović I, Tomin D, Gotić M, Mihaljević B. The maintenance therapy with thalidomide in elderly patients with multiple myeloma. 15th Congress of the European Hematology Association, Spain, Barcelona, June 10-13, 2010, P1460.
82. Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic N, Antic D, Bila J, Vidovic A, Milosevic-Jovcic N. Hemostatic disorders associated with paraproteinaemia. Blood Transfusion 2011; 9 Supplement 3: s15-s16.
83. Djunic I, Elezovic I, Tomin D, Bila J, Antic D, Vidovic A, Suvajdzic-Vukovic N. Hemostatic abnormalities in monoclonal gammopathies. 16th International Meeting Danubian League against Thrombosis and Haemorrhagic Disorders, Timisoara, Abstract book, 2011: 43.
84. Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic , Bila J, Antic D, Vidovic A, Milosevic-Jovcic N. Causes of platelets dysfunction in multiple myeloma. Journal of Thrombosis and Haemostasis 2011; 9 Supplement 2: I-970.

85. Djunic I, Virijevic M, Djurasinovic V, Novkovic A, Colovic N, Kraguljac-Kurtovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. *Liječnički Vijesnik* 2011; 133 Supplement 4: 89-89.
86. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Suvajdzic-Vukovic N, Tomin D. Pretreatment risk factors and importance of comorbidity index for overall survival, complete remission and early death in patients with acute myeloid leukemia. *Liječnički Vijesnik* 2011; 133 Supplement 4: 108.
87. Virijevic M, Suvajdzic N, Djunic I, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Tomin D. FLAD-IDA as the salvage regime for relapsed and refractory acute leukemias. *Liječnički Vijesnik* 2011; 133 Supplement 4: 109.
88. Mitrovic M, Suvajdzic N, Bogdanovic A, Novkovic A, Kraguljac N, Sretenovic A, Antic D, Djunic I, Vidovic A, Colovic N, Virijevic M, Djurasinovic V, Elezovic I, Tomin D. Clinical outcome and prognosis related factor in acute promyelocytic leukemia patients treating with PETHMA LPA 099 protocol. . *Liječnički Vijesnik* 2011; 133 Supplement 4: 109-110.
89. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, Tomin D. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission and early death in patients with acute myeloid leukemia. *Haematologica* 2011; 96 Supplement 2: 254.
90. Djunic I, Suvajdzic-Vukovic N, Djurasinovic V, Vidovic A, Virijevic M, Novkovic A, Colovic N, Tomin D. Importance of pre-medication in decreasing the incidence of infusion-related reaction before use of amphotericin B colloidal dispersion in patients with acute leukemia. *Haematologica* 2011; 96 Supplement 2: 634.
91. Suvajdzic N, Vidovic A, Djunic I, Djurasinovic V, Antic D, Mitrovic M, Andjelic B, Elezovic I, Tomin D. Incidence of infusion-related reaction in premedicated patients receiving Amphocyl: a single center experience. *Haematologica* 2011; 96 Supplement 2: 635-636.
92. Vidovic A, Gligoric J, Djunic I, Tomin D, Perunicic-Jovanovic M, Djurasinovic V, Virijevic M, Mihaljevic B. T cell/histiocyte rich large B-cell lymphoma (THRLBCL): clinical characteristics, prognosis and management: a report on 17 cases. *Haematologica* 2011; 96 Supplement 2: 560.
93. Marković O, Marisavljević D, Mihaljević B, Čemerikić V, Peruničić- Jovanović M, Savić A, Todoriović M, Vidović A. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). *Haematologica* 2011; 96 Supplement 2:0373.
94. Bogunović M, Kraguljac- Kurtovic N, Bogdanović A, Peruničić M, Đorđević V, Lazarević V, Novaković V, Leković D, Čolović M, Janković G, Suvajdžić N, Gotić M, Vidović A, Tomin D, Elezović I, Mihaljević B. Mixed phenotype acute leukemia (MPAL) according to the WHO 2008 classification- report of 17 cases. *Haematologica* 2011; 96 Supplement 2:0562.
95. Vidovic A, Jankovic G, Tomin D, Mirkovic Z, Suvajdzic-Vukovic N, Djunic I, Perunicic-Jovanovic M, Kraguljac N, Colovic N, Bogdanovic A, Bila J. Leukemic transformation of the Philadelphia (bcr/abl) – negative myeloproliferative neoplasms. *Haematologica* 2011; 96 Supplement 2: 547.
96. Suvajdzic N, Cvetkovic Z, Djordjevic V, Kraguljac N, Stanisavljevic D, Mitrovic M, Virijevic M, Colovic M, Antic D, Djunic I, Vidovic A, Elezovic I, Tomin D. Outcome of therapy related acute myeloid leukemia – a single centre experience. *Haematologica* 2011; 96 Supplement 2:259-260.
97. Čolović N, Vidović A, Tomin D, Miljić P, Čolović R. Thrombotic complications in patients with adult immune thrombocytopenic purpura. 16th Congress of the International Society of Hematology. *Haematologica* 2011; 96 Supplement 2: 1655.
98. Bila J, Bodrožić J, Smiljanić M, Anđelić B, Antić D, Todorović M, Vidović A, Gotić M, Elezović I, Tomin D, Mihaljević B. The relevance of international staging system in multiple myeloma in the era of new treatment modalities. *Haematologica* 2011; 96 Supplement 2:1340.
99. Suvajdzic-Vukovic N, Zivkovic R, Pekmezovic T, Vidovic A, Djunic I, Elezovic I, Tomin D, Marisavljevic D, Markovic O. Health-related quality of life in adult patients with chronic immune thrombocytopenic purpura. *Haematologica* 2011; 96 Supplement 2: 329.
100. Suvajdzic-Vukovic N, Jovanovic J, Djunic I, Vidovic A, Novkovic A, Tomin D. Incidence of antiphospholipid antibodies and their significance in the patients with immune thrombocytopenic purpura. *Haematologica* 2011; 96 Supplement 2: 331.
101. Tosic N, Spasovski V, Suvajdzic N, Vidovic A, Djunic I, Tomin D, Elezovic I, Colovic N, Colovic M, Pavlovic S. The presence of NPM1 mutations as an unfavorable factor for overall survival and for achieving complete remission in acute myeloid leukemia (AML). *Haematologica* 2011; 96 Supplement 2: 470.
102. Colovic N, Tomin D, Vidovic A, Jankovic G, Suvajdzic N, Palibrk V, Djunic I, Djurasinovic V, Virijevic M, Kraguljac N, Djordjevic V. Primary resistant acute myeloid leukemia. *Haematologica* 2011; 96 Supplement 2: 471.
103. Mitrovic M, Suvajdzic N, Bogdanovic A, Novkovi A, Sretenovic A, Kraguljac N, Antic D, Djunic I, Vidovic A, Colovic N, Virijevic M, Djurasinovic V, Elezovic I, Tomin D. Efficacy of PETHMA LPA-99 protocol: a single center experience. *Haematologica* 2011; 96 Supplement 2: 474.
104. Djunic I, Elezovic I, Tomin D, Ilic V, Suvajdzic-Vukovic N, Bila J, Antic D, Vidovic A, Milosevic-Jovcic N. Disturbances of platelet adhesion in patients with multiple myeloma. *Haematologica* 2010; 95 Supplement 2: 1952.

105. Arsic V, Barac A, Ratkov E, Vidovic A, Suvajdzic-Vukovic N, Janic D. Screening for Mannan and anti-Candida antibodies in haematological patients suspected for developing invasive candidosis. *Mycoses*, 54: 90-91.
106. Ratkov E S, Vidovic A D, Dzamic A M, Mitrovic S, Arsic-Arsenijevic V S. Significance of early laboratory biomarkers for the survival of patients with haematological malignancies suspected for invasive aspergillosis, *Mycoses* 201; 55: 280-281 (Meeting Abstract)
107. Djunic I, Elezovic I V, Vucic M D, Srdic-Rajic T V, Konic-Ristic A I, Illic V, Milic N M, Bila J, Suvajdzic-Vukovic N D, Antic D A, Vidovic A D, Tomin D S. Paraprotein specific binding for platelet receptor glycoprotein Ib as a cause of acquired von Willebrand syndrome in monoclonal gammopathies, *Haemophilia* 2012; 18: 195-195 (Meeting Abstract)
108. Djunic I, Elezovic I V, Illic V Lj, Tomin D S, Bila J, Suvajdzic-Vukovic N D, Antic D A, Vidovic A D, Milosevic-Jovcic N. Platelets dysfunction in multiple myeloma, *Thrombosis Research* 2012; 129: S173-S173 (Meeting Abstract)
109. Djordjevic M, Vidovic A. D, Tomin D S, Mihaljevic B S, Juranic Z D, Ristic S, Grozdanic N Dj, Djordjic M J (2012) Humoral and cellular immunity to food antigens in patients with leukemia, *Immunology* 2012; 137: 214-214 (Meeting Abstract)
110. Djunic I, Virijevic M, Novkovic A, Suvajdzic-Vukovic N D, Elezovic I V, Miljic P S, Vidovic A D, Colovic N R, Tomin D S. Central venous catheter-related thrombosis in patients with acute leukemia, *Thrombosis Research* 2012; 130: S165-S165 (Meeting Abstract)
111. Matic I Z, Djordjevic M, Vidovic A D, Bila J, Ristic S, Mihaljevic B S, Tomin D S, Milanovic N, Ristic D J, Juranic Z D. DPPIV - Serum Activity and Expression on Lymphocytes in Different Hematological Malignancies, *European Journal Of Cancer* 2012; 48: S261-S261 (Meeting Abstract)
112. Djunic I, Jovanovic J, Suvajdzic-Vukovic N D, Bonaci-Nikolic B M, Novkovic A, Vidovic A D, Tomin D S (2013) Antiphospholipid antibodies: Incidence and implications in women with immune thrombocytopenic purpura, *Thrombosis Research* 2013; 131: S96-S96 (Meeting Abstract)
113. Mitrovic M, Suvajdzic N D, Elezovic I V, Bogdanovic A D, Djunic I, Colovic N R, Virijevic M, Vidovic A D, Tomin D S. Thrombotic events in acute promyelocytic leukemia - Single center experience, *Journal Of Thrombosis And Haemostasis* 2013, 11: 988-988 (Meeting Abstract)
114. Colovic N R, Suvajdzic N D, Kosanovic-Jakovic N G, Vidovic A D, Miljic PS, Djunic I, Mitrovic M, Virijevic M, Tomin D S (2013) Unusual thrombotic complications in patients with acute promyelocytic leukemia, *Journal Of Thrombosis And Haemostasis*, 2013; 11: 1021-1021 (Meeting Abstract)
115. Colovic N R, Djunic I, Suvajdzic N D, Vidovic A D, Miljic P S, Tomin D S, Colovic M D (2013) Thrombotic complications in patients with adult chronic immune thrombocytopenic purpura, *Journal Of Thrombosis And Haemostasis* 2013; 11: 1150-1150 (Meeting Abstract)
116. Mitrovic M, Suvajdzic N D, Elezovic I V, Bogdanovic A D, Djordjevic V J, Djunic I, Gvozdenov M, Colovic N R, Virijevic M, Vidovic A D, Tomin D S (2014) Risk Factors for Thrombosis in Acute Promyelocytic Leukemia, *Thrombosis Research* 2014; 133: S104-S105 (Meeting Abstract)
117. Virijevic M, Suvajdzic-Vukovic N, Djunic I, Tosic N, Novkovic A, Colovic N, Vidovic A, Pavlovic S, Tomin D. Adverse prognostic impact of IDH mutations on outcome in acute myeloid leukemia with normal karyotype. 19th Congress of the European Hematology Association, June 12-15, 2014. Milano, *Haematologica* 2014, 99 (s1):302-03. P824.
118. Virijevic M, Tomin D, Djunic I, Novkovic A, Vidovic A, Colovic N, Mitrovic M, Suvajdzic-Vukovic N. Prognostic impact of body mass index on acute myeloid leukemia outcome. 19th Congress of the European Hematology Association, June 12-15, 2014. Milano, *Haematologica* 2014, 99 (s1): 574. abs. PB1475.
119. Djunic I, Virijevic M, Tomin D, Novkovic A, Vidovic A, Suvajdzic-Vukovic N. Pretreatment risk score for prediction of early death after induction therapy in patients with newly diagnosed acute myeloid leukemia. 19th Congress of the European Hematology Association, June 12-15, 2014. Milano, *Haematologica* 2014, 99 (s1):28. P167.
120. Vidovic A, Virijevic M, Djunic I, Tomin D, Suvajdzic-Vukovic N, Novkovic A, Colovic N, Mitrovic M, Arsic Arsenijevic V, Pavlovic S, Mihaljevic B. Significance of febrile neutropenia score in patients with acute myeloid leukemia. 19th Congress of the European Hematology Association, June 12-15, 2014. Milano, *Haematologica* 2014, 99 (s1):574-75. abs. PB1478.
121. Mitrović M, Tosic N, Suvajdžić N, Djunić I, Vidović A, Virijević M, Čolović N, Kostic T, Glumac I, Pavlovic S, Elezović I, Tomin D. Adverse prognostic significance of Wilms tumor gene 1 overexpression in acute promyelocytic leukemia. 19th Congress of the European Hematology Association, June 12-15, 2014. Milano, *Haematologica* 2014, 99 (s1):575. abs. PB1479.
122. Čolović N, Arsic-Arsenijević V, Suvajdžić N, Djunić I, Virijević M, Vidović A, Tomin D. Favourable Outcome of Treatment of the Hepatosplenic Candidiasis in a Patient with Acute Leukaemia. The Importance of Serological Tests for the Timely Establishment of the Diagnosis and Beginning of the Antifungal Therapy. The 6th Eurasia Congress of Infectious Diseases. 24-27.09.2014, Beograd. P163.
123. Virijevic M, Djunic I, Suvajdzic-Vukovic N, Tosic N, Novkovic A, Mitrovic M, Colovic N, Vidovic A, Pavlovic S, Tomin D. Favorable prognostic impact of NPM1 mutation in elderly patients with normal karyotype acute myeloid leukemia. 20 th Congress of European hematology Association, Wien, june 11-14, 2015. *Haematologica* 2015, 100 (s1):369. PE 923.

124. Mitrović M, Suvajdzic N, Novkovic A, Djunic I, Vidovic A, Virijevic M, Colovic N, Elezovic I, Tomin D. Prognostic risk score for haemorrhagic early death in acute promyelocytic leukemia. 20 th Congress of European hematology Association, Wien, june 11-14, 2015. Haematologica 2015, 100 (s1):377. PE 940.
125. Djunic I, Suvajdzic-Vukovic N, Virijevic M, Kraguljac-Kurtovic N, Knezevic V, Mitrovic M, Novkovic A, Colovic N, Vidovic A, Tomin D. Central nervous system involvement at diagnosis in patients with acute myeloid leukemia: risk factors, treatment and outcome. 20th Congress of European hematology Association, Wien, june 11-14, 2015. Haematologica 2015, 100 (s1):378. PE 946.
126. Mitrović M, Tosic N, Suvajdzic N, Djunic I, Vidovic A, Virijevic M, Colovic N, Glumac I, Kostic T, Pavlovic S, Elezovic I, Tomin D. Prognostic impact of WT1 gene expression quantification during minimal residual disease monitoring of acute promyelocytic leukaemia. 20 th Congress of European hematology Association, Wien, june 11-14, 2015. Haematologica 2015, 100 (s1):375. Abs E 944.
127. Djunic I, Virijevic M, Suvajdzic-Vukovic N, Novkovic A, Mitrovic M, Colovic N, Vidovic A, Tomin D. Intensity of chemotherapy influencing an overall survival of patients with acute myeloid leukaemia older than 70 years. 20th Congress of European hematology Association, Wien, june 11-14, 2015. Haematologica 2015, 10 (s1):653. abs. PB1641.
128. Virijevic M, Tošić N, Djunić I, Karan-Djurasevic T, Glumac I, Mitrovic M, Colovic N, Novkovic A, Vidovic A, Suvajdzic-Vuković N, Pavlovic S, Tomin D. The isocitrate dehydrogenase 1 (IDH1) and IDH2 Mutations are Prognostic and Follow-Up Markers in Patients with Acute Myeloid Leukemia with Normal Karyotype (AML-NK), Leukemia & Lymphoma 2015, Dubrovnik, Croatia, P1005.
129. Djunic I, Suvajdzic-Vukovic N, Virijevic M, Kraguljac-Kurtovic N, Knezevic V, Mitrovic M, Novkovic A, Colovic N, Vidovic A, Tomin D. Central Nervous system involvement at diagnosis in patients with acute myeloid leukemia: risk factors, treatment and outcome, Leukemia & Lymphoma 2015, Dubrovnik, Croatia, P1004.
130. Virijevic M, Suvajdzic-Vukovic N, Djunic I, Tosic N, Novkovic A, Colovic N, Mitrovic M, Vidovic A, Pavlovic S, Tomin D. Favorable prognostic impact of NPM1 mutation in elderly patients with normal karyotype acute myeloid leukaemia. International conference on acute myeloid leukaemia „Molecular and translational“ advances in biology and treatment. Budapest, Hungary, september 10-12, 2015. P 74.
131. Djunic I, Virijevic M, Suvajdzic-Vukovic N, Novkovic A, Mitrovic M, Colovic N, Vidovic A, Tomin D. Correlation between expression of CD56 antigen on leukaemic cells and trisomy 8 in patients with acute myeloid leukaemia. International conference on acute myeloid leukaemia „Molecular and translational“ advances in biology and treatment. Budapest, Hungary, september 10-12, 2015. P17.
132. Mitrovic M, Tosic N, Suvajdzic-Vukovic N, Djunic I, Vidovic A, Virijevic M, Colovic N, Kostic T, Glumac I, Pavlovic S, Elesovic I, Tomin D. Adverse prognostic significance of Wilms tumor gene 1 overexpression in acute promyelocytic leukaemia. International conference on acute myeloid leukaemia „Molecular and translational“ advances in biology and treatment. Budapest, Hungary, september 10-12, 2015. P48.
133. Karan-Đurašević T, Glumac I, Tošić N, Spasovski V, Virijević M, Djunić I, Čolović N, Vidović A, Suvajdžić N, Tomin D, Pavlović S: WT1 expression at diagnosis and follow-up in Serbian acute myeloid leukemia patients with normal karyotype. 11th Balkan Congress of human genetics, Belgrade 17-19.09. 2015.
134. Virijevic M, Djunic I, Mitrovic M, Novkovic A, Suvajdzic-Vukovic N, Vidovic A, Tomin D. Applicability of the Patient's "Fitness" Criteria in Elderly AML in clinical practice. 21th EHA Congress, Copenhagen, Denmark, june 9-12 2016. Hematologica 2016; 101(s1): 677, abs.1656.
135. Djunic I, Virijevic M, Kraguljac-Kurtovic N, Knezevic V, DragovicIvancevic T, Novkovic A, Mitrovic M, Colovic N, Vidovic A, SuvajdzicVukovic N, Tomin D. Prognostic impact of CD20 expression in adults with Philadelphia chromosome negative precursor B-cell acute lymphoblastic leukemia. 21th EHA Congress, Copenhagen, Denmark, june 9-12 2016. Hematologica 2016; 101(s1): 660-661, abs.1609.
136. Vidovic A, Arsic Arsenijevic V, Virijevic M, Tomin D, Suvajdzic Vukovic N, Djunic I, Mitrovic M, Tojic P, Marinkovic D, Mihaljevic B. Invasive aspergillosis in patients with acute leukemias: prognostic value of laboratory biomarkers defining high risk patients. 21th EHA Congress, Copenhagen, Denmark, june 9-12 2016. Hematologica 2016; 101(s1): 487-488. P1179.
137. J. Peric, T. Karan Djurasevic, T. Kostic, I. Marjanovic, J. Lazic, M. Virijevic, N. Krstovski, L. Dokmanovic, D. Tomin, A. Vidovic, N. Suvajdzic Vukovic, D. Janic, S. Pavlovic, N. Tosic. Targeted mutational profiling of childhood and adult acute lymphoblastic leukemia patients. 22th EHA Congress, Madrid, Spain, june 22-25 2017. Hematologica 2017; 102(s1): 382. PB1612.
138. A. Vidovic, M. Virijevic, D. Tomin, N. Suvajdzic Vukovic, V. Milosevic, I. Djunic, M. Mitrovic, N. Colovic, N. Kraguljac Kurtovic, M. Perunicic Jovanovic, B. Mihaljevic. Clinical, cytomorphologic and immunopheno/immunohistochemical characteristics of patients with blastic plasmacytoid dendritic cell neoplasm-diagnostic and therapeutic dilemma. 22th EHA Congress, Madrid, Spain, june 22-25 2017. Hematologica 2017; 102(s1): 382. PB1704.
139. M. Virijevic, N. Suvajdzic-Vukovic, I. Djunic, M. Mitrovic, N. Tosic, A. Novkovic, A. Vidovic, D. Tomin. FTL3 positivity as the most significant risk factor for early relapsed and refractory acute myeloid leukemia. ESH 4th International Conference on Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, Estoril, Portugal October 5-7, 2017. P
140. Djunic I, Virijevic M, Barac A, Vidovic A, SuvajdzicVukovic N, Tomin D, Novkovic A, Arsic-Arsenijevic V. Epidemiology, diagnosis and treatment of invasive fungal disease in adult patients with acute leukemia: a 5-

- years experience in tertiary Serbian centre. 8th Trends in Medical Mycology, EORTC-IDG and ECMM, 6–9 October 2017 Belgrade, Serbia.
141. Vidović A, Virijević M, Tomin D, SuvajdzicVukovic N, Djunic I, Mitrovic M, Tojic P, Marinkovic D, Mihaljevic B, Arsic Arsenijevic V. Invasive aspegillosis in patients with acute leukemias: prognostic value of laboratory biomarkers defining high risk patients. 8th Trends in Medical Mycology, EORTC-IDG and ECMM, 6–9 October 2017 Belgrade, Serbia.
  142. Arsic-Arsenijevic V, S, Janic D, M, Minic P B, Vidović A D, Vukovic N S, Otasevic S A (2017) Proven emerging, rare and mixed fungal infections and outbreaks in Serbia: National reference medical mycology laboratory experience of ten years, MYCOSES, vol. 60, br. , str. 128-128 (Meeting Abstract)
  143. Vidović A, Tomin D, Djunic I, Arsic Arsenijevic V. Proven pulmonary mucomycosis with acute myeloblastic leukemia and positive anti-Aspergillus? Antibodies and galactomannan –double moulds infection or cross reactivity? . 8th Trends in Medical Mycology, EORTC-IDG and ECMM, 6–9 October 2017 Belgrade, Serbia. P263.
  144. Sabljic N, Mitrović M, Kočica T, Virijevuić M, Pravdić Z, Rajić J, Milošević V, Vidović A, Suvajdžić N, Tomin D. The role of rotem in predicting hemorrhage and ghaemorrhagic early death risk in patients with acute promylocytic leukemia. 24th Congress of the European Hematology Association, Amsterdam, The Netherlands, June 13-16, 2019, Educational Updates in hematology Bool, PB1734.
  145. Virijević M, Mitrović M, Sabljic N, Pravdić Z, Rajić J, Kraguljac N, Knežević V, Milošević V, Vidović A, Suvajdžić-Vuković N, Tomin D. Prognostic factors for survival in adult with acute lymphoblastic leukemia-single center experience. International conference Acute lymphoblastic leukemia, Berlin, Germany, May 17-19, 2019, p59.

#### **Izvod u zborniku nacionalnog skupa**

1. Suvajdžić N., Vidović-Marić A., Vezmar M., Janković G., Petrović M: "Terapija komponentama krvi u lečenju bolesnika sa akutnom leukemijom tretiranih citostatskim protokolima LALA 87 i 01 AM 86". VI Kongres hematologa i transfuziologa jugoslavije sa međunarodnim učešćem, Zagreb 1990, abstract 06-17.
2. Vidović A., Jovanović V, Basara N, Novak A., Janković G., Čolović M: "Hronična mijeloproliferativna bolest sa eozinofilijom". Bilten za Hematologiju, 1994, 22: 74, abstract 13-7.
3. Elezović I., Matijević-Aleksić N., Čolović M., Bošković D, Mijović A., Tomin D, Suvajdžić N, Vidović A., Rolović Z: "Poremećaji hemostaze u akutnim leukemijama." Osnivački Kongres hematologa Jugoslavije, Beograd, 27-29. oktobar, 1994, abstract 16-2, str. 86.
4. Elezović I., Matijević-Aleksić N., Čolović M, Bošković D, Tomin D, Mijović A, Suvajdžić N, Vidović A., Rolović Z: "Diseminovana intravaskularna koagulacija u akutnoj leukemiji." Osnivački Kongres hematologa Jugoslavije, Beograd 27-29 oktobar 1994, abstrakt 16-4, str. 87.
5. Vidović A., Jovanović V, Suvajdžić N, Čolović M: "Agnogena mijeloidna metaplazija: korelacija histomorfometrijskog nalaza kostne srži sa laboratorijskim prametrima periferne krvi i veličinom slezine". Jugoslovenski hematološki dani sa međunarodnim učešćem, Niš, 10-12 oktobar, 1996, 80-81.
6. Elezović I., Čolović M., Bošković D, Miljić, Vidović A., Bila J, Rolović Z: "Diseminovana intravaskularna koagulacija kod bolesnika sa akutnom promijelocitnom leukemijom u toku lečenja all-trans retinoičnom kiselinom". Jugoslovenski hematološki dani sa međunarodnim učešćem, Niš, 10-12 oktobar, 1996, 126-7.
7. Pantić M., Pendić V, Elezović I., Vidović A., Čolović M., Novak A: Citogenetska analiza u dijagnostici akutne promijelocitne leukemije". Jugoslovenski hematološki dani sam međunarodnim učešće, Niš, 10-12 oktobar, 1996, 52-3.
8. Ilić V, Milošević-Jovčić N, Čolović M., Suvajdžić N, Vidović A. "Protein pattern changes in multiple myeloma peripheral blood mononuclear cells." In the Scientific meeting of Yugoslav Immunologists, Belgrade, Yugoslavia, 25 - 27 sept, 1997, abstract 97-O/P.
9. Vidović A., Šefer D, Jovanović V, M. Čolović. "Cirkulirajući progenitori hematopoeze u bolesnika sa primarnom osteomijelofibrozmom". Bilten za hematologiju, 8. Kongres Hematologa Jugoslavije sa međunarodnim učešćem, Herceg Novi, septembar 1998, 26(2/3), US 55.
10. Vidović A., Vulović V, Čolović R, Janković G, Čolović M. "Splenektomija u bolesnika sa hroničnom limfocitnom leukemijom". 8. Kongres hematologa Jugoslavije, Herceg Novi 1998. Bilt Hematol 1998; 26 (2/3): US66.
11. Terzić T, Boričić I, Vidović A., Stojanović R, Radojević S, Basta-Jovanović G, Sopta J, Nenadović M, Tatić S, Shahgoli B. "Autoimmune myelofibrosis associated with juvenile Sjögren's syndrome. A case report". Archive of Oncology, Vol 10, Suppl 1, 10th Yugoslav Congress with International participation, Tara, Serbia, Yugoslavia, 24-28 September, 2002; abstract No 153
12. Bila J, Elezović I, Tomin D, Vidović A., Gotić M, Bošković D. "Morbus Waldenström: kliničko-biološke karakteristike obolelih i mogući prognostički faktori". Bilten za hematologiju, 9. Kongres hematologa Jugoslavije, Beograd, Oktobar 2002, 30(1;2/3): PP51.
13. Denčić M, Novak A, Jovanović J, Đorđević V, Vidović A., Lazarević V, Antić D, Verbić V, Bižić S, Mijailović S, Bogdanović A, Kraguljac N, Gotić M. "Delecija dugog kraka hromozama 5 u malignim hemopatijama". Bilten za hematologiju, 9. Kongres hematologa Jugoslavije, Beograd, Oktobar 2002, 30(1;2/3): PP31.
14. Vidović A., Janković G, Čolović M, Lazarević V, Tomin D, Antić D, Kraguljac N, Čemerikić V, Denčić M, Milić N, Bošković D. "Imunofenotipske i citogenetske karakteristike blastne kroze hronične granulocitne

- leukemije“. Bilten za hematologiju, 9. Kongres hematologa Jugoslavije, Beograd, Oktobar 2002, 30(1;2/3): US26.
15. Antić D, Jaković LJ, Tomin D, Čemerikić-Martinović V, Vidović A, Milivojević G, Suvajdžić N, Lazarević V, Bogdanović A, Sretenović M, Milić N, Bošković D. “Kliničke, hematološke i laboratorijske karakteristike bolesnika sa metastazama tumora u kostnoj srži“. Bilten za hematologiju, 9. Kongres hematologa Jugoslavije, Beograd, Oktobar 2002, 30(1;2/3): US64.
  16. Vidović A, Tomin D, Janković S, Jančić-Nedeljkov R, Suvajdžić N, Bila J, Čemerikić V, Petrović M. “T-ćelijama bogat B-ćelijski limfom-kliničko pataološka studija 11 pacijenata“. Bilten za hematologiju, 9. Kongres hematologa Jugoslavije, Beograd, Oktobar 2002, 30(1;2/3): US31.
  17. Bakrač M, Peruničić-Jovanović M, Vidović A, Petrović M, Elezović I, Tomin D, Čolović M, Bošković D. “Ekspresija proliferativnih i apoptotskih antigena u novodijagnostikovanih bolesnika sa recidivom akutne limfoblastne leukemije“. Bilten za hematologiju, XII Hematološki dani, Beograd, Oktobar 2004, 32(1/2), US08.
  18. Marković O, Marisavljević D, Čemerikić V, Peruničić M, Vidović A, Bakrač M, Suvajdžić N, Čolović M. “Biološki i klinički značaj ekspresije ciklina D1 kod bolesnika sa novootkrivenim multiplim mijelomom“. Bilten za hematologiju, XII Hematološki dani, Beograd, Oktobar 2004, 32(1/2), PP19.
  19. Đunić I, Vidović A, Čemerikić-Martinović V, Peruničić M, Antić D, Janković G, Tomin D, Bošković D. „Kutana infiltracija kao indikator loše prognoze kod bolesnika sa anaplastičnim Ki-1 limfomom-prikaz slučaja“. Bilten za hematologiju, XII Hematološki dani, Beograd, Oktobar 2004, 32(1/2), PP25.
  20. Antić D, Tomin D, Čemerikić-Martinović V, Mihaljević B, Janković G, Vidović A, Đunić I, Babić D, Bošković D. „Tumor supresor geni p53 i Rb kao prognostički faktori kod bolesnika sa morbus Hodgkin“. Bilten za hematologiju, XII Hematološki dani, Beograd, Oktobar 2004, 32(1/2), pp22.
  21. Marković, D. Marisavljević, V. Čemerikić, Vidović A, Bakrač M, Peruničić M, Suvajdžić N, Čolović M. „Proliferativna aktivnost mijelomskih ćelija merena antitelom Ki-67; biološki i klinički značaj“. Bilten za hematologiju, XII Hematološki dani, Beograd, Oktobar 2004, 32(1/2); US12.
  22. Antić D, Tomin D, Čemerikić-Martinović V, Mihaljević B, Janković G, Vidović A, Đunić I, Babić D, Bošković D. Tumor supresor geni p53 i Rb kao prognostički faktori kod bolesnika sa Morbus Hodgkin. Bilten za hematologiju 2004; 32 (1/2):P22.
  23. Đunić I, Tomin D, Antonijević N, Kovač M, Janković G, Vidović A, Elezović I. Dijagnostikovanje i lečenje heparin-indukovane trombocitopenije: prikaz slučaja. Bilten za hematologiju 2007; 35 (3): 121.
  24. Đunić I, Elezović I, Milošević-Jovčić N, Ilić V, Suvajdžić N, Bila J, Vidović A, Tomin D. Uticaj paraproteina na agregaciju trombocita. Bilten za hematologiju 2007; 35 (3): 121.
  25. Vidović A, Janković G, Čolović M, Tomin D, Peruničić M, Bila J, Đunić I, Bošković D. Ekspresija proto-onkogeni u evoluciji hronične granulocitne leukemije. Bilten za hematologiju 2007; 35 (3): 72.
  26. Đurašinović V, Tomin D, Salemović D, Đunić I, Vidović A, Janković G. Bicitopenija u akutnom HIV sindromu: prikaz slučaja. Bilten za hematologiju 2007; 35 (3): 154.
  27. Djunic I, Elezovic I, Ilic V, Tomin D, Suvajdzic-Vukovic N, .Antic D, Bila J, Vidovic A, Milosevic-Jovcic N: “Acquired von Willebrand syndrome in monoclonal gammopathies”, Bilt Transf 2010;56(1-2):168. Kongres transfuziologa Srbije, Beograd, 10-12 Novembar, Abstract No2B.
  28. Đunić I, Virijeвиć M, Novković A, Đurašinović V, Čolović N, Vidović A, Suvajdžić-Vuković N, Tomin D. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission and early death in patients with acute myeloid leukemia. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 92.
  29. Djunić I, Virijeвиć M, Đurašinović V, Novković A, Čolović N, Kraguljac-Kurtoović N, Vidović A, Suvajdžić-Vuković N, Tomin D. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 105.
  30. Đurašinović V, Tomin D, Suvajdžić-Vuković N, Vidović A, Đunić I, Virijeвиć M, Čolović N, Anđelić B, Elezović I, Mihaljević B. Invasive fungal infection in hematological malignancies. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 105.
  31. Đunić I, Elezović I, Ilić V, Tomin D, Suvajdžić-Vuković N, Bila J, Antić D, Vidović A, Milošević-Jovčić N. Stečeni von Willebrandov sindrom kod bolesnika sa multiplim mijelomom. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 116.
  32. Đunić I, Elezović I, Marinković M, Suvajdžić-Vuković N, Tomin D, Janković G, Bila J, Antić D, Vidović A, Nešković B, Nikolić-Vukosavljević D. Markeri osteolize u multiplom mijelomu. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 158.
  33. Vidović A, Gligorić J, Đunić I, Tomin D, Peruničić-Jovanović M, Virijeвиć M, Đurašinović V, Mihaljević B. T ćelijama/histiocitima bogat krupnoćelijski B limfom (THRLBC): kliničke karakteristike, prognoza i terapija: prikaz 17 bolesnika. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 182.
  34. Virijeвиć M, Todorović M, Anđelić B, Đunić I, Novković A, Vidović A, Suvajdžić-Vuković N, Tomin D, Mihaljević B. Independent prognostic factors in patients with mucosa-associated lymphoid tissue non-Hodgkin lymphoma. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 182.
  35. Mitrović M, Suvajdžić N, Elezović I, Bogdanović A, Antić D, Đunić I, Sretenović A, Vidović A, Bogunović M, Kraguljac N, Đorđević V, Čolović N, Virijeвиć M, Đurašinović V, Tomin D. All-trans retinoic acid in the

- treatment of acute promyelocytic leukemia – 20 years of single center experience. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 95.
36. Cvetković Z, Suvajdžić N, Đorđević V, Kraguljac N, Stanisavljević D, Bogdanović A, Đunić I, Čolović N, Vidović A, Elezović I, Tomin D. Prognostic factors for therapy related acute myeloid leukemia (t-AML) – a single centre experience. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 103.
  37. Čolović N, Tomin D, Vidović A, Suvajdžić N, Janković G, Palibrk V, Đunić I, Đurašinović V, Virijević M. Prognostic factors for overall survival in primary resistant acute myeloid leukemia. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 104.
  38. Tošić N, Spasovski V, Kostić T, Karan-Đurašević T, Nikčević G, Čolović N, Suvajdžić N, Vidović A, Đunić I, Tomin D, Elezović I, Virijević M, Čolović M, Pavlović S. The frequency of nucleophosmin gene mutations and their prognostic significance in acute myeloid leukemia patients. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 112.
  39. Virijević M, Tomin D, Vidović A, Đunić I, Đurašinović V, Čolović N, Suvajdžić-Vuković N. Tuberoznosklerozni kompleks i akutna leukemija: prikaz slučaja. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 113.
  40. Suvajdžić N, Živković R, Pekmezović T, Vidović A, Đunić I, Elezović I, Tomin D. Health-related quality of life (HRQoL) in adult patients with chronic thrombocytopenic purpura. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 131.
  41. Vidović A, Janković G, Čolović M, Tomin D, Peruničić-Jovanović M, Đunić I, Bila J, Marković O. The proto-oncogene expression varies over the course of chronic myeloid leukemia. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 149.
  42. Vidović A, Janković G, Tomin D, Mirković Z, Suvajdžić-Vuković N, Đunić I, Peruničić-Jovanović M, Kraguljac N, Čolović N, Bogdanović A, Bila J. Leukemic transformation of the Philadelphia (bcr/abl) – negative myeloproliferative neoplasms. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 155.
  43. Antić D, Elezović I, Peruničić-Jovanović M, Suvajdžić N, Todorović M, Bila J, Vidović A, Sretenović M, Đunić I, Mitrović M, Tomin D. Isolated myeloid sarcoma – single centre experience. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 197.
  44. Knežević V, Kraguljac-Kurtović N, Dragović-Ivančević T, Bogdanović A, Jovanović J, Tomin D, Suvajdžić-Vuković N, Vidović A, Todorović M, Gotić M. Imunofenotipski profil B Akutne limfoblastne leukemije. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011: 035.
  45. Kraguljac-Kurtović N, Knežević V, Dragović-Ivančević T, Bogdanović A, Peruničić-Jovanović V, Jovanović J, Suvajdžić-Vuković N, Tomin D, Vidović A, Bogunović M, Gotić M. Akutne leukemije mešovitih linije: imunofenotipske karakteristike glavnih varijanti. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:036.
  46. Mioljević V, Vidović A, Tomin D, Bila J, Suvajdžić N, Mihaljević B, Tošić T, Jovanović S. The causes of Hospital-acquired infections at the Clinic of Hematology CCS in 2010. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:038.
  47. Stanisavljević N, Mihaljević B, Čolović M, Suvajdžić N, Vidović A, Tomin D. Prognostički faktori akutne mijeloblastne leukemije kod starijih osoba. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:041.
  48. Jovanović J, Đorđević V, Denčić-Fekete M, Vidović A, Bogunović M, Todorčić-Živanović B, Gotić M. Filadelfija hromozom u transformaciji mijelodisplastičnog sindroma-prikaz slučaja. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:116.
  49. Bogunović M, Kraguljac- Kurtovic N, Bogdanović A, Peruničić M, Đorđević V, Lazarević V, Vidović A, Suvajdžić N, Čolović M, Janković G, Gotić M, Tomin D, Elezović I, Mihaljević B. Mixed phenotype acute leukemia (MPAL) according to the WHO 2008 classification- report of 18 cases. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:026.
  50. Bila J, Bodrožić J, Smiljanić M, Leković D, Antić D, Janković S, Milićević S, Todorović M, Vidović A, Bogdanović A, Gotić M, Tomin D, Elezović I, Mihaljević B. Multipli mijelom- neizlečivi malignitet ili hronično stanje: rezultati dvadesetogodišnjeg praćenja u Klinici za hematologiju KCS. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:127.
  51. Bila J, Bodrožić J, Smiljanić M, Bogunović M, Anđelić B, Antić D, Janković S, Milićević S, Todorović M, Vidović A, Bogdanović A, Gotić M, Tomin D, Mihaljević B. Bortezomib u multiplom mijelomu: rezultati lečenja bolesnika u recidivu. 2 Kongers Hematologa Srbije, 6th Balcan Day of Hematology, Beograd, Abstract book 2011:128.
  52. Vidović A, Tomin D, Suvajdžić-Vuković N, Čolović N, Đunić I, Barać A, Đurašinović V, Virijević M, Lazić Lj, Mihaljević B, Arsić-Arsenijević V. Invazivna zigomikoza pluća kod bolesnika sa akutnom mijeloblastnom leukemijom-prikaz bolesnika-. 3. Simpozijum dijagnoza i terapija gljivičnih oboljenja, Beograd, 01-02 mart 2012:22.
  53. Đunić I, Suvajdžić-Vuković N, Arsić-Arsenijević V, Virijević M, Novković A, Đurašinović V, Vidović A, Tomin D. Značaj premedikacije u smanjenju infuzionih reakcija u toku primene koloidne disperzije Amphotericina B kod bolesnika sa akutnom leukemijom. 3. Simpozijum dijagnoza i terapija gljivičnih oboljenja, Beograd, 2012: 20.

54. Virijević M, Suvajdžić-Vuković N, Djunić I, Tošić N, Mitrović M, Novković A, Čolović N, Vidović A, S Pavlović, D Tomin. Prognostički značaj IDH mutacija u akutnoj mijeloidnoj leukemiji sa normalnim kariotipom. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015:112. P04.
55. Virijević M, Djunić I, Suvajdžić-Vuković N, Novković A, Tošić N, Mitrović M, Čolović N, Vidović A, S Pavlović, D Tomin. Povoljan prognostički značaj NPM1 mutacije kod starijih pacijenata sa akutnom mijeloidnom leukemijom sa normalnim kariotipom. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 133. P07.
56. Mitrović M, Suvajdžić-Vuković N, Novković A, Djunić I, Vidović A, Virijević M, Čolović N, Elezović I, Tomin D. Prediktivni skor za hemoragijsku ranu smrt u akutnoj promijelocitnoj leukemiji, 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 113. P06.
57. Kraguljac-Kurtović N, Knežević V, Dragović-Ivančević T, Bogdanović A, Suvajdžić-Vuković N, Novković A, Djunić I, Virijević M, Mitrović M, Čolović N, Mitrović-Ajtić O, Vidović A, Tomin D, Suvajdžić-Vuković N. Uloga protočne citometrije u detekciji minimalne rezidualne bolesti u akutnoj mijeloidnoj leukemiji, 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 114. P08.
58. Djunić I, Virijević M, Suvajdžić-Vuković N, Novković A, Mitrović M, Čolović N, Vidović A, Tomin D. Korelacija ekspresije CD56 antigena na leukemijskim ćelijama i trizomije 8 kod bolesnika sa akutnom mijeloidnom leukemijom. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 130. P01.
59. Djunić I, Virijević M, Suvajdžić-Vuković N, N.Kraguljac-Kurtović, V.Knežević, Novković A, M.Mitrović, Čolović N, Vidović A, D Tomin. CNS leukemija kod bolesnika akutnom mijeloidnom leukemijom. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 130. P02.
60. Karan-Durašević T, Glumac I, Tošić N, Spasovski V, Virijević M, Đunić I, Čolović N, Vidović A, Suvajdžić-Vuković N, Tomin D, Pavlović S. Kvantitativno određivanje nivoa ekspresije WT1 gena kod obolelih od akutne mijeloidne leukemije normalnog kariotipa. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 131. P04.
61. Čolović N, Arsić-Arsenijević V, Tomin D, Vidović A, Suvajdžić N, Virijević M, Đunić I. Mukormikoza sinusa kod pacijenta sa akutnom mijeloidnom leukemijom. 3. Kongres hematologa Srbije, Kragujevac, Abstract book 2015: 134. P09.
62. Čolović N, Tomin D, Vidović A, Suvajdžić N, Đunić I, Virijević M, Grubor N. Indukciono lečenje akutne mijeloidne leukemije protokolom 3+7 i neutropenijski enterokolitis kao komplikacija lečenja. 3. Kongres hematologa Srbije, Kragujevac, Abstract book, 2015: 134. P11.
63. Čolović N, Suvajdžić N, Vidović A, Đunić I, Mitrović M, Virijević M, Tomin D. Tromboza leve hepatične vene kao komplikacija lečenja akutne promijelocitne leukemije. 3. Kongres hematologa Srbije, Kragujevac, Abstract book, 2015: 135. P12.
64. Čolović N, Tomin D, Vidović A, Suvajdžić N, Đunić I, Virijević M. Prognozni faktori ukupnog preživljavanja kod primarno rezistentnih akutnih mijeloidnih leukemija. 3. Kongres hematologa Srbije, Kragujevac, Abstract book, 2015: 135. P15.

#### **Monografije, knjige**

1. Vidović A, Krstić A: Pacijenti sa digestivnim malignitetom-rano otkrivanje flebotromboza donjih ekstremiteta.Zadužbina Andrejević, Beograd, 2019. (recenzenti:Prof.dr Živan Maksimović, Prof.dr Dragan Čanović, prof.dr Dragče Radovanović).

#### **Poglavlja u udžbenicima:**

1. Vidović A: Periferni T-ćelijski limfomi U: Klinička hematologija, Zavod za udžbenike i nastavna sredstva, Beograd 2012, 553-563

#### **Poglavlja u knjigama**

1. Vidović A: Slezina u mijeloproliferativnim bolestima U:Čolović M i Čolović R. Slezina, Zavod za udžbenike i nastavna sredstva, Beograd, 1996, 119-36.
2. Vidović A: Hipohromna anemija U: Mihaljević B i Stojimirović B. Anemije, Libri Medicorum, Beograd, 2007, 37-44.
3. Vidović A: Terapija invazivnih gljivičnih infekcija u hematoloških bolesnika U: Invazivne gljivične infekcije u humanojoj populaciji, Akademija medicinskih nauka Srpskog lekarskog društva, Beograd, 2009, 113-122.

#### **b) Rukovođenje ili učešće u projektima**

- Saradnik na projektu Ministarstva prosvete i tehnološkog razvoja RS, Broj projekta OI 175034, rukovodilac Prof dr Valentina Arsić-Arsenijević, za period 2011-2014, i od 2014 – do daljeg
- Saradnik na projektu Ministarstva prosvete i tehnološkog razvoja RS, Broj projekta III 41004, rukovodilac podprojekta Prof dr Nada Suvajdžić-Vuković, za period 2011-2014.godina i od 2014-2018.

#### **c) Citiranost**

Citiranost radova prof dr Ane Vidović je oko 348, uz h indeks 10 prema SCOPUS bazi podataka

#### **d) Organizovanje naučnih sastanaka i simpozijuma**

- Kurs o Febrilnim neutropenijama , 10. maj 2010, Svečana sala Dekanata Medicinskog fakulteta Univerziteta u Beogradu
- Organizator i jedan od predavača na Simpozijumu, pod nazivom “Novine u dijagnostici i terapiji Akutne promijelocitne leukemije“, sa temom, “ Diferencijacioni sindrom – kako ga prepoznati i lečiti ”, 20. Maj 2016, Beograd, Srbija.
- Organizator i jedan od predavača na Simpozijumu, pod nazivom “Trendovi u dijagnostici i terapiji akutnih leukemija“, sa temom “Novine u dijagnostici i terapiji Akutne mijeloblastne leukemije”; 22.decembar 2017, Beograd, Srbija.
- Organizovala je značajan stručni sastanak novembra 2015. godine, kada je predavanje po pozivu održao Prof.dr Mohamad Mohtij, direktor klinike iz Pariza, tadašnji predsednik mnogih međunarodnih hematoloških organizacija, posebno EBMT (European Association of Bone marrow transplantation) i njegovog promovisanja u zvanje viziting profesora Medicinskog fakulteta Univerziteta u Beogradu.

#### **F. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Dr Ana Vidović je objavila i priložila spisak od 273 rada i 3 poglavlja u knjigama i udžbenicima, i 1. monografiju, sa kumulativnim impakt faktorom 62,155. Ukupno je objavila 66 radova u celosti, od tog broja prvi autor je u 15 radova. U časopisima sa JCR liste je objavljeno 44 rada. Autor i koautor je poglavlja “Hipohromna anemija” u monografiji «Anemije» ed. Biljana Mihaljević, Biljana Stojimirović, kao udžbenika za poslediplomsku nastavu iz hematologije. Takođe, autor je poglavlja: “Periferni T-ćelijski limfomi” u Klinička hematologija, kao udžbenika za poslediplomsku nastavu iz hematologije. Autor je i poglavlja: “Slezina u mijeloproliferativnim bolestima” u monografiji Slezina. Autor je monografije, sa Dr. Krstić Aleksandrom, pod nazivom “Pacijenti sa digestivnim malignitetom-rano otkrivanje flebotromboza donjih ekstremiteta.”

Dugogodišnji rad iz oblasti biologije akutnih leukemija, te dijagnostičkog i terapijskog pristupa ovim bolesnicima, rezultovalo je započinjanju i daljem razvijanju suportivne terapije kod ovih bolesnika. To je podrazumevalo sagledavanje značaja prevencije i lečenja svih komplikacija hemioterapijskog lečenja bolesnika sa akutnim leukemijama, pre svega razvoja febrilnih neutropenija, izazvanih kako bakterijskim, tako i invazivnim gljivičnim infekcijama. Dr Ana Vidović, u saradnji sa timom sa lečenje akutnih leukemija na Klinici za hematologiju , posebno sa kliničkim farmakologom dr Dijanom Šefer, je sačinila 2011.godine, Vodič za suportivnu terapiju bolesnika sa hematološkim malignitetima, podržan od strane Aktiva za Akutne leukemije, pri Hematološkoj Sekciji Srpskog lekarskog društva, čiji je osnivač i Predsednik. Pomenuti vodič, koji sadrži prevenciju i lečenje Mukozitisa, Febrilnih neutropenija, neuzeje i povraćanja i Bola, je do sada abdejtovan dva puta 2013. i 2015.godine. Novo izdanje ovog Vodiča, sa pridodatim poglavljem o Sepsu (autor Doc dr Jelena Veličković) je izdala marta 2020 godine.

Time su u svakodnevnu stručnu praksu dijagnostike i lečenja bolesnika sa Akutnim leukemijama na Klinici za Hematologiju KCS uvedeni najsavremeniji stavovi u lečenju bolesnika sa hematološkim malignitetima.

#### **G. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

Dr Ana Vidović aktivno učestvuje u svim oblicima: 1) Dodiplomske nastave (interna medicina-redovna nastava; mentorstvo brojnih studentkih radova; i spiti iz predmeta Interna medicina; mentorstva i brojna učešća u komisijama za diplomski ispit); 2) Poslediplomske nastave na Medicinskom fakultetu (praktična i teorijska nastava u okviru užih specijalizacija iz hematologije, urgentne medicine i palijativne medicine; brojna mentorstva u okviru uže specijalizacije iz hematologije; kao i 3) U okviru organizacije i učešća u programima kontinuirane medicinske edukacije.

Dugogodišnji rad dr Ane Vidović na poljima dijagnostike i lečenja akutnih leukemija je uslovio i organizovanje velikog broja predavanja, simpozijuma i okruglih stolova posvećenih dijagnostici i lečenju bolesnika sa akutnim leukemijama, kao i prevenciji i lečenju bakterijskih i gljivičnih infekcija kod imunokompromitovanih bolesnika (navedenih prethodno).

#### **IZBORNI USLOVI ZA IZBOR U ZVANJE REDOVNOG PROFESORA**

**ZA STRUČNO- PROFESIONALNI DOPRINOS:**

***Angažovanost u sprovođenju složenih dijagnostičkih, terapijskih i preventivnih procedura***

***Broj i složenost složenih, dijagnostičkih, terapijskih i preventivnih procedura koje je kandidat uveo, ili je učestvovao u njihovom izvođenju***

Dr Ana Vidović je Načelnik Odeljenja Akutne leukemije 2.

1. U skladu sa intenzivnom hemioterapijom, koja se primenjuje u lečenju bolesnika sa akutnim leukemijama i sledstvom dugotrajnim jatrogenim aplazijama, dr Ana Vidović je postavila osnove principa suportivne terapije kod ovih bolesnika. Sa kliničkim farmakologom dr Dijanom Šefer je napisala Vodič Suportivne terapije za prevenciju i lečenje najvažnijih komplikacija kod bolesnika sa akutnim leukemijama: za mukozitis, mučninu i povraćanje, bol i za febrilne neutropenije 2011, a zatim su abdejtovani 2013. i 2015.godine (u skladu sa preporukama ESMO i NCCN vodiča).

Novo izdanje je štampano 2020.godine, sa pridodatim poglavljem o Sepsu (autor Doc dr Jelena Veličković). Takođe je jedan od autora vodiča za primenu hemioterapijskih protokola u lečenju malignih hemopatija, pre svega akutnih leukemija (mijeloblastne i limfoblastne).

2. Posebno se posvetila izučavanju invazivnih gljivičnih infekcija, u saradnji sa prof. dr Valentinom Arsić Arsenijević kod hematoloških bolesnika, što je rezultovalo većim brojem poziva za predavanja iz ove oblasti

3. Od 2010 do 2016 je rukovodila stručnim skupovima Klinike za hemtologiju pod nazivom Stručni seminari, koji je podrazumevao organizaciju i moderatorstvo nad prezentacijama kolega hematologa, ali i kolega iz drugih medicinskih specijalnosti ili užih specijalnosti Interne medicine. Veliki broj tih sastanaka je bio akreditovan bodovima KME.

***Broj organizovanih i održanih programa kontinuirane medicinske edukacije na Fakultetu koji nisu ocenjeni ocenom manjom od 3,75 od strane polaznika***

Kurs o Febrilnim neutropenijama , 10. maj 2010, Svečana sala Dekanata Medicinskog fakulteta Univerziteta u Beogradu

**ZA DOPRINOS AKADEMSKOJ I ŠIROJ ZAJEDNICI:**

***Predsedavanje nacionalnim ili međunarodnim strukovnim ili naučnim organizacijama***

Bila je sekretar hematološke sekcije Srpskog lekarskog društva, u periodu od 2004. do 2008.godine.

Pokrenula je inicijativu 2015. godine za osnivanje Aktiva za Akutne leukemije pri Hematološkoj sekciji Srpskog lekarskog društva, a na osnivačkom sastanku pomenutog Aktiva 2013.godine je izabrana za predsednika istog.

Na Četvrtom Kongresu Hematologa Srbije održanom u Nišu, od 17-20.oktobra 2019. godine je izabrana za Predsednika Hematološke Sekcije Srpskog lekarskog društva.

***Rukovođenje ili angažovanje u nacionalnim ili međunarodnim naučnim ili stručnim organizacijama***

Član je: Evropskog udruženja Hematologa (EHA), Predsednik Hematološke sekcije Srpskog lekarskog društva, Član Multinacionalne asocijacije za suportivnu terapiju kod obolelih od kancera (MASCC).

***Rukovođenje ili angažovanje u nacionalnim ili međunarodnim institucijama od javnog značaja***

Načelnik Odeljenja Akutne leukemije 2, na Klinici za Hematologiju, KCS

Član Republičke stručne komisije za hematologiju u Ministarstvu zdravlja RS

**ZA SARADNJU SA DRUGIM VISOKOŠKOLSKIM, NAUČNO-ISTRAŽIVAČKIM USTANOVAMA U ZEMLJI I INOSTRANSTVU-MOBILNOST:**

***Predavanja po pozivu ili plenarna predavanja na domaćim akreditovanim skupovima***

- Predavanje o Invazivnim gljivičnim infekcijama odraslih, u oorganizaciji Mikološkog društva Srbije, 2016.
- Kao predavač po pozivu na Simpozijumu CEEA 3: Intenzivno lečenje, urgentna medicina i transfuzija, 09.mart - 12.mart, 2017, Hotel Grand, Kopaonik, sa temom:”Invazivne gljivične infekcije kod imunokompromitovanih bolesnika”
- Vidović A :” Lečenje invazivnih gljivičnih infekcija kod hematoloških bolesnika”, “Nacionalni MSD simpozijum”, Beli Dvor, 17. oktobar 2018.
- Vidović A :”Klinička sumnja na gljivične infekcije kod neutropeničnih bolesnika”. Pfizer, Ecalta launch, 30. maj. 2019, Promenada, Beton Hala.
- Vidović A : “Akutna mijeloblastna leukemija - Novine u dijagnostičkom pristupu: Da li smo spremni?”. Novartis Oncology Academy, 25. maj 2019, Radisson Blu, Beograd.

***Predavanja po pozivu ili plenarna predavanja na međunarodnim akreditovanim skupovima u zemlji i inostranstvu***

- III Simpozijum Lekara intenzivista, sa međunrodnim učešćem, održanom u Crown Plasa 2015.;
- Moderator na „First Regional Education Meeting on Supportive care in Cancer Patients for Eastern European and Balkan region“. Decembar 02-03.; 2016, Belgrade, Serbia, sesije „Febrile neutropenia and the guidelines for the use of WBC growth factors“, spiker Matti Aapro, ESO lecture moderator: Ana Vidović
- Kao predavač po pozivu na “Second Regional Education Meeting on Supportive care in Cancer Patients for Eastern European and Balkan region“. Decembar 01-02, 2017, Belgrade Serbia, sa temom“ The Integration of Supportive Care into Hematology Scope of Actions“.
- Predavač na Scientific round table:“ New perspectives on the menagement of invasive fungal infections in hemato-oncology patients“, January 19-20, 2017. Hotel Bristol, Opatija, Croatia. Predavač prof. dr Ana Vidović (Srbija) and con debate: azoles vs echinocandine prof. dr SamoZver (Slovenia). kao i na većem broju Advajzeri bordova (Phiser, Astellas, MSD, Medicopharma).
- Kao predavač po pozivu na Scientific Meeting, “Scientific update on APL management“, May 30, 2017, Zagreb, Hotel Sheraton Zagreb, Croatia. Sa temom” Case report: How we treated patient with two relapses of APL and neuroleukemia”.

- Vidović A: "Antifungal resistance-clinical rarity or impending disaster?", Symposium- "Management of invasive fungal infections, now and in the future", 28. Novembar 2018, Hotel Hilton, Beograd

#### ***Učešće u međunarodnim projektima***

A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus voriconazole for the Treatment of invasive Aspergilosis in Adults and Adolescents (Phase 3)-

A Phase 3 double-blind, placebo-controlled study of Quizartinib (AC220) administered with combination with induction and consolidation chemotherapy, and administered as maintenance therapy subjects 18 to 75 years old with newly diagnosed FLT-ITD(+) acute myeloid leukemia AC220-A-U302

### **Kandidat br. 2. dr MILENA (Radula) TODOROVIĆ BALINT**

#### **A. OSNOVNI BIOGRAFSKI PODACI**

Milena (Radula) Todorović Balint, rođena 02. 07. 1965 godine u Beogradu, zaposlena na Klinici za hematologiju KCS, kao vanredni profesor Medicinskog fakulteta Univerziteta u Beogradu, za užu naučnu oblast Interna medicina (hematologija). Načelnik je Odeljenja za transplantaciju koštane srži i zamenik direktora klinike.

#### **B. STRUČNA BIOGRAFIJA, DIPLOME I ZVANJA**

##### **Osnovne studije**

Dr Milena Todorović, školske 1984/85 godine upisuje Medicinski fakultet u Beogradu a diplomirala je 1990. god. sa prosečnom ocenom 10,00.

U toku studija 1987. godine postavljena je za demonstratora za predmet patološka anatomija, gde je radila do do završetka Medicinskog fakulteta. U toku studija dobila je 4 Univerzitetske nagrade i dva legata za postnut uspeh.

##### **Magisterijum**

Magistarske studije iz oblasti imunologije na Medicinskom fakultetu u Beogradu upisuje školske 1991/92 godine, a završava odbranom magistarske teze pod nazivom: "Klinički značaj hematoloških, bioloških i imunoloških parametara u bolesnika sa nehoćkinskim limfomima" dana 14. 07. 1994. pred komisijom u sastavu: Akad. Prof. dr Ivan Spužić, Prof. dr Milica Čolović, Doc. dr Milan Petrović, mentor na Medicinskom Fakultetu u Beogradu.

##### **Doktorat**

Doktorsku tezu pod nazivom "Značaj određivanja proliferativnih i apoptotskih antigena u bolesnika sa akutnom limfoblastnom leukemijom" odbranila je 03. 06. 2004. pred komisijom u sastavu: Prof. dr Darinka Bošković, Prof. dr Milan Petrović, Prof. dr Pavle Milenković, mentor: Prof. dr Milica Čolović na Medicinskom Fakultetu u Beogradu.

##### **Specijalizacija**

Specijalistički ispit iz interne medicine položila je 28.06. 1996. sa odličnim uspehom.

##### **Uža specijalizacija**

Rad uže specijalizacije iz hematologije pod nazivom "Kliničko biološke karakteristike bolesnika sa mantl ćelijskim limfomom" odbranila je 17. 06. 2005. godine pred komisijom u sastavu: Prof. dr Darinka Bošković, Prof. dr Biljana Mihaljević, Prof. dr Milan Petrović, mentor.

##### **Master akademske studije**

Master rad iz Master akademskih studija menadžmenta u sistemu zdravstvene zaštite u okviru Medicinskog fakulteta i Fakulteta organizacionih nauka Univerziteta u Beogradu, pod nazivom „Edukativne potrebe zaposlenih u kontekstu implementacije ISO standarda u Centru za transplantaciju matičnih ćelija“ odbranila je 27.09.2018. pred komisijom u sastavu: Prof.dr Vesna Bjegović Mikanović, Prof. dr Jovan Filipović, Prof.dr Milena Šantrić Milićević, mentor, na Medicinskom fakultetu u Beogradu.

##### **Dosadašnji izbori u nastavna i naučna zvanja**

Od oktobra 2008. do septembra 2014. radila kao docent na Katedri za internu medicinu – nastavna baza hematologija Medicinskog Fakulteta u Beogradu, (reizabrana za docenta decembra 2013.godine).

Od septembra 2014. radi kao vanredni profesor na Katedri za internu medicinu – nastavna baza hematologija Medicinskog Fakulteta u Beogradu (reizabrana u septembru 2019.godine).

### **OBABVEZNI USLOVI ZA IZBOR U ZVANJE REDOVNOG PROFESORA**

#### **C. OCENA O REZULTATIMA PEDAGOŠKOG RADA**

Od izbora u zvanje asistenta na predmetu Interna medicina (1999. godina) redovno obavlja kako praktičnu tako i teorijsku nastavu sa punim fondom časova predviđenim planom i programom nastave za studente 3.i 4. godine osnovnih studija medicine.

Predavanja u osnovnoj i posleddiplomskoj nastavi (za lekare na specijalizaciji, specijalističkim akademskim studijama i subspecijalističkim studijama) i to:

- u osnovnoj studentskoj nastavi na srpskom i engleskom jeziku
- u posleddiplomskoj nastavi (specijalizantima iz interne medicine, lekarima na SAS iz hematologije, užoj specijalizaciji iz hematologije, imunologije i transplanatologije)

Od 2009. godine učestvuje u ispitima studenata OAS iz predmeta interna propedeutika, a od 2014. ispituje studente iz predmeta interna medicina. Od 2014. godine ispituje lekare na specijalizaciji interne medicine kolokvijum iz hematologije. Od 2015. godine član je komisije za polaganje subspecijalističkog ispita iz hematologije. Od 2018. je član komisije za polaganje specijalističkog ispita iz predmeta interna medicina. Predsednik je ispitne komisije za polaganje specijalističkog ispita iz transfuziologije od 2018. godine, a takođe je i predsednik komisije za polaganje subspecijalističkog ispita iz predmeta Klinička transfuziologija.

Kao lekar specijalista svakodnevno pomaže u obučavanju lekara na specijalizaciji i užoj specijalizaciji iz hematologije u sticanju stručnih teorijskih saznanja, kao i svakodnevnog izvođenja dijagnostičkih i terapijskih intervencija neophodnih u ovoj oblasti interne medicine.

Mentor je u velikom broju studentskih stručnih i diplomskih radova.

U izvođenju nastave i edukacije svoja izlaganja vodi jasno na osnovu dobro osmišljenog i pripremljenog plana, a u praktičnoj nastavi se trudi da navede studente na logično razmišljanje, analizu i sintezu problema.

Dosadašnje ocene studenata su visoko afirmativne i validirane su sa najvišm ocenom **5,00**.

## **D. OCENA REZULTATA U OBEZBEDIVANJU NAUČNO-NASTAVNOG PODMLATKA**

### **MENTORSTVO**

#### ***Diplomski radovi***

1. Limfoproliferativne bolesti, kandidat Ana Sarić, januar 2012. godine
2. Savremeno lečenje Hodgkinovog limfoma, kandidat Milena Stanimirović, maj 2013.
3. Savremeno lečenje Hočkinovog limfoma, kandidat Ivan Rajičić oktobar 2014.
4. Uloga i značaj transplantacije matičnih ćelija hematopoeze u lečenju hematoloških oboljenja, kandidat Margareta Stefanović mart 2017.
5. Transplantacija matičnih ćelija hematopoeze i njena primena u hematologiji, kandidat Sanja Stanojević, jun 2017.
6. Hočkinov limfom, od savremenih dijagnostičkih principa do terapije, kandidat Nevena Stanišić, septembar 2017.
7. Savremeno lečenje Hočkinovog limfoma, kandidat Radmila Milaković, novembar 2017.
8. Transplantacija matičnih ćelija hematopoeze kod hematoloških bolesnika, kandidat Miljana Petrović, jul 2018.
9. Savremeno lečenje relapsa limfoma, kandidat Bojana Petrović, jul 2018.

#### ***Poslediplomski radovi (SAS i polazna istraživanja):***

1. Uporedna analiza leukemijske faze B hroničnih limfoproliferativnih neoplazmi, kandidat Enisa Žarić, april 2014 (MF Podgorica)
2. Limfomi u trudnoći: specifičnost izbora dijagnostičkih i terapijskih modaliteta, kandidat dr Ana Božović, septembar 2016.

#### ***Poslediplomski radovi -Rad uže specijalizacije:***

1. Kliničko biološke osobine recidiva difuznog B krupnoćelijskog limfoma, kandidat dr Životije Radisavljević, jun, 2011
2. Kliničko biološke osobine slabo diferentovane akutne mijeloidne leukemije, kandidat dr Danijela Selaković, novembar 2013.
3. Analiza kliničkih i laboratorijskih parametara kod bolesnika sa leukemijskom fazom limfoma marginalne zone, kandidat dr Enisa Žarić, novembar 2014.
4. Kliničko-patološke karakteristike i terapijski odgovor primarnih, nehočkinskih limfoma slezine, kandidat dr Rajko Milošević, decembar 2018.
5. Analiza kliničkih karakteristika i terapijskog odgovora bolesnika sa primarno rezistentnim Hočkinovim limfomom lečenih visokodoznom hemioterapijom sa autolognom transplantacijom matičnih ćelija hematopoeze, kandidat dr Senad Brunčević, decembar 2018.

#### ***Doktorske disertacije:***

1. Prognostički značaj vaskularizacije i adhezivnih molekula stromalnih ćelija kod difuznog B krupnoćelijskog i folikularnog limfoma, kandidat dr Jelena Jeličić, odbrana april 2016..
2. Značaj ekspresije ABC proteina, survivina i bcl-2 kod difuznog B krupnoćelijskog ne-Hočkin limfoma u nastanku rezistencije na hemioterapiju, kandidat dr Danijela Mandić, odluka 18/3121/18, april 2018, MF Banja Luka.

## **UČEŠĆE U KOMISIJAMA ZA ODBRANU RADOVA**

#### ***Diplomski rad:***

1. Hemoragijski sindrom, kandidat Milena Ćirović, jul 2012.
2. Anemija zbog nedostatka gvoždja, kandidat Tatjana Turanjanin, decembar 2012.
3. Von Willebrandova bolest, kandidat Aleksandar Gavrić, decembar 2012.
4. Ekstranodalni limfom želuca, kandidat Snežana Jeremić, decembar 2013.
5. Mijeloidni sarkom, kandidat Gorana Janačković, decembar 2013.
6. Hronična limfocitna leukemija, principi dijagnostike i lečenja, kandidat Ivana Marjanović, decembar 2013.
7. Mijelodisplastični sindrom, principi dijagnostike i lečenja, kandidat Marija Jelikić, decembar 2013.
8. Prognostički faktori kod bolesnika sa difuznim B krupnoćelijskim limfomom, kandidat Borko Gobeljić, jul 2014.
9. Prognostički značaj nalaza molekularne genetike kod obolelih od multiplog mijeloma, kandidat Sanja Stanković, oktobar 2015.
10. Prognostički faktori kod starijih pacijenata sa Hočkinovim limfomom, kandidat Ana Bogut, 2016.
11. Tromboembolijske komplikacije u hematološkim malignitetima. Kandidat Dragana Erak, april 2016.
12. Principi dijagnostike i lečenja hronične limfocitne leukemije, kandidat Milica Ostojić jul 2017.

13. Graft versus host disease-kutane i isistmeske manifestacije, kandidat Tara Gunja, decembar 2018.
14. Dijagnostika i lečenje von Willebrandove bolesti, kandidat Katarina Simić, septembar 2019.
15. Indications for stem cell transplantation in acute leukemia, kandidat Petar Kandić, decembar 2019.

**Poslediplomski radovi -Rad uže specijalizacije:**

1. Procena efekta lečenja protokolom BEACOPP u bolesnika sa uznapredovalim Hočkinovim limfomom, kandidat dr Snežana Andjelković, jul 2009.
2. Uporedna petogodišnja analiza lečenja folikularnih limfoma hemioterapijom-purin analogima i imunohemioterapijom, kandidat dr Svetlana Mladenović Radovanović, maj 2010.
3. Kliničke i laboratorijske karakteristike bolesnika u relapsu folikularnog limfoma i njihov prognostički značaj za ishod lečenja, kandidat dr Boško Andjelić, april 2011
4. Kliničke karakteristike i ishod terapije nehočkinskih limfoma u dece, naše iskustvo, kandidadt dr Lidija Dokmanović-Krivokapić maj 2011.
5. Lečenje akutne promijelocitne leukemije u indukciji samo all trans retinoičnom kiselinom (ATRA-om), kandidadt dr Anka Popović, novembar 2012.
6. Desetogodišnja kliničko-laboratprojska analiza ektranodalnih limfoma marginalne zone MALT tipa negastrične lokalizacije, kandidadr Katarina Marković, januar 2013. Predsednik komisije
7. Autologna transplantacija matičnih ćelija hematopoeze u lečenju multiplog mijeloma, kandidadr Predrag Krstić (VMA), april 2013.
8. Efikasnost primene hemioterapijskog protokola fludarabin-ciklofosamid kod bolesnika sa hroničnom limfocitnom leukemijom, kandidadr dr Violeta Milošević, septembar 2013.
9. Udruženi maligniteti sa hroničnom limfocitnom leukemijom, kandidat dr Vladimir Kecman, novembar 2013.
10. Mijelodisplastični sindrom sa izolovanom delecijom 5q—kliničko laboratorijske odlike i rezultati lečenja, kandidadr dr Jelena Vukićević, oktobar 2014.
11. Prognostički značaj ekspresije gena cereblon kod bolesnika sa multiplim mijelomom, kandidat dr Mila Purić, mart 2016.
12. Kliničko laboratorijske karakteristike pacijenata obolelih od hronične limfocitne leukemije mlađih od 55 godina, kandidat dr Danijela Jovanović, februar 2020.
13. Primena traneksamične kiseline kod ugradnje endoproteze kuka i uticaj na potošnju krvi i krvnih komponenata, kandidat dr Danijela Drndarević, jun 2020.
14. Akutna limfoblastna leukemija, Filadelfija pozitivna: kliničke, hematološke osobine i procena terapijskog odgovora, kandidadt dr Rada Marković, jul 2020.

**Poslediplomski radovi -Magistarska teza i akademski specijalistički rad:**

1. Prognostički faktori kod bolesnika sa nehočkinskim limfomima želuca i creva, kandidat dr Vesko Vujičić, Medicinski Fakultet Podgorica, april 2009 godina.
2. Korelacija imunohematoloških, citogenetskih molekulskih ispitivanja za definisanje stepena donorskog himerizma kod bolesnika sa alogenom transplantacijom matičnih ćelija, kandidat dr Marika Ljubenov (VMA) decembar 2008.
3. Značaj uporedne analize FLIPI indeksa i biomarkera LAM (makrofazi pridruženi limfomskim ćelijama) na efekat terapije i prognozu novodijagnostikovanih folikularnih limfoma, kandidat dr Boško Andjelić, mart 2010.
4. Nuklearna ekspresija BCL-10 o NF-kappa B kod bolesnika sa MALT limfomom želuca, kandidat dr Jelena Hajder, jul 2010.
5. Komparativna analiza MALT limfoma gastrointestinalne i negastrointestinalne lokalizacije: značaj kliničko-laboratorijskih parametara i proliferativnog markera Ki-67 za ishod bolesti, kandidat dr Marjana Virijejić, jul 2010.
6. Molekularno genetska analiza polimorfizma gena za odgovarajuće citokine u bolesnika sa multiplim mijelomom, kandidat dr Natalija Mladenović mart 2012.
7. MALT Limfomi orbite i okularnih adneksa, kandidadt dr Mihailo Smiljanić, mart 2013.
8. Kliničke, citološke i citogenetske karakteristike recidiva akutne limfoblastne leukemije kod dece, kandidat dr Dračan Mičić, septembar 2014.
9. Hemofagocitna limfohistiocitoza u infektivnim bolestima, kandidat dr Marko Janković, jul 2015.
10. Primena metoda inaktivacije patogena na labilnim krvnim komponentama, kandidat dr Andrijana Kulić, septembar 2015.
11. Rane komplikacije transplantacije matičnih ćelija hematopoeze kod dece, kandidat dr Milica Zečević, septembar 2015.
12. Patogeneza, kliničke karakteristke i lečenje B ćelijskih limfoma udruženih sa hepatitisom C, kandidat dr Jelena Đurđević, jun 2016.
13. Primena point of care metoda u perioperativnom zbrinjavanju bolesnika, kandidat dr Nemanja Dinić, novembar 2017.
14. Značaj primene farmakogenetskih testova u proceni osetljivosti na antitromboznu terapiju, kandidat dr Aleksandra Arežina Mihailović, jul 2018.

**Doktorske disertacije:**

1. Ocena efikasnosti originalnog sistema za ekstrakorporalnu imunoadsopciju kod transplantacije ABO - inkompatibilnih bubrega, kandidat dr Gordana Ostojić, VMA dec 2008.
2. Primarni nehočkinski limfomi slezine: kliničke odlike, hostopatološke imunofenotipske karakteristike i prognoza, kandidadt dr Rajko Milošević, januar 2009.

3. Doprinos optimizaciji vremena i protokola afereznog prikupljanja autolognih matičnih ćelija hematopoeze kod bolesnika sa malignim hemopatijama, kandidat dr Ivana Urošević, MF Novi Sad, januar 2010.
4. Hemofagocitna limfohistiocitoza-karakteristike, klinički tok, imunoterapija i transplantacija matičnih ćelija hematopoeze, kandidat dr Ankica Jovanović, jun 2014.
5. Prognostički značaj angiogeneze i mikrosredine tumora na ishod lečenja bolesnika sa Hočkinovim limfomom, kandidat dr Boško Anđelić, decembar 2014.
6. Ocena efekata ABO inkompatibilnosti i periransplantacijskih in vivo i ex vivo tretmana na prihvatanje alokalema i pojavu komplikacija posle transplantacije matičnih ćelija hematopoeze, kandidat dr Marika Ljubenov, VMA decembar 2015.
7. Značaj Galektina-1 kao prognostičkog faktora u lečenju Hočkinovog limfoma, kandidat dr Olivera Simonović, Niš, januar 2018.
8. Molekularno genetički mehanizmi rezistencije u prognozi bolesnika sa multiplim mijelomom, kandidat dr Aleksandra Sretenović, septembar 2018.

## E. NAUČNI I STRUČNI RAD

### a) *Spisak objavljenih radova*

#### Originalni radovi in extenso u časopisima sa JCR liste

1. Mihaljević B, Donfrid M, Jančić-Nedeljov R, Jovanović V, Petrović M. Angioimmunoblastic lymphadenopathy (AILD) with benign course. *Haematologia (Budap)* 1996; 28(1): 21–25. **M23 IF 0,104**
2. Donfrid M, Janković G, Strahinja R, Čolović R, Begić-Janeva A, Čolović M. Idiopathic thrombocytopenia associated with Wilson disease. *Hepato-Gastroenterol* 1997; 44: 10–11. **M22 IF 0.925**
3. Kraguljac N, Marisavljević D, Janković G, Radošević N, Pantić M, Donfrid M, Miletić N, Bošković D, Čolović M. Characterisation of CD13 and CD33 surface antigen negative acute myeloid leukemia. *Am J Clin Pathol* 2000; 114: 29–34. **M21 IF 2,939**
4. Donfrid M, Apostolski S, Suvajdžić N, Janković G, Čemerikić V, Atkinson D, Čolović M. Monocytoid B-cell lymphoma associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. *Acta Haematol* 2001; 106: 130–132. **M23 IF 1,128**
5. Suvajdžić N, Stanković B, Artiko V, Cvejić T, Bulat V, Bakrač M, Čolović M, Obradović V, HD Atkinson. *Helicobacter pylori* eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. *Platelets* 2006; 17: 227–230. **M23 IF 1,679**
6. Pekmezović T, Suvajdžić N, Kisić D, Grgurević A, Bogdanović A, Gotić M, Bakrač M, Brkić N. A case-control study of myelodysplastic syndromes in Belgrade (Serbia and Montenegro). *Ann Hematol* 2006; 85: 514–519. **M23 IF 2,254**
7. Bakrač M, Jurisic V, Kostic T, Popovic V, Pekic S, Kraguljac N, Colovic M. Pure red cell aplasia associated with type I autoimmune polyglandular syndrome: successful response to therapy with mycophenolate mofetil: case report and review of literature. *J Clin Pathol* 2007; 60(6): 717–720. **M22 IF 2,426**
8. Todorovic M, Pavlovic M, Balint B, Kraguljac N, Mihaljevic B, Bogdanovic A, Elezovic I, Boskovic D, Colovic M. Immunophenotypic Profile And Clinical Characteristics in Patients with Advanced Stage Mantle Cell Lymphoma. *Med Oncol* 2007; 24(4): 413–418. **M23 IF 1,356**
9. Todorovic M, Balint B, Suvajdzic N, Jevtic M, Pavlovic M, Petrovic M, Krstic M, Popovic V, Ivanovic B, Elezovic I, Milenkovic R, Colovic M. Triple-way therapeutic approach for paraganglioma-dependent erythrocytosis: drugs and surgery plus "multi-manner" apheresis. *Med Oncol* 2008; 25(2): 148–153. **M23 IF 1,134**
10. Todorovic M, Balint B, Jevtic M, Suvajdzic N, Cerić A, Stamatovic D, Markovic O, Marjanovic S, Krstic M. Primary gastric mucosa associated tissue lymphoma: Clinical data predicted treatment outcome. *World J Gastroenterol* 2008; 14 (15): 2388–2393. **M23 IF 2,081**
11. Marković O, Marisavljević D, Čemerikić V, Vidović A, Peruničić M, Todorović M, Elezović I, Colović M. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. *Med Oncol* 2008; 25(4): 451–457. **M23 IF 1,134**
12. Sretenovic M, Colovic M, Jankovic G, Suvajdzic N, Mihaljevic B, Colovic N, Todorovic M, Atkinson HD. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey. *Eur J Haematol* 2009; 82(5): 373–380. **M23 IF 2.345**
13. Milosevic R, Todorovic M, Balint B, Jevtic M, Krstic M, Ristanovic E, Antonijevic N, Pavlovic M, Perunicic M, Petrovic M, Mihaljevic B. Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma. *World J Gastroenterol*. 2009; 15(32): 4009–4115. **M23 IF 2.092**
14. Balint B, Pavlovic M, Todorovic M, Jevtic M, Ristanovic E, Ignjatovic Lj. The use of simplified *ex vivo* immunoadsorption and "multi-manner" apheresis in ABO/H-mismatched kidney transplant setting – phase II clinical study. *Transfus Apher Sci* 2010; 43(2): 141–148. **M23 IF 1,587**
15. Balint B, Stamatovic D, Todorovic M, Elez M, Vojvodic D, Pavlovic M, Cucuz-Jokic M. Autologous transplant in the treatment of severe aplastic anemia--a case report. *Transfus Apher Sci* 2011; 45(2): 137–141. **M23 IF 1,250**
16. Stamatovic D, Balint B, Tukic Lj, Elez M, Tarabar O, Todorovic M, Ostojic G, Tatomirovic Z, Marjanovic S, Malesevic M. Impact of stem cell source on the allogeneic stem cell transplantation outcome in hematological malignancies. *Vojnosanit Pregl* 2011; 68(12): 1026–32. **M23 IF 0,179**

17. Jocić M, Trkuljić M, Jovicić D, Borovcanin N, Todorović M, Balint B. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model. *Vojnosanit Pregl* 2011; 68(12):1041-6. **M23 IF 0,179**
18. Antic D, Smiljanic M, Bila J, Jankovic S, Todorovic M, Andjelic B, Mihaljevic B. Hypothalamic dysfunction in a patient with primary lymphoma of the central nervous system. *Neurol Sci* 2012; 33(2):387-390. **M23 IF 1,412**
19. Andjelic B, Mihaljevic B, Todorovic M, Bila J, Jakovic L, Jovanovic MP. The Number of Lymphoma-associated Macrophages in Tumor Tissue Is an Independent Prognostic Factor in Patients With Follicular Lymphoma. *Appl Immunohisto M M* 2012;20(1):41-46. **M22 IF 1,828**
20. Suvajdzic N, Djurdjevic P, Todorovic M, Perunicic M, Stojanović R, Novkovic A, Mihaljevic B. Clinical characteristics of patients with lymphoproliferative neoplasms in the setting of systemic autoimmune diseases. *Med Oncol* 2012; 29(3):2207-2211. **M23 IF 2,147**
21. Mihaljevic BS, Todorovic MR, Andjelic BM, Antic DA, Perunicic Jovanovic MD. Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient. *Med Oncol* 2012 ;29(2):1186-1189. **M23 IF 2,147**
22. Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Kraguljac Kurtovic N, Radisavljevic Z, Mihaljevic B. Outcome prediction of advanced mantle cell lymphoma by international prognostic index vs. different mantle cell lymphoma indexes – one institution study. *Med Oncol* 2012; 29(3): 2212–2219. **M23 IF 2,147**
23. Todorovic M, Radisavljevic Z, Balint B, Andjelic B, Todorovic V, Perunicic Jovanovic M, Mihaljevic B. Increased angiogenesis associated poor outcome in acute lymphoblastic leukemia-a single center study. *Appl Immunohisto M M* 2012; 20(5): 488–493. **M22 IF 1,828**
24. Stanojkovic Z, Balint B, Antic A, Todorovic M, Ostojic G, Pavlovic M. Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification. *Transfus Apher Sci* 2012;47(1):33-37. **M23 IF 1,225**
25. Stamatovic D, Balint B, Tukic Lj, Elez M, Tarabar O, Todorovic M, Tordoric–Zivanovic B, Ostojic G, Tatomirotic Z, Marjanovic S, Malesevic M. Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy. *Vojnosanit Pregl* 2012 ;69(1):37-42. **M23 IF 0,210**
26. Balint B, Jovovic-Gojkov D, Todorovic-Balint M, Subota V, Pavlovic M, Goodrich R. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment - A comparative study. *Transfus Apher Sci* 2013;49(3):434-9. **M23 IF 1,072**
27. Todorovic M, Balint B, Andjelic B, Mihaljevic B. Multiple malignancies in female patient with common variable immunodeficiency syndrome. *Singap Med J* 2014; 55(10):e162-4. DOI: [10.11622/smedj.2014147](https://doi.org/10.11622/smedj.2014147) **M23 IF 0,597**
28. Smiljanic M, Milosevic R, Antic D, Andjelic B, Djurasinovic V, Todorovic M, Bila J, Bogdanovic A, Mihaljevic B. Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience. *Med Oncol* 2013;30(4):722. **M23 IF 2,058**
29. Čolović M, Todorović M, Čolović N, Terzić T, Karadžić K, Jurišić V. Appearance of estrogen positive bilateral breast carcinoma with Her-2 gene amplification in a patient with aplastic anaemia. *Pol J Pathol* 2014;65(1):66-9. **M23 IF 1,128**
30. Bila J, Andjelic B, Bodrozic J, Jakovic Lj, Perunicic Jovanovic M, Vidovic A, Todorovic M, Mihaljevic. Extramedullary plasmacytoma of the tongue base: a rare presentation of head and neck plasmacytoma. *Vojnosanit Pregl* 2013;70: 972-975. **M23 IF 0,269**.
31. Todorovic M, Balint B, Andjelic B, Radisavljevic Z, Mihaljevic B. Switching to BCL-6 negativity in relapsed diffuse large B cell lymphoma correlated with more aggressive disease course. *Indian J Hematol Blood Transfus* 2014;30(4):269-74. **M23 IF 0,198**
32. Markovic O, Popović L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, Matovina-Brko G, Hajder J, Matkovic T, Živković R, Stanisavljevic N, Todorović M, Petrovic D, Mihaljevic B. Comparison of prognostic impact of absolute lymphocyte count (ALC), absolute monocyte count (AMC), ALC/AMC prognostic score and ALC/AMC ratio in patients with diffuse large B cell lymphoma. *Eur J Intern Med* 2014;25(3):296-302.. **M21 IF 2,891**
33. Andjelic B, Todorovic M, Antic D, Bila J, Djurasinovic V, Mihaljevic B. Follicular lymphoma patients with a high flapi score and high tumor burden: a risk stratification model. *Vojnosanit Pregl* 2015;72(1):26-32. **M23 IF 0,355**
34. Balint B, Vucic M, Todorovic M, Antic A, Stanojkovic Z, Vucic J, Pavlovic M, Vucetic D. Radically reduced ex vivo cell activation by using "in-line" filtered whole blood as a source of platelet concentrate. *Blood Transfus* 2014;12(3):440-2. **M22 IF 2,372**
35. Mihaljevic B, Vukovic V, Smiljanic M, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Jelcic J, Antic D. Single-center experience in the treatment of primary testicular lymphoma. *Oncol Res Treat*. 2014;37(5):239-42 **M23 IF 0,835**
36. Andjelic B, Antic D, Jakovic L, Todorovic M, Bogdanovic A, Djurasinovic V, Bila J, Mihaljevic B. A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice. *Eur J Haematol* 2014; 93(5):392-9. **M22 IF 2,066**
37. Bila J, Jelcic J, Djurasinovic V, Vukovic V, Sretenovic A, Andjelic B, Antic D, Todorovic M, Mihaljevic B. Prognostic effect of comorbidity indices in elderly patients with multiple myeloma. *Cl Lymph Myelom Leuk* 2015;15(7):416-9. **M23 2,316**
38. Gojkovic-Jovovic D, Todorovic-Balint M, Kanjuh V, Vucetic D, Pavlovic M, Balint B. Extended platelet concentrate storage/practice - A model based on the rationalized microbial monitoring. *Transfus Apher Sci* 2015;53(1):82-4 . **M23 IF 0,963**

39. Jelacic J, Todorovic Balint M, Sretenovic DA, Balint B, Perunicic Jovanovic M, Andjelic B, Vukovic V, Djurasinovic V, Bila J, Pavlovic M, Smiljanic M, Mihaljevic B. Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy. *Neoplasma* 2015;62(6):988-95. **M23 IF 1,961**
40. Jelacic J, Todorovic Balint M, Raicevic S, Ilic R, Stanisavljevic D, Bila J, Antic D, Balint B, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Mihaljevic B. The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system - a one-decade single-centre experience. *Br J Neurosurg* 2016;30(1):80-5. **M23 IF 1,051**
41. Jelacic J, Balint MT, Jovanovic MP, Boricic N, Micev M, Stojic J, Antic D, Andjelic B, Bila J, Balint B, Pavlovic S, Mihaljevic B. The role of lymphocyte to monocyte ratio, microvessel density and high CD44 tumor cell expression in Non Hodgkin lymphomas. *Pathol Oncol Res* 2016; 22(3): 567-77 **M 23 IF 1,736**
42. Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B et al. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. *Endocr Relat Cancer* 2016 ; 23: 899–908. **M21 IF 5,267**
43. Todorovic-Balint M, Jelacic J, Mihaljevic B, Kostic J, Stanic B, Balint B, et al. Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: Next generation sequencing analyses. *Inter J Mol Sci* 2016; 17(5): pii: E683. doi: 10.3390/ijms17050683. **M22 IF 3,226**
44. Jevtic A, Todorovic M, Ostojic G, Vasiljic S, Pavlovic M, Balint B. Autologous transfusions for elective surgery – from existing approaches to upcoming challenges. *Vojnosanit Pregl* 2017; 74(7): 676–680. **M23 IF 0,405**
45. Mihaljevic B, Jelacic J, Andjelic B, Antic D, Markovic O, Petkovic I, Jovanovic MP, Trajkovic G, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Balint MT. FCG (FLIPI, Charlson comorbidity index, and histological grade ) score is superior to FLIPI in advanced follicular lymphoma. *Int J Hematol* 2016;104(6):692-699. **M23 IF 1,610**
46. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelacic J, Hayman S, Mihaljevic B. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. *Am J Hematol* 2016;91(10):1014-9. **M21 IF 5,275**
47. Balint B, Stanojevic I, Todorovic M, Stamatovic D, Pavlovic M, Vojvodic D. Relative frequency of immature CD34+/CD90+ subset in peripheral blood following mobilization correlates narrowly and inversely with the absolute count of harvested stem cells in multiple myeloma patients. *Vojnosanit Pregl* 2017; 74(11): 1071–7. **M23 IF 0,405**
48. Markovic O, Andjelic B, Tarabar O, Todorovic M, Filipovic B, Stanisavljevic D, Bila J, Antic D, Marisavljevic D, Mihaljevic B. Late relapse of Hodgkin's lymphoma – is it different in clinical characteristics and outcome? *J BUON* 2017;22(2):481-486. **M23 IF=1,766**
49. Simonović O, Todorović M, Mihaljević B, Stoimenov-Jevtović T, Petković I, Mačukanović-Golubović L, Marjanović G. Serum biomarkers and clinical characteristics of patients with Hodgkin lymphoma . *Vojnosanit Pregl* 2018; 75(9): 911–917 **M23 IF 0,272**
50. Vucetic D, Ilic V, Vojvodic D, Subota V, Todorovic M, Balint B. Flow cytometry analysis of platelet populations: usefulness for monitoring the storage lesion in pooled buffy-coat platelet concentr. *Blood Transfus* 2018; 16(1): 83–92. **M22 IF 3,352**
51. Antic D, Jelacic J, Trajkovic G, Balint MT, Bila J, Markovic O, Petkovic I, Nikolic V, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Mihaljevic B. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. *Ann Hematol* 2018;97(2):267-276. **M22 IF 2,850**
52. Djurašinović V, Mihaljević B, Šipetić Grujičić S, Ignjatović S, Trajković G, Todorović-Balint M, Antić D, Bila J, Andjelić B, Jeličić J, Vuković V, Nikolić A, Klek S. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it? *Support Care Cancer* 2018;26:2825–32. **M21 IF 2,754**
53. Borovcanin N, Ristanovic E, Todorovic M, Borovcanin M, Jovanovic M, Balint B. The use of complementary serological and molecular testing for blood-borne pathogens and evaluation of socio-demographic characteristics of intravenous drug users on substitution therapy from Shumadia District of Serbia. *Vojnosanit Pregl* 2019; 76(6): 587–592. **M23 IF 0,152**
54. Todorovic Balint M, Jelacic J, Bila J, Balint B, Antic D, Trajkovic G , et al. Influence of applied CD34<sup>+</sup> cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants *Vojnosanit Pregl* 2018. DOI: <https://doi.org/10.2298/VSP180808160T> **M23 IF 0,405**
55. Lukić S, Dragašević S, Zgradc S, Todorović M, Đuranović S, Anđelić B, Popović D. Plasmablastic lymphoma as a rare cause of subocclusive events - case report and review of the literature. *Vojnosanit Pregl* 2019; 76(12): 1297–1300. **M23 IF 0,152**
56. Stanojković Z, Antić A, Balint B, Todorović M, Vučić M, Vacić N, Milan Lazarević M. Evaluation of the anticoagulant effect of vitamin K antagonists in patients with non-valvular atrial fibrillation. *Vojno Sanit Pregl* 2020; <https://doi.org/10.2298/VSP181214008S> **M23 IF 0,152**

#### Ostali radovi u časopisima sa JCR liste \*\*

1. Jankovic S, Kraguljac N, Basara N, Donfrid M, Petrovic M. Paroxysmal nocturnal hemoglobinuria: golden standards vs. modern technologies. *Am J Hematol* 1995;50(1):66–67. **M22 IF 1,649/2.**

2. Colovic M, Jankovic G, Cemerikic–Martinovic V, Latkovic Z, Donfrid M. Primary intraocular marginal zone B–cell (MALT) lymphoma. *Eur J Haematol* 1998; 60(1): 61–62. **M22 IF 1,846/2**
3. Kraguljac N, Marisavljevic D, Jankovic G, Radošević N, Pantic M, Donfrid M, Miletic N, Boskovic D, Colovic M. Induction of CD13 in vitro culture and assesment of negative or positive in acute myeloid leukemia cases. *Am J Clin Pathol* 2001; 116: 945–948. **M21 IF 3,136/2**
4. Kühne T, Berchtold W, Michaels L, Wu R, Donato H, Espina B, Tamary H, Rodeghiero F, Chitlur M, Rischewski J, and Imbach P on behalf of the Intercontinental Cooperative ITP Study Group (Todorovic M). Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. *Haematologica* 2011; 96(12):1831-1837. **M21a IF 6,424/2**
5. Balint B, Vucetic D, Todorovic-Balint M, Borovcanin N, Jovanovic-Cupic S, Mandusic V. Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period. *Transfus Apher Sci* 2013;49(1):103-4. **M23 IF 1,072/2**.
6. Balint B, Todorovic-Balint M, Petakov M, Ostojic G, Vucetic D. Effectively “cross-bridged” hemostatic and blood screening test defects due to glycogenosys type 1 associated extremely hyperlipidemia. *Transfus Apher Sci* 2014 ;50(2):314-5. **M23 IF 0,768/2**.
7. Balint B, Gazivoda D, Todorovic-Balint M, Lazic Z, Pavlovic M, Kanjuh V. "Triple-way" approach for the treatment of dry socket: surgery and drugs plus fibrin sealant - as a biomatrix for "ultra-concentrated" platelets. *Transfus Apher Sci* 2014;51(2):221-2. **M23 IF 0,768/2**.
8. Balint B, Stepic N, Todorovic M, Zolotarevski L, Ostojic G, Vucetic D et al. Ibuprofen induced extensive toxic epidermal necrolysis – a single center experience with multidisciplinary therapeutic approach. *Blood Transfus* 2014; 12: 438-9. **M22 IF 2,372/2**
9. Balint B, Todorovic-Balint M, Ljubenov M, Tarabar O, Pavlovic M, Kanjuh V. Apheretic "rescue-protocol" designed for treatment of CLL associated life-threatening hemolytic crisis. *Transfus Apher Sci* 2015;52(2):256-8. **M23 IF 0,963/2**.
10. Moskowitz CH, Nademane A, Maszi T, Agura E, Holowiecki J, Abidi M et al,for the Aethera study group (Todorovic M). Brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in patients with Hodgkin’s lymphoma at the risk of relapse or progression (AETHERA): a randomized, double – blind, placebo-controlled, phase 3 trial. *Lancet* 2015;385: 1853-1862. **M21a IF 44,002/2**
11. Mihaljevic B, Smiljanic M, Antic D, Kurtovic NK, Balint MT. Chronic lymphocytic leukemia involvement of central nervous system: Clinical diversity, diagnostic algorithm and therapeutic challenges. *Ann Indian Acad Neurol* 2018;21(1): 85-87. **M23 IF 0,898/2**
12. Balint B, Pavlovic M, Ostojic G, Vucetic V, Todorovic M. Improved cytoreductive potential of plateletapheresis in treatment of symptomatic thrombocytosis: A single center study. *Vojnosanit Pregl* 2019; 76(5): 559–560. **M23 IF =0,152/2**
13. Avila ML, Amiri N, Pullenayegum E, Blanchette V, Imbach P, Thomas Kühne T and al for Intercontinental Cooperative ITP Study Group (Todorovic M). Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group. *Haematologica* Published Ahead of Print on December 19, 2019, as doi:10.3324/haematol.2019.236737. **M21a IF= 7,116/2**

#### **Radovi u časopisima indeksiranim u SCIENCE CITATION INDEX Expanded, bez IF**

1. Bakrac M, Bonači B, Krstić M, Simić S, Čolović M. A rare case of enteropathy– associated T–cell lymphoma presenting as acute renal failure. *World J Gastroentero* 2006; 12(14): 2301–2304.
2. Balint B, Ljubenov M, Stamatović D, Todorović M, Pavlović M, Ostojić G, Jocić M, Trkuljić M. Stem cell harvesting protocol research in autologous transplantation setting: large volume vs. conventional cytapheresis. *Vojnosanit Pregl* 2008; 65(7): 1-10.
3. Rajić Z, Colović N, Sretenović M, Plečić M, Janković S, Bakrac M, Colović M. Hepatosplenic candidiasis in acute leukaemia patients. *Srp Ark Celok Lek*. 2008;136(7-8):414-418.
4. Antić D, Elezović I, Suvajdžić N, Todorović M, Bila J, Mitrović M, Andjelkovic N. Application of recombinant activated factor VII in treatment of intracranial haemorrhage in haemophilic patient with inhibitor. *Srp Ark Celok Lek* 2008;136 (3):218-221.
5. Mitrović-Vasiljević M, Antić D, Elezović I, Bila J, Todorović M. Acquired haemophilia A presenting in postpartum period--case report. *Srp Ark Celok Lek*. 2008;136 (3):214-217
6. Savic A, Balint B, Urosevic I, Rajic N, Todorovic M, Percic I Popovic S. Syngeneic peripheral blood stem cell transplantation with immunosuppression for hepatitis-associated severe aplastic anemia. *Turk J Hematol* 2010; 27(4): 294-298.
7. Yang CZ, Hong CS , Prchal JT, Balint MT, Pacak K and Zhuang Z. Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. *Human Genome Variation* 2015; 2, 15053; doi:10.1038/hgv.2015.53.

#### **Radovi u časopisima indeksiranim u MEDLINE-u**

1. Sretenović M, Milivojević G, Donfrid M, Petrović M, Nedeljkov– Jančić R, Milojević M, Jovanović V, Bošković D, Petrović M. Nechočinski limfomi sa lokalizacijom u koži. *Srp Ark Celok Lek* 1994; 122 (3–4): 75–78.

2. Čolović M, Dimitrijević M, Sonnenburg C, Suvajžić N, Donfrid M, Bogdanović A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. The Hematology Journal, 2003; 4: 358–362.
3. Nedeljkov–Jancic R, Mihaljevic B, Bakrač M, Petrovic M. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland—a case report Srp Ark Celok Lek 2005;133(5–6):272–275.
4. Marković O, Marisavljević D, Čemerikić V, Vidović A, Bakrač M, Peruničić M, Suvajdžić N, Čolović M. Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance. Vojnosanit Pregl 2005; 62: 33–38.
5. Bakrač M, Bonači B, Krstić M, Simić S, Čolović M. Enteropathy associated T-cell lymphoma – a case report Srp Ark Celok Lek 2007; 135 (1-2): 80-84.
6. Balint B, Stamatovic D, Todorović M, Ostojic G, Pavlovic M, Obradovic M. Stem cells in the arrangement of bone marrow repopulation and regenerative medicine. Vojnosanit Pregl 2007; 64(7): 481-484.
7. Balint B, Todorovic M Urosevic I, Pavlovic M. Stem cell transplat: from cell harvesting to cryopreservation. Med Pregl 2017; 70(Suppl 1): 41–45.
8. Todorovic Balint M, Balint B, Bila J, Vujic D, Andjelic B, Mihaljevic B. Autologous stem cell transplants - single center standpoints for lymphoma patients. Med Pregl 2017; 70(Suppl 1): 47–50.

#### **Radovi u časopisima koji nisu indeksirani u navedenim bazama podataka**

1. Donfrid M, Petrović M, Marinković M, Mihaljević B, Čolović M. Prognostički značaj imunoglobulina kod bolesnika sa nehoćkinskim limfomima. Med Istraž 1997; 31(2): 44–49.
2. Donfrid M, Petrović M. Prognostički značaj performace statusa kod bolesnika sa nehoćkinskim limfomima. Bilt Hematol 1997; 25(2–3): 132–134.
3. Donfrid M, Petrović M, Mihaljević B, Bumbaširević Lj, Čolović M. Neurološka komplikacija hemioterapije u bolesnika sa non–Hodgkin limfomima. Med Istraž 1998; 32(2): 14–15.
4. Čemerikić–Martinović V, Stojšić J, Bogdanović A, Donfrid M, Suvajdžić N, Sretenović M, Milivojević G, Čolović M. The bone marrow spicules (particles): a morphologic and immunocytochemical evaluation. Archive of Oncology, 1998, 6:117–118.
5. Nedeljkov– Jančić R, Mihaljević B, Donfrid M, Čemerikić V. Infiltracija kože u Hodgkinovom limfomu. Med Istraž 2000; 34(3): 15–18.
6. Donfrid M, Čemerikić V, Jevtović Đ, Nedeljkov–Jančić R, Suvajdžić N, Bila J, Čolović M. Promene u kostnoj srži kod bolesnika sa AIDS–om. Bilt Hematol 2001; 29(3): 105–107.
7. Nedeljkov–Jančić R, Mihaljević B, Donfrid M, Lazarević V, Petrović M, Čemerikić V. Održavanje remisije interferonom alfa u bolesnika sa non–Hodgkin limfomom niskog stepena malignosti. Bilt Hematol 2001; 29(3): 115–117.
8. Donfrid M, Trišić B, Kraguljac N, Čemerikić V, Suvajdžić N, Čolović M. Subcapsular splenic hematoma as the initial manifestation of gama–delta TCR+acute lymphoblastic leukemia. Haema 2001; 4(1): 49–51.
9. Suvajdžić N, Sretenović M, Čemerikić V, Donfrid M, Krstić M, Bogdanović A, Tomin D, Čolović M. Systemic lupus erythematosus and Burkitt lymphoma: a case report. Haema 2002; 5(2): 125–129.
10. Elezović I, Suvajdžić N, Miljić P, Bila J, Bakrač M, Sretenović M, Bila J, Adžemović A, Bošković D: Uspešno zaustavljanje krvarenja u hemofiliji sa inhibitorom i kod urođenog nedostatka faktora VII primenom aktiviranog rekombinantnog faktora VII. Bilt Hematol, 2005, 33:16–20.
11. Todorović M, Peruničić M, Elezović I, Bila J, Čolović M, Bošković D. Ekspresija antigena p53 i bcl–2 u bolesnika sa akutnom limfoblastnom leukemijom. Anest Reanim Transf 2006; 34: 157–167
12. Balint B, Todorović M, Pavlovic M, Elezović I, Urošević I, Obradovic S, Rafajlovski S. Stem cells – application for marrow repopulation and in regenerative medicine. Anest Reanim Transf 2006; 34: 151–156.
13. Todorović M. Patohistološka evaluacija celularnosti kostne srži i stepena fibroze kod odraslih bolesnika sa akutnom limfoblastnom leukemijom. Anest Reanim Transf 2007; 35: 35–38.
14. Balint B, Jevtić M, Todorović M, Ostojić M, Trkuljić M, Ignjatović Lj, Rafajlovski S, Jocić M. Afereze – opšti principi i upotreba za selektivno otklanjanje plazmatskih konstituenata. Anest Reanim Transf 2007; 35: 1–22.
15. Balint B, Ljubenov M, Todorović M, Ostojić G, Stamatović D, Trkuljić M. In vivo "remodeliranje/serokonverzija" tkivno–krvnogrupnog sistema ABO/H transplantacijom matičnih ćelija hematopoeze. Anest Reanim Transf 2008; 36(1–2): 43–54.
16. Balint B, Ostojić G, Todorović M, Ignjatović Lj, Rafajlovski S, Trkuljić M. Imunoadsorpcijom posredovana selektivna izmena plazme – principi i terapijski efekti. Anest Reanim Transf 2008; 36(1–2): 61–8.
17. Bila J, Vujčić D, Veljković D, Elezović I, Antić D, Šefer D, Kraguljac N, Todorovic M, Anđelić B, Gotić M, Mihaljević B. Visokodozna hemioterapija i autologna trasplantacija matične ćelije hematopoeze u lečenju bolesnika sa multiplim mijelomom. Bilt Transfuziol 2009; 55: 60-65.
18. Todorović M, Locasciulli A, Balint B, Colovic M, Gotic M, Suvajdzic N, Bila J, Andjelic B, Sefer D, Kraguljac N, Mihaljevic B. Matched unrelated donor stem cell transplants: limitations and perspectives-single center experience. Bilt Transfuziol 2009; 55: 75-78.
19. Pavlovic M, Todorovic M, Tyagi V, Todorovic V, Balint B. Adult Stem Cell Research And Regenerative Therapy In Neurological Diseases – Limitations And Perspectives – Part I: Basic Research Data Necessary For Understanding Stem Cell Treatment Approaches In Neuro-Regenerative Therapy. Bilten za Transfuziologiju 2009; 55: 4–14.

20. Pavlovic M, Todorovic M, Tyagi V, Todorovic V, Balint B. Adult Stem Cell Research And Regenerative Therapy In Neurological Diseases – Limitations And Perspectives – Part II: Neurological Diseases And Stem Cell Therapy. Bilt za Transfuziologiju 2009; 55: 15–30.
21. Balint B, Ostojić G, Todorović M. Donorske vs. terapijske cifaferenze – principi i klinički aspekti. Anest Reanim Transf 2009; 37 (1–2): 9–22.
22. Ljubenov M, Todorović M, Todoric–Živanović B, Ostojić G, Stamatović D, Balint B, Trkuljić M. Citogenetski i molekularno – genetski markeri prihvatanja alokalema matičnih ćelija. Anest Reanim Transf 2009; 37 (1–2): 23–31.
23. Todorović M, Andrejević S, Balint B, Andjelić B, Palibrk V, Kraguljac N, Mihaljević B. Successful treatment of diffuse large B–cell lymphoma as a complication of „common variable immunodeficiency“. Anest Reanim Transf 2009; 37 (1–2): 41–44.
24. Balint B, Todorovic M. Stem cells – critical hemobiological aspects and clinical practice. Anest Reanim Transf 2010; 38 (1–2): 9–22.
25. Milošević R, Todorović M, Balint B, Smiljanić M, Mihaljević B. Splenični limfom marginalne zone: lečenje splenektomijom sa ili bez hemioterapije-dugotrajna dilema? Acta Clinica, 2010; 10(3):97-114.
26. Todorović M, Mihaljevic B. Kliničke karakteristike bolesnika sa uznapredovalim stadijumom mantl ćelijskog limfoma. Acta Clinica, 2010;10(3): 63-80.
27. Balint B, Pavlović M, Todorović M, Obradović S. Recent strategies vs. challenges in stem cell–based grafting: research and clinical practice. Bilt Transfuziol 2011; 57 (1–2): 9–25.
28. Todorović M, Balint B, Radisavljević Z, Andjelić B, Todorović V, Peruničić-Jovanović M, Mihaljević B. Microvessel density evaluation in acute lymphoblastic leukemia – a study of angiogenesis. Bilt Transfuziol 2011; 57 (1–2): 49–51.
29. Balint B, Obradović S, Todorović M. Hemobiologija i terapijska primena MĆ prikupljenih iz "steady state" vs. aktivisane kostne srži. Bilt Transfuziol 2012; 58 (1–2): 1–4.
30. Pavlovic M, Balint B, Todorovic M. Stem cell concept: entity of function. Bilt Transfuziol 2013; 59(1-2): 5-8.
31. Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Krstic M, Jeličić J, Cerić A, Peruničić M, Mihaljević B. Primary gastric MALT lymphoma: clinical characteristics and outcome. Bilt Transfuziol 2013; 59(1-2): 46-50.
32. Anđelić B, Todorović M, Antić D, Bila J, Đurašinović V, Mihaljević B. Analysis of the long term survival of patients with follicular lymphoma-our experience. Bilt Transfuziol 2013; 59(1-2): 51-56.
33. Mihaljević B, Todorović M, Bila J, Antić D. Da li je danas moguća individualizacija terapije kod bolesnika sa HLL. Med Istraž 2013; 47 (2): 5-10.
34. Pavlovic M, Balint B, Todorovic–Balint M. Stem cell concept: entity or function? Bilt Transfuziol 2014; 59: 5–8.
35. Todorovic–Balint M, Balint B, Andjelic B, Stanisavljevic D, Krstic M, Jeličić J, et al. Primary gastric mucosa associated lymphoid tissue lymphoma: clinical characteristics and outcome. Bilt Transfuziol 2014; 59: 46–50.
36. Balint B, Todorović–Balint M, Vučetić D, Ostojić G, Rafajlovski N. Hemobiologija i primena trombocita u tretmanu trombocitopenija. Anest Reanim Transf 2014; 41(1–2): 9–17.
37. Gojkov D, Todorović–Balint M, Ljubenov M, Jocić M, Pejović J, Balint B. Ispitivanje konstituenta u plazmi inaktivisanom pomoću riboflavina i UV–zračenja. Anest Reanim Transf 2014; 41(1–2): 27–31.
38. Todorović–Balint M, Salemović D, Balint B, Vučetić D, Peruničić M, Jeličić J, Mihaljević B. Transfuziološko/hematološki aspekti i posledice infekcije virusom humane imunodeficiencije. Anest Reanim Transf 2014; 41(1–2): 61–68.
39. Ostojić G, Balint B, Todorović–Balint M, Rafajlovski N, Vučetić D. Prikupljanje krvnih sastojaka upotrebom separatora krvnih ćelija – donorske hemaferenze/afereze. Anest Reanim Transf 2014; 41(1–2): 69–75.
40. Balint B, Kanjuh V, Todorovic-Balint M, Ostojic G, Stamatovic D, Obradovic S et al. Cobe-Spectra vs. Spectra-Optia apheresis systems – an overview of current status and a comparative research. Bilt Transfuziol 2014; 60 (1–2): 1–5.
41. Vucetic D, Balint B Todorović–Balint M, Jovičić M, Ilić V, Jovanović–Čupić S. Komparativna enzimoimunska ispitivanja i molekularno testiranje davanja krvi u periodu serološkog "prozora/window". Bilt Transfuziol 2014; 60(1–2): 37–42.
42. Todorovic M, Bila J, Balint B, Anđelić B, Vujić D, Kraguljac-Kurtović N et al. Uloga autologne transplantacije u lečenju limfoproliferativnih bolesti. Bilt Transfuziol 2014; 60 (1–2): 54–57.
43. Balint B, Jocić M, Todorović–Balint M, Vučetić D, Ostojić G, Pavlovic M. Hemobiologija i terapijska primena krvne plazme i njenih komponenti/derivata. Anest Reanim Transf 2015; 42(1–2): 9–20.
44. Ostojić G, Ljubenov M, Obradović D, Todorović–Balint M, Jovičić-Gojkov D, Balint B. Terapijske izmene plazme u lečenju imunoneuroloških bolesnika. Anest Reanim Transf 2015; 42(1–2): 57–62.
45. Jovičić-Gojkov D, Ostojić G, Todorović–Balint M, Vučetić D, Rafajlovski N, Balint B. Inaktivacija/redukcija patogena u krvi/hemoproduktima. Anest Reanim Transf 2015; 42(1–2): 63–70.
46. Todorović–Balint M, Jeremić K, Balint B, Kesić V, Antić D, Bila J, et al. Limfomi u trudnoći – dijagnostičko terapijski principi. Anest Reanim Transf 2015; 42(1–2): 83–6.
47. Jelacic J, Todorovic-Balint M, Antic D, Balint B, Perunicic-Jovanovic M, Boricic N, et al. Prognostički značaj hansovog i visco-youngovog imunohistohemijskog algoritma kod difuznog b krupoćelijskog limfoma. Bilt Transfuziol 2015; 61 (1–2): 19–26.
48. Muchatti-Luff Z, Kotlarchyk A, Mayfield J, Todorovic-Balint M, Balint B, Pavlovic M. Altered DNA-methylation involved in Cancer Stem Cell (CSC) emergence and their profiles: A review and proposed concept for Bioinformatics approach. Bilt Transfuziol 2015; 61 (1–2): 27–36.
49. Balint B, Kanjuh V, Todorovic-Balint M, Petkovic S, Balint V, Pavlovic M. Stem cell harvesting and ex vivo manipulations. Bilt Transfuziol 2015; 61 (1–2): 37–42.

50. Jovičić-Gojkov D, Todorović-Balint M, Vučetić D, Balint B. Inovativna paradigma bezbedne hemoterapije: inaktivacija/redukcija patogena – za i protiv. Bilt Transfuziol 2016; 62 (1–2): 5–8.
51. Dejoie A, Balint B, Todorovic-Balint M, Pavlovic M. Donor-less organ transplantation: Achievements and challenges. Bilt Transfuziol 2016; 62 (1–2): 9–15.
52. Ostojić G, Todorović-Balint M, Tarabar O, Vučetić D, Balint V, Ljubenov LJ, Balint B. Terapijska eritrocitafereza kao vid lečenja. Bilt Transfuziol 2016; 62 (1–2): 48–51.
53. Balint B, Todorovic M, Ostojic G, Ljubenov M, Dusan Vucetic, Aleksandar Jevtic et al. Hematopoietic stem cells – from hemobiology to the extracorporeal manipulative viewpoints. Anest Reanim Transf 2017; 43(1–2): 9–22.
54. Levy J, Balint B, Todorovic M, Pavlovic M. What are positive results of stem cell therapies? Anest Reanim Transf 2017; 43(1–2): 23–40.
55. Todorovic Balint M, Jelacic J, Balint B, Bila J, Antic D, Smiljanic M et al. The number of CD34<sup>+</sup> cell dose strikingly influenced survival after autologous stem cell transplantation in Hodgkin's lymphoma patients. Anest Reanim Transf 2017; 43(1–2): 41–6.
56. Ostojić G, Todorović M, Balint V, Jevtić A, Ljubenov M, Balint B. Ekstrakorporalna imunomodulacija – primena fotofereznih postupaka u transplantacijskoj medicini. Anest Reanim Transf 2017; 43(1–2): 51–60.
57. Jovanović I, Gojkov D, Todorović M, Ostojić G, Balint V, Jevtić A, Balint B. Lečenje produktima i preparatima od krvi – usmerena hemoterapija. Anest Reanim Transf 2017; 43(1–2): 73–80.
58. BalintB, Todorovic M, Ostojic G, Dusan Vucetic, Pavlovic M. Apheretic cyto reduction: thrombocy-todepletion – a critical review and our approaches/ experience. Anest Reanim Transf 2018; 44(1–2): 5–16.
59. Borovcanin N, Vucetic D, Ristanovic E, Todorovic M, Mirjana Pavlovic M, Balint B. Molecular testing for blood-borne pathogens in transfusion medicine – a review and our ten-years experience. Anest Reanim Transf 2018; 44(1–2): 17–21.
60. Lagalante K, Todorovic-Balint M, Balint B, Pavlovic M. Stem cells used in dentistry – state of the art. Anest Reanim Transf 2018; 44(1–2): 23–34.
61. Rose R, Balint B, Todorovic-Balint M, Pavlovic M. CRISPR/Cas9 in Bioengineering. Anest Reanim Transf 2018; 44(1–2): 45–56.
62. Rubin M, Balint B, Todorovic M, Radotic K, Pavlovic M. Functional role of wuschel in stem apical meristems. Anest Reanim Transf 2018; 44(1–2): 85–8.
63. Balint B, Todorovic-Balint M, Stamatovic D, Ostojic G. Apheresis in the clinical settings – existing/upcoming therapeutic approaches. Bilt Transf 2018; 63(1-2): 14–6.
64. Balint B, Pavlovic M, Todorovic M. The concept and practice of living cells cryopreservation. Anest Reanim Transf 2019; 45(1–2): 7-20.
65. Fritz K, Todorovic M, Balint B, Pavlovic M. Review of pulmonary arteriole hypertension (PAH) with an emphasis on treatment methods involving bioengineering. Anest Reanim Transf 2019; 45(1–2): 43-59.
66. Todorović Balint M, Balint B, Đunić I, Pavlović M, Šantrić Miličević M. Funkcionisanje i akreditacija Centra za transplantaciju matičnih ćelija u kontekstu implementacije ISO standarda. Anest Reanim Transf 2019; 45(1–2): 59-70.
67. Balint B, Todorović M, Janković S, Samardžić D, Devrnja T, Ćunić J, Vučetić D, Ostojić G, Ljubenov M, Pavlović M. Hemoterapija: autentični pristupi koncentrovani eritrociti, trombociti, kriprecipitat, fibrinski lepak i selektivna afereza. Anest Reanim Transf 2019; 45(1–2): 71-98.

#### **Ceo rad u zborniku sa međunarodnog skupa**

1. Donfrid M, Janković G, Kraguljac N, Suvajdžić N, Čemerikić V, Bogdanović A, Petrović M, Čolović, M. Prognostic significance of immunophenotype in mantle cell lymphoma. 17th International Cancer Congress. Rio de Janeiro (Brazil) 1998; August 24–28 1998, Monduzzi Editore str. 1363–1365.
2. Bogdanovic A, Todorovic M, Mihaljevic B. Mantle cell lymphoma, challenges and knowledge in last three decades. What we can offer to patients into Balcans?. Abstract book of 8<sup>th</sup> Balcan Day of hematology, Turkey, Antalia, 23-26 Oct 2013.

#### **Ceo rad u zborniku sa nacionalnog skupa**

1. V. Čemerikić Martinović, J. Stojišić, A.D. Bogdanović, M. Donfrid, N. Suvajdžić, M. Sretenović, G. Milivojević, M. Čolović. The bone marrow spicules (particles): a morphological and immunocytochemical evaluation. Kongres patologa Jugoslavije, S. Kamenica 1998. Arch Oncol 1998; Supp 2: 117-118.
2. Bakrač M. Proliferacija i apoptoza u bolesnika sa akutnom limfoblastnom leukemijom. XII hematološki dani, Niš 27–30 oktobar 2004, Bilt Hematol 2004; 32(3): 179–182.
3. Vidovic A, Bakrač M, Janković G, Tomin D, Đunić I, Antić D, Čemerikić V, Peruničić M, Đorđević V, Milić N, Bošković D. Korelacija nivoa ekspresije VEGF i P53 sa kliničkim karakteristikama bolesnika u blastnoj krizi hronične granulocitne leukemije. XII hematološki dani, Niš 27–30 oktobar 2004, Bilt Hematol 2004; 32(3): 175–178.
4. Todorović M. Savremeni trendovi u dijagnostici i lečenju odraslih bolesnika sa akutnom limfoblastnom leukemijom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(4): 230-235.
5. Balint B, Stamatovic D, Todorovic M, Obradovic S, Trifunovic Z, Elez M, et al. Preclinical investigations and therapeutic use of stem cells for conventional transplants and organ repair. Bilt Transfuziol 2010; 56: 9–12.
6. Balint B, Kanjuh V, Obradović S, Rusović S, Todorović M, Lazarević S, Rafajlovski S. Terapijska primena matičnih ćelija kod ishemijske bolesti srca. Zbornik radova 3. naučnog skupa SANU. Eds. Kanjuh V, Bukarica–

- Gojković Lj. Beograd: SANU; 2011. p. 15–18.
7. Todorović M, Anđelić B, Balint B, Bila J, Antić D, Vujić D, Kraguljac Kurtović N, Šefer D, Stanisavljević D, Mihaljević B. Autologna transplantacija u Hodgkinovom limfomu. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p. 83-5.
  8. Stamatović D, Balint B, Tukić Lj, Elez M, Tarabar O, Todorović M, Ostojić G, Tatomirović Ž, Marjanović S, Malešević M. The influence of stem cell source on the allogeneic stem cell transplantation outcome in hematological malignancies. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p. 46-9.
  9. Nikolić V, Antić D, Anđelić B, Todorović M, Vukićević T, Pejičić I, Petković I, Popović S, Popović L, Anđelković N, Sretenović S, Marković O, Knežević j, Mihaljević B. Prognostički značaj ki67 indeksa u bolesnika sa difuznim b krupnoćelijskim limfomom koji su lečeni rituximabom plus CHOP-iskustva srpske limfomske grupe. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.23-25.
  10. Antic D, Milic N, Vukovic V, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jeličić J, Mihaljevic B. Da li se može predvideti razvoj tromboembolijskih komplikacija kod bolesnika sa limfomom? 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematološka sekcija SLD 2015:96-98.
  11. Djurasinovic V, Vukovic V, Antic D, Andjelic B, Bila J, Sretenovic A, Jeličić J, Todorovic M, Mihaljevic B. Primena imunohemioterapije kod bolesnika sa HLL-iskustva Klinike za hematologiju KCS. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematološka sekcija SLD 2015:57-58.
  12. Andjelic B, Todorovic M, Bila J, Antic D, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Smiljanic M, Mihaljevic B. Hodgkinov limfom – gde smo sada? 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematološka sekcija SLD 2015: 67-68.
  13. Todorovic Balint M, Bila J, Antic D, Andjelic B, Stanisavljevic D, Vujic D, Balint B, Kraguljac Kurtovic N, Sefer D, Lazic E, Jelcic J, Sretenovic , Djurasinovic V, Vukovic V, Mihaljevic B. Uloga visokodozne hemoterapije u lečenju limfoproliferativnih bolesti. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematološka sekcija SLD 2015: 72-73.
  14. Todorović Balint M. Alogena transplantacija matičnih ćelija hematopoeze: kurativni potencijal i rane komplikacije. 4. kongres hematologa Srbije sa međunarodnim učešćem, Niš, 17-20.10.2019. Hematološka sekcija SLD 2019: 26-28.

#### Izvod u zborniku međunarodnog skupa

1. Petrović M, Mihaljević B, Jančić–Nedeljkov R, Tomin D, Donfrid M, Janković S, Sretenović M, Milivojević G, Petrović Z, Jovanović V, Čolović M. An effect of treatment of patients with Hodgkin lymphoma with the protocol POF–H–89. 1<sup>st</sup> World Congress on Advance in Oncology Athens 22–26 Oct 1995, Int J Oncol: 258.
2. Milivojević G, Nedeljkov–Jančić R, Donfrid M, Perišić M, Jovanović V, Nenadović M, Petrović M. Gaucher disease with nodular infiltration of the spleen: a case report. 1<sup>st</sup> World Congress on Advance in Oncology Athens 22–26 Oct 1995, Int J Oncol: 283.
3. Nedeljkov–Jančić R, Jovanović V, Donfrid M, Petrović M. idiopathic hypereosinophilic syndrome with myelofibrosis and T–cell lymphoma– a case report. 1<sup>st</sup> World Congress on Advance in Oncology Athens 22–26 Oct 1995, Int J Oncol.
4. Donfrid M, Marinković M, Milivojević G, Petrović M. Prognostic significance of immunoglobulins in patients with non–Hodgkin lymphomas. First Balcan Immunology Conference, Belgrade 29. 11.–02.12 1995, Program and Abstract Book1995, 221.
5. Milivojević G, Jančić–Nedeljkov R, Donfrid M, Sretenović M, Petrović M. Monoclonal gammopathy in patients with Hodgkin disease. First Balcan Immunology Conference, Belgrade 29. 11.–02.12 1995, Program and Abstract Book1995, 221.
6. Donfrid M, Janković G, Kraguljac N, Čemerikić V, Bogdanović A, Čolović M. Prognostic significance of immunophenotype in mantle cell lymphoma. ISH–EHA combined haematology congress, 4–8 July, 1998, Amsterdam, Br J Haematol 1998; 102: 124.
7. Suvajdzic N, Donfrid M, Bogdanović A, Pantić M, Kraguljac N, Novak A, Čolović M. Immunophenotype and cytogenetic features in acute myelofibrosis. ISH–EHA combined haematology congress, 4–8 July, 1998, Amsterdam, Br J Haematol 1998; 102: 106
8. Bogdanović A, Tomin D, Suvajdzic N, Janković G, Bošković D, Donfrid M, Vidović A, Tomašević R, Bogdanović G, Kraguljac N, Novak A, Pantić M, Čolović M. Long term follow–up of the adults with acute lymphoblastic treated by conventional and intensive chemotherapy. ISH–EHA combined haematology congress, 4–8 July 1998, Amsterdam, Br J Haematol 1998; 102: 230.
9. Jurišić V, Konjević G, Donfrid M, Spužić I. Different correlation ratio between NK cell activity and spontaneous LDH release in non–Hodgkin lymphomas. 2<sup>nd</sup> International Symposium of Malignant lymphoma, Sep 1998, Ann Haematol; 83.
10. Čolović M, Donfrid M, Janković G, Čemerikić–Martinović V, Bogdanović A, Kraguljac N, Carvalho MG. Prognosis, clinical course and immunophenotype in mantle cell lymphoma. 17<sup>th</sup> International Cancer Congress, Aug 1998, Rio de Janeiro, Abstract Book 1998; 68: 279.
11. Donfrid M, Kraguljac N, Bogdanović A, Suvajdzic N, Tomin D, Bošković D, Čemerikić V, Čolović M, Janković G. Prognostic significance of immunophenotype markers in B–type adult acute lymphoblastic leukaemia. Fourth EHA Congress Barcelona, June 9–12,1999, Spain, Haematologica 1999; 84: 5.

12. Donfrid M, Janković G, Čemerikić V, Kraguljac N, Suvajdžić N, Bogdanović A, Petrović M, Čolović M. Clinical and biological analyses of mantle cell lymphoma. A single Institution study. Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 16.
13. Čemerikić V, Stojšić J, Micev M, Latković Z, Bogdanović A, Donfrid M, Tomin D, Mihaljević B, Milivojević G, Janković S, Petrović M, Čolović M. Mucosa-associated lymphoid tissue lymphomas. Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 74.
14. Čemerikić V, Stojšić J, Micev M, Latković Z, Bogdanović A, Donfrid M, Tomin D, Mihaljević B, Milivojević G, Janković S, Petrović M, Čolović M. Primary extranodal non-Hodgkin lymphomas. Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 75.
15. Čolović M, Kraguljac N, Bogdanović A, Janković S, Donfrid M, Miletic N, Jovanović V, Petrović M, Bošković D, Janković G. Prognostic significance of immunophenotypic markers in B- chronic lymphocytic leukemia. Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 93.
16. Čolović M, Janković G, Bogdanović A, Donfrid M, Bogunović M, Suvajdžić N, Čemerikić V, Jovanović V, Tomašević R, Bogdanović G, Nedeljković T. Analysis of treatment outcome of patients with hypoplastic acute myeloid leukaemia. Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 146.
17. Bogdanović A, Janković G, Donfrid M, Bogunović M, Suvajdžić N, Rajić Z, Vidović A, Čemerikić V, Tomašević R, Bogdanović G, Nedeljković N. Do elderly patients with acute myeloid leukemia benefits from standard intensive induction chemotherapy? Fourth EHA Congress Barcelona, June 9–12, 1999, Spain, Haematologica 1999; 84: 146.
18. Čolović M, Bogdanović A, Kraguljac N, Janković G, Donfrid M, Đurić N, Čemerikić V, Jovanović V, Petrović M, Bošković D, Janković G. Prognostic significance of degree of CD23 positivity in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. VIIth International Conference on malignant lymphoma, Jun 1999, Ann Oncol Abstract Book 1999; 10(3): 456.
19. Čolović M, Bogdanović A, Donfrid M, Janković G, Suvajdžić N, Bogunović M. Therapy with 3+7 ADE and MAE schedule with and without HIDAC postremission therapy. Single study experience. Fifth EHA Congress Birmingham, United Kingdom, 25–28 June 2000. The Hematology Journal 2000; 1: 104.
20. Donfrid M, Janković G, Čemerikić V, Kraguljac N, Suvajdžić N, Bogdanović A, Petrović M, Čolović M. CD25 and lambda expression in mantle cell lymphoma. Fifth EHA Congress Birmingham, United Kingdom, 25–28 June 2000. The Hematology Journal 2000; 1: 173.
21. Čolović M, Čemerikić V, Rolović Z, Janković G, Miljić P, Kraguljac N, Donfrid M, Bogdanović A. Prognostic factors and clinicopathological features of low grade non-Hodgkin lymphoma. Fifth EHA Congress Birmingham, United Kingdom, 25–28 June 2000. The Hematology Journal 2000; 1: 180.
22. Donfrid M, Čemerikić V, Simić S, Bonačić B, Čolović M. Enteropathy associated T-cell lymphoma (case report). 11<sup>th</sup> Panhellenic Congress of Hematology Nov 2000, Haema 2000; 3(1): 194.
23. Bila J, Bošković D, Kraguljac N, Elezović I, Tomin D, Donfrid M, Janković G. Expression of CD7 antigen as a prognostic factor in acute myeloid leukemia. 11<sup>th</sup> Panhellenic Congress of Hematology Nov 2000, Haema 2000; 3(1): 254.
24. Čolović M, Dimitrijević M, Sonnenburg C, Suvajdžić N, Donfrid M. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. 7<sup>th</sup> EHA Meeting Florence, Italy, 6–9 June 2002. The Hematology Journal 2002; 3(1): 92.
25. Suvajdžić N, Pandurović R, Rajić Z, Milošević R, Lazarević V, Bogdanović A, Donfrid M, Bogdanović G, Tomašević R, Elezović I, Čolović M, Bosković D. Thrombotic thrombocytopenic purpura: report of 29 cases. 7<sup>th</sup> EHA Meeting Florence, Italy, 6–9 June 2002. The Hematology Journal 2002; 3(1): 93.
26. Donfrid M, Čemerikić V, Simić S, Bonačić B, Suvajdžić N, Čolović M. Enteropathy associated T-cell lymphoma. 7<sup>th</sup> EHA Meeting Florence, Italy, 6–9 June 2002. The Hematology Journal 2002; 3(1): 382.
27. Donfrid M, Čemerikić V, Jevtović Đ, Nedeljković-Jančić R, Suvajdžić N, Čolović M. Bone marrow changes in patients with AIDS. 7<sup>th</sup> EHA Meeting Florence, Italy, 6–9 June 2002. The Hematology Journal 2002; 3(1): 382.
28. Čolović M, Vugdelija D, Čemerikić V, Marisavljević D, Mihaljević B, Čolović N, Bakrač M, Jurišić V, Suvajdžić N. Cyclin D1 expression is useful in distinguishing mantle cell lymphoma from follicular and small lymphocytic lymphoma. 9<sup>th</sup> EHA Congress 10–13 June 2004, Geneva, Switzerland, The Hematology Journal 2004; 5(2): 240.
29. Bakrač M, Čolović M, Čemerikić V, Marković O, Petrović M, Elezović I, Bošković D. Expression of Ki-67, p53 and bcl-2 antigens in acute lymphoblastic leukemia: an immunohistochemical study. 9<sup>th</sup> EHA Congress 10–13 June 2004, Geneva, Switzerland, The Hematology Journal 2004; 5(2): 320.
30. Bakrač M, Peruničić M, Vidović A, Petrović M, Elezović I, Čolović M, Bošković D. Expression of proliferation and apoptotic antigens in newly diagnosed and relapsed acute lymphoblastic leukemia. 9<sup>th</sup> EHA Congress 10–13 June 2004, Geneva, Switzerland, The Hematology Journal 2004; 5(2): 320.
31. Bakrač M, Čemerikić V, Čolović M, Elezović I, Tomin D, Petrović M, Suvajdžić N, Bošković D. Bone marrow biopsy in adult acute lymphoblastic leukemia: proliferative activity and morphological characteristics. 10<sup>th</sup> EHA Congress 10–13 June 2005, Stockholm, Sweden, The Hematology Journal 2005; 90(2): 393.
32. Bakrač M, Čemerikić V, Bila J, Čolović M, Elezović I, Petrović M, Tomin D, Bošković D. Increased angiogenesis in the bone marrow of patients with acute lymphoblastic leukemia. 10<sup>th</sup> EHA Congress 10–13 June 2005, Stockholm, Sweden, The Hematology Journal 2005; 90(2): 171.

33. Suvajdžić–Vuković N, Stanković B, Artiko V, Cvejić T, Bulat V, Bakrač M, Čolović M, Bošković D: Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura (ITP chr). 10<sup>th</sup> EHA Congress 10–13 June 2005, Stockholm, Sweden, The Hematology Journal 2005; 90(2): 276.
34. Bakrač M, Kraguljac N, Bila J, Mihaljević B, Elezović I, Petrović M, Gotić M, Vidović A, Perunović M, Čolović M, Suvajdžić N, Marković O, Bošković D: Evaluation of peripheral blood and bone marrow involvement in mantle cell lymphoma (MCL)– immunophenotypic and morphological findings. 11<sup>th</sup> EHA Congress 15–18 June 2006, Amsterdam, The Netherlands, Haematologica 2006; 91(1): 1379.
35. Bila J, Perunović M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Tomin D, Vidović A, Čemerikić V, Bosković D. Tumor–host interactions in the bone marrow of multiple myeloma patients: analysis of clinical relevance and prognostic significance. 11<sup>th</sup> EHA Congress. 15–18 June 2006, Amsterdam, The Netherlands, Haematologica 2006; 91(1): 766.
36. Vidović A, Janković G, Colović M, Tomin D, Perunović M, Djunić I, Antić D, Bila J, Bakrač M, Marković O, Čemerikić V, Bosković D. The expression of proto-oncogenes in the course of chronic myeloid leukemia. 11<sup>th</sup> EHA Congress. 15–18 June 2006, Amsterdam, The Netherlands, Haematologica 2006; 91(1): 680.
37. Marković O, Marisavljević D, Čemerikić V, Perunović M, Bakrač M, Vidović A, Elezović I, Colović M. VEGF expression and microvessel density in patients with multiple myeloma: clinical and prognostic significance. 11<sup>th</sup> EHA Congress. 15–18 June 2006, Amsterdam, The Netherlands, Haematologica 2006; 91(1): 759.
38. Matić S, Milovanović A, Antić A, Petrović M, Milanović A, Bakrač M, Bila J, Elezović I, laparoscopska splenektomija u lečenju ITP–a. Beogradsko iskustvo. Book of abstract of 7<sup>th</sup> Congress of Croatian Association of Digestive Surgery. May 16–19. 2007, Opatija–Rijeka, Croatia; p. 152.
39. Marković O, Marisavljević D, Čemerikić V, Perunović M, Vidović A, Bakrač M, Elezović I, Colović M. Different methods for estimation of angiogenesis in patients with multiple myeloma. 12<sup>th</sup> EHA Congress. 7–10 June 2007, Vienna, Austria, Haematologica 2007; 92(1): 1104.
40. Bila J, Perunović M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Mihaljević B, Vidović A, Tomin D, Čemerikić V, Bosković D. The relation between proliferation index and angiogenesis in multiple myeloma. 12<sup>th</sup> EHA Congress. 7–10 June 2007, Vienna, Austria, Haematologica 2007; 92(1): 683.
41. Bila J, Perunović M, Elezović I, Bakrač M, Suvajdžić N, Gotić M, Mihaljević B, Tomin D, Vidović A, Čemerikić V, Bosković D. Clinical relevance of regulatory network in the bone marrow compartment of patients with multiple myeloma. 12<sup>th</sup> EHA Congress. 7–10 June 2007, Vienna, Austria, Haematologica 2007; 92(1): 1069.
42. Bila J, Elezović I, Perunović M, Suvajdžić–Vuković N, Todorović M, Tomin D, Vidović A, Mihaljević B, Gotić M, Bosković D. Analysis of distinct multiple myeloma subgroups based on biological characteristics, bone marrow microenvironment and international staging system. 13<sup>th</sup> EHA Congress. 12–15 June 2006, Copenhagen, Denmark, Haematologica 2008; 93(1): 670.
43. Todorović M, Suvajdžić N, Perunović M, Balint B, Krstić M, Bosković D. Clinical features and treatment outcome of primary gastric mucosa associated lymphoid tissue lymphoma. 13<sup>th</sup> EHA Congress. 12–15 June 2006, Copenhagen, Denmark, Haematologica 2008; 93(1): 1307.
44. Mihaljević B, Janković S, Andjelic B, Jancić–Nedeljković R, Milošević V, Sretenović A, Bogunović M, Vidović A, Todorović M, Bila J, Sretenović M, Colović N, Virijević M, Marković O, Djurdjević P, Sretenović S, Jaković Lj, Perunović M, Petrović M, Bosković D. 3 years outcome of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients treated with immunochemotherapy–Serbian lymphoma study group (SLG) experience. 10<sup>th</sup> International Conference on Malignant lymphoma 4–7 June 2008, Lugano, Switzerland, Ann Oncol 2008; 19 (4): 473.
45. Rafajlovski S, Ostojic G, Todorović M, Balint B, Jevtić M. The role of therapeutic apheresis in the treatment of immune-mediated disorders. Haematologica The Hematology Journal 14<sup>th</sup> Congress of the European Hematology Association Berlin Germany June 4–7 2009, Abs 1800.
46. Todorović M, Mihaljević B, Balint B, Kraguljac N, Andjelic B, Perunović M, Marković O, Petrović M. Immunological profile linked clinical appearance and outcome in advanced stage mantle cell lymphoma. Haematologica The Hematology Journal 14<sup>th</sup> Congress of the European Hematology Association Berlin Germany June 4–7 2009, Abs 1694.
47. Mitrović–Vasiljević M, Djunić I, Tomin D, Suvajdžić N, Elezović I, Todorović M, Vidović A, Antić D. Results of treatment with Hyper-CVAD in adult acute lymphoblastic leukemia: single center study. Haematologica The Hematology Journal 14<sup>th</sup> Congress of the European Hematology Association Berlin Germany June 4–7 2009, Abs 1451.
48. Rafajlovski A, Todorović M, Marjanović S, Obradović S, Balint B, Jevtić M. Influence of stem cell subsets on marrow repopulation capacity or solid organ regenerative potential. Haematologica The Hematology Journal 14<sup>th</sup> Congress of the European Hematology Association Berlin Germany June 4–7 2009, Abs 1169.
49. Balint B, Todorović M, Jevtić M, Ostojic G, Ristanović E, Vojvodić D, Obradović S, Urošević I, Trkuljić M. The use of stem cells for marrow repopulation and in the field of regenerative medicine. Books of Abstracts III Congress of macedonian Society of Transfusion medicine Ohrid 10–14. 06. 2009. p 12–19.
50. Todorović M, Andjelic B, Mihaljević B. Mantle cell lymphoma in leukemic phase as specific entity disease characteristics and clinical outcome: single center study. V Congress of Internal medicine for the South-Eastern Europe March 6–9<sup>th</sup> 2009, Belgrade Serbia Abstract book, Vol 2(11): p 33.
51. Sretenović M, Colović M, Janković G, Suvajdžić N, Mihaljević B, Colović N, Todorović M, Atkinson HD. More than a third of non-gastric malt lymphomas have disseminated at diagnosis: a single center survey. V Congress of Internal medicine for the South-Eastern Europe March 6–9<sup>th</sup> 2009, Belgrade Serbia Abstract book, Vol 2(11): O 33

52. Balint B, Ostojic G, Ignjatovic Lj, Todorovic M, Trkuljic M. ABO/H histo-blood group "sero-conversion" by simplified immunoadsorption and the use of "multi-manner" apheresis in renal transplants. *Vox Sang* 2009; 96(1): 48.
53. Balint B, Stamatovic D, Urosevic I, Todorovic M, Trkuljic M. Optimized stem cell harvesting protocol to expand immature CD34-subset ratio for marrow repopulating and regenerative potential. *Vox Sang* 2010
54. Todorovic M, Andjelic B, Palibrk V, Balint B, Kraguljac-Kurtovic N, Mihaljevic B. International Prognostic Index (IPI) vs. Mantle-IPI (MIPI) relation in the patients with advanced stage mantle cell lymphoma (MCL): the correlation between laboratory data and clinical outcome. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95(2): 625.
55. Bila J, D Lekovic D, Smiljanic M, Sretenovic A, Vujic D, Veljkovic D, Antic D, Sefer D, Kraguljac N, Andjelic B, Todorovic M, Elezovic I, Tomin D, Gotic M, Mihaljevic M. The role of thalidomide maintenance following high dose therapy in patients with multiple myeloma. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95(2): p 391, Abs 945.
56. Milošević V, Bogunovic M, Jankovic S, Antic D, Tomin D, Todorovic M, Kraguljac Kurtovic N, Perunicic Jovanovic M, Bogdanovic A, Mihaljevic B, Gotic M. The efficacy of fludarabine and cyclophosphamide combination in untreated vs pretreated patients with B-cell chronic lymphocytic leukemia. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95(2): p 391, p 527, Abs 1297.
57. Bila J, Lekovic D, Smiljanic M, A Sretenovic, Andjelic B, Vidovic A, Todorovic M, Elezovic I, Tomin D, Gotic M, Mihaljevic M. The maintenance therapy with thalidomide in elderly patients with multiple myeloma. . *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Barcelona Spain June 10-13 2010*; 95(2): p 583, Abs.1460.
58. Andjelic B, Todorovic M, Bila J, Smiljanic M, Perunicic-Jovanovic M, Jakovic Lj, Petrovic M, Mihaljevic M. Prognostic significance of lymphoma associated macrophages (lam), ki-67 and histological grade in newly diagnosed follicular lymphoma patients. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95(2): p 618, Abs 1560.
59. Lekovic D, Bila J, Todorovic M, Andjelic B, Sretenovic A, Smiljanic M, Mihaljevic B. Prognostical significance of ki-67 expression and ipi score in patients with primary mediastinal large B-cell lymphoma: a single centre retrospective analysis. *The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95( 2): p 619, Abs 1565.
60. Suvajdzic N, Djurdjevic P, Colovic N, Petrovic M, Elezovic I, Tomin D, Gotic M, Jankovic G, Todorovic M, Vidovic A, D Bila, T Djunic, Perunicic M, Mihaljevic B. Clinical features of the patients with lymphoproliferative disorders and associated autoimmune rheumatic diseases: single center study. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association Barcelona Spain June 10-13 2010*; 95(2): p 620, Abs 1569.
61. Markovic O, Marisavljevic D, Filipovic B, Cemerikic V, Todorovic M, Perunicic M, Mihaljevic M. Expression of c-flip in nodal diffuse large b cell lymphoma (DLBCL): an immunohistochemical study. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association. Barcelona Spain June 10-13 2010*; 95(2): p 624, Abs 1578.
62. Todorović M, Andjelic B, Palibrk V, Balint B, Kraguljac Kurtovic N, Mihaljevic B. International prognostic index IPI vs. mantle IPI relation in patients with mantle cell lymphoma MCL: correlation between laboratorz data and clinical outcome. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association. Barcelona Spain June 10-13 2010*; 95(2): p 625, Abs 1581.
63. Andjelic B, Todorovic M, Bila J, Smiljanic M, Perunicic-Jovanovic M, Jakovic Lj, Sretenovic A, Palibrk V, Mihaljevic B. Immunochemotherapy versus chemotherapy in 90 newlydiagnosed patients with follicular lymphoma: a singleinstitution study. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association. Barcelona Spain June 10-13 2010*; 95(2): p 630, Abs 1597.
64. Todorovic M, Andrejevic S, Andjelic B, Palibrk V, Kraguljac Kurtovic N, Mihaljevic B. Diffuse large B - cell lymphoma in the course of commonvariable immunodeficiency succesfully treated withimmunochemotherapy: a case report. *Haematologica The Hematology Journal 15<sup>th</sup> Congress of the European Hematology Association. Barcelona Spain June 10-13 2010*; 95(2): p 640, Abs 1626.
65. Balint B, Todorovic M. Istraživanje i primena matičnih ćelija u ransplantaciji i na polju regenerativne medicine-overview. *Knjiga sažetaka, prvi kongres hematologa i transfuziologa Bosne i Hercegovine sa međunarodnim učešćem. 19-22Maj Sarajevo BIH*, p 22, Abs 30.
66. Balint B, Todorovic M, Vucetic D, Jovicic D, Jocić M, Subota V, Mijuskopvic Z. Compar.ative effectiveness of prestorage vs. poststorage riboflavin and ultraviolet-light treatment on the quantity and functionality of fresh frozen plasma constituents. *Vox Sang* 2011; 101(2): 77.
67. Andjelic B, Mihaljevic B, Antic D, Todorovic M. Risk factors in first relapse of follicular lymphoma.. 11-ICML 11<sup>th</sup> International Conference on malignant lymphoma 15-18 June 2011 Lugano Switzerland. *Ann Oncol Vol 22(4)*: p 218, Abs 427
68. Mihaljevic B, Andjelic B, Antic D, Todorovic M, Vukicevic T, Nikolic V, Pejčić i, Petkovic I, Popovic S, Savic I, Popovic I, Andjelkovic N, Sretenovic S, Knezevic J, Kecman Z. Diffuse large B cell lymphoma: germinal center vs non germinal center- treatment response on immunochemotherapz, Serbian lymphoma study group., Abs 448. 11-ICML 11<sup>th</sup> International Conference on malignant lymphoma 15-18 June 2011 Lugano Switzerland. *Ann Oncol Vol 22(4)*: p 224.

69. Markovic O, Marisavljevic D, Mihaljevic B, Cemerikic V, Perunicic Jovanovic M, Savic A, Todorovic M, Vidovic A, Zivkovic R. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96( 2): p 155, Abs 373.
70. Todorovic M, Andjelic B, Balint B, Radisavljevic Z, Mihaljevic B. Switching BCL6 positive to negativity in relapsing diffuse large B cell lymphoma. 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96( 2): p 395, Abs 947.
71. Bila J, Bodrozic J, Smiljanic M, Andjelic B, Antic D, Todorovic M, Vidovic A, Gotic M, Elezovic I, Tomin D, Mihaljevic B. The relevance of the international staging system in multiple myeloma in the era of new treatment modalities. 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96( 2): p 542, Abs 1340.
72. Virijevic M, Andjelic B, Todorovic M, Smiljanic M, Novkovic A, Djunic I, Mihaljevic B. Hypoalbuminemia as the most significant predictor of poor overall survival in the patient with mucosa associated lymphoid tissue non Hodgkin lymphoma. 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96(2): p 566, Abs 1417.
73. Andjelic B, Mihaljevic B, Antic D, Todorovic M. Different risk factors for relapsed follicular lymphoma treated with chemotherapy versus immunochemotherapy. 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96(2): p 574, Abs 1442.
74. Mihaljevic B, Antic D, Andjelic B, Todorovic M, Vukicevic T, Nikolic V, Pejic I, Petkovic I, Popovic S, Popovic L, Andjelkovic N, Sretenovic S, Smiljanic M, Markovic o, Kneyevic J. Prognostic significance of the Ki-67 index in diffuse large b cell lymphoma pateients tretaed with rituximab plus CHOP. Experience of serbian lymphoma Studu group. 16th Congress of the European Hematology Association London UK, June 9-12 2011. *Haematologica The Hematology Journal* Vol 96( 2): p 575, Abs 1445.
75. Vucetic D, Balint B, Borovcanin N, Ljubenov M, Jovicic D, Todorovic M, Graovac R. Seroprevalence of trasfusion-transmitted infections- are there confirmed benefits from paralel investigatio by ELISA and NAT. 21st Regional Congress of the ISBT Europe Lisbon Portugal, June 18-22 2011. *Vox Sang* 2011; 101(1): p 195, Abs p-289.
76. Balint B, Stamatovic D, Todorovic M, Elez M. The use of autologous transplant in aplastic anemia: correlation of CD34+/CD90+ cells applied and clinical outcome. 21st Regional Congress of the ISBT Europe Lisbon Portugal, June 18-22 2011. *Vox Sang* 2011; 101(1): p 340, Abs p-655.
77. Balint B, Todorovic M, Vucetic D, Jovicic D, Jovic M, Subota V, Mijuskovic Z. Comparative effectiveness of prestorage vs poststorage riboflavin and ultraviolet loight tratment on the quantity and functionality of fresh frozen plasma constituents. 22st Regional Congress of the ISBT Asia Taipei Taiwan, Nov 19-23 2011. *Vox Sang* 2011; 101(2): p 77, Abs p-138.
78. Andjelic B, Todorovic M, Antic D, Bila J, Mihaljevic B. High FLIPI risk follicular lymphoma: Combining histological grade, erythrocyte sedimentation rate and hypoalbuminemia can additionally contribute in prognosis. 17th Congress of the European Hematology Association, Amsterdam The Netherlands, June 14-17 2012. *Haematologica The Hematology Journal* 2012;97(Suppl 1):667.
79. Balint B, Stamatovic D, Todorovic M, Ostojic G, Elez M, Bila J, Vucetic D, Andjelic B, Mihaljevic B. Conventional vs. Large volume apheresis for allogeneic and autologous stem cell transplants. 17th Congress of the European Hematology Association, Amsterdam The Netherlands, June 14-17 2012. *Haematologica The Hematology Journal* 2012;97(Suppl 1):718.
80. Bila J, Vujic D, Veljkovic D, Todorovic M, Sefer D, Kraguljac N, Antic D, Andjelic B, Smiljanic M, Jankovic S, Gotic M, Mihaljevic B. Efficacy of induction treatment with cyclophosphamide, thalidomide and dexamethasone (CTD) chemotherapy in newly diagnosed myeloma patients eligible for the autologous stem cell transplantation. 17th Congress of the European Hematology Association, Amsterdam The Netherlands, June 14-17 2012. *Haematologica The Hematology Journal* 2012;97(Suppl 1):614.
81. Todorovic M, Balint B, Andjelic B, Bila J, Elezovic I, Antic D, Vujic D, Veljkovic D, Kraguljac-Kurtovic N, Sefer D, Stanisavljevic D, Mihaljevic B. Risk profile of relapsed/refractory Hodgkin lymphoma patients treated with high dose chemotherapy and autologous stem cell transplant- a single center experience. 17th Congress of the European Hematology Association, Amsterdam The Netherlands, June 14-17 2012. *Haematologica The Hematology Journal* 2012;97(Suppl 1):566.
82. Balint B, Stamatovic D, Todorovic M, Ostojic G, Elez M, Vucetic D. Conventional vs. large volume apheresis for allogeneic and autologous stem cell transplants. 17th Congress of the European Hematology Association, Amsterdam The Netherlands, June 14-17 2012. *Haematologica* 2012;97(Suppl 1).
83. Todorovic M, Balint B, Andjelic B, Bila J, Antic D, Elezovic I, Vujic D, Veljkovic D, Ostojic G, Kraguljac Kurtovic N, Sefer D, Stanisavljevic D, Mihaljevic B. Positioning of the high-dose therapy and autologous stem cell transplant in refractory and/or relapsed Hodgkin lymphoma – single center study; 38<sup>th</sup> EBMT Annual Meeting; 1–4. 04. 2012; Geneva. *Bone Marrow Transpl* 47(1): p 452, Abs 1156.
84. Balint B, Todorovic M, Andjelic B, Veljkovic D, Ostojic G, Vucetic D, Mihaljevic B. Clinical recovery following the treatment of invasive fungal sepsis by antimycotic drugs and rHuG-CSF plus Dexametasone mobilized granulocytes in autologous stem cell recipient; 38<sup>th</sup> EBMT Annual Meeting; 1–4. 04. 2012; Geneva. *Bone Marrow Transplantat* 47(1): p 129, Abs 482.

85. Balint B, Ljubenov M, Ostojic G, Stamatovic D, Todorovic M, Elez M, et al. Semiquantitative column agglutination technology for the confirmation of donor himerism following allogeneic stem cell transplants; 38<sup>th</sup> EBMT Annual Meeting; 1–4. 04. 2012; Geneva. Bone Marrow Transpl 47(1): p 263, Abs 766.
86. Balint, B, Todorovic M, Vucetic D, Draskovic B, Ostojic G, Rafajlovski N. The use of controlled-rate vs uncontrolled-rate freezing in lymphocyte and platelet cryopreservation setting. 23th ISBT Regional Congress July 2012 Cancun Mexico, Vox Sang 2012; 103(1): p257, Abs 618.
87. Vucetic D, Balint, B, Todorovic M, Ristanovic E, Protic-Djokic V, Ljubenov M, Jovicic D. Are there recognized benefit from paired syphilis antibody plus confirmatory testing of blood donors? 23th ISBT Regional Congress July 2012 Cancun Mexico Vox Sang 2012; 103(1): p177, Abs 346.
88. Balint B, Todorovic M, Ostojic G, Vucetic D, Krstic M, Radovic M, Petakov M. Immediate benefit from plasma exchange in the treatment of severe hypertriglyceridemia using spectra-optia vs. cobe spectra. . 24st Regional Congress of the ISBT Europe Amsterdam Nitherland, June 2-5 2013. Vox Sang 2013; 105(1): p 256, Abs p-570.
89. Mihaljevic B, Jovanovic D, Andjelkovic N, Popovic S, Vukicevic T, Andjelic B, Popovic L, Todorovic M, Vlaisavljevic N, Sretenovic A, Djurdjevic P, Sretenovic S, Jankovic S, Markovic O, Marjanovic G, Vrbic S, Hajder J, Zivic D. Maximizing therapeutic benefit of rituximab for relapsed/resistant follicular lymphoma: 2 years maintenance therapy results. 12<sup>th</sup> -ICML International Conference on malignant lymphoma June 19-22 2013 Lugano Switzerland. Hematol Oncol 31( 4): p 221, Abs 379.
90. Andjelic B, Todorovic M, Antic D, Bila J, Jankovic S, Smiljanic M, Sretenovic A, Jelcic J, Vukovic V, Mihaljevic B. R-HyperCVAD in treatment of gastrointestinal Burkitt lymphoma-risk stratification and treatment outcome. 12<sup>th</sup> -ICML International Conference on malignant lymphoma June 19-22 2013 Lugano Switzerland. Hematol Oncol 31( 4): p 226, Abs 395.
91. Antic D, Jelcic J, Djurasinovic V, Vukovic V, Milic N, Todorovic M, Bila J, Andjelic B, Perunicic Jovanovic M, Jakovic Lj, Mihaljevic B. Treatment approach and prognostic factors in patients with primary gastric diffuse large B cell lymphoma. 12<sup>th</sup> -ICML International Conference on malignant lymphoma June 19-22 2013 Lugano Switzerland. Hematol Oncol 31( 4): p 235, Abs 425.
92. Antic D, Jelcic J, Djurasinovic V, Vukovic V, Milic N, Todorovic M, Bila J, Andjelic B, Perunicic Jovanovic M, Jakovic Lj, Mihaljevic B. C-reactive protein as an independent prognostic factor for gastric diffuse large B cell lymphoma treated with rituximab plus chemotherapy. 12<sup>th</sup> -ICML International Conference on malignant lymphoma June 19-22 2013 Lugano Switzerland. Hematol Oncol 31( 4): p 236, Abs 427.
93. Andjelic B, Todorovic M, Antic D, Bila J, Jankovic S, Smiljanic M, Sretenovic A, Jelcic J, Vukovic V, Mihaljevic B. Advanced Hodgkin lymphoma in pregnancy-a single center experience. 12<sup>th</sup> -ICML International Conference on malignant lymphoma June 19-22 2013 Lugano Switzerland. Hematol Oncol 31( 4): p 23644, Abs 455.
94. Antic D, Jelcic J, Djurasinovic V, Vukovic V, Milic N, Todorovic M, Bila J, Andjelic B, Perunicic Jovanovic M, Jakovic Lj, Mihaljevic B. A 10-year single center experience in primary gastric diffuse large B cell lymphoma: from presentation to treatment and prognosis. 18th Congress of the European Hematology Association, Stockholm Sweden, June 13-16 2013. Haematologica The Hematology Journal 2013; 98( 1):p 642, Abs B1628.
95. Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Mihaljevic B, Stanisavljevic D, Hajder J, Zivkovic N, Petrovic D, Stanisavljevic N, Matovina-Brko G, Todorovic M, Bila J. Prognostic significance of low lymphocyte count in the patients with diffuse large B cell lymphoma (DLBCL). 18th Congress of the European Hematology Association, Stockholm Sweden, June 13-16 2013. Haematologica The Hematology Journal 2013; 98( 1):p 643, Abs B1632.
96. Andjelic B, Todorovic M, Antic D, Bila J, Mihaljevic B. Follicular lymphoma in first relapse: anemia and high erythrocyte sedimentation strongly predict the outcome. 18th Congress of the European Hematology Association, Stockholm Sweden, June 13-16 2013. Haematologica The Hematology Journal 2013; 98( 1):p 644, Abs B1635.
97. Smiljanic M, Milosevic R, Antic D, Andjelic B, Djurasinovic V, Todorovic M, Mihaljevic B. Orbital and ocular adnexal MALT (mucosa associated lymphoid tissue) lymphomas ten year experience. 18th Congress of the European Hematology Association, Stockholm Sweden, June 13-16 2013. Haematologica The Hematology Journal 2013; 98( 1):p 645, Abs B1636.
98. Andjelic B, Antic D, Jakovic Lj, Todorovic M, Bogdanovic A, Bila J, Mihaljevic B. The identification of high risk abvd treated advanced hodgkin's lymphomapatients-ips remains the most appropriate prognostic tool. 9th international symposium on H odgkin lymphoma, Keln, 12-15.10.2013.
99. Andjelic B, Jakovic Lj, Antic D, Todorovic M, Bila J, SretenovicA, Djurasinovic V, Mihaljevic B The differences in risk profile of male and female patients with advancedhodgkin's lymphoma.. 9th international symposium on hodgkin lymphoma, Keln, 12-15.10.2013.
100. Antic D, Andelic B, Milic N, Durašinovic V, Todorovic M, BilaJ, Vukovic V, Jelcic J, Mihaljevic B. New prognostic score based on bcl-6 expression and ips strongly predictssurvival in patients with hodgkin lymphoma9th international symposium on hodgkin lymphoma, Keln, 12-15.10.2013.
101. Smiljanic M, Milosevic R, Antic D, Andjelic B, Djurasinovic V, Todorovic M, Bila J, Bogdanovic A, Mihaljevic B. Obital and ocular adnexal malt (mucosa-associated lymphoid tissue) lymphomas: a single-center ten year experience..Lymphoma and Myeloma 2013; New York, 24-26.10.2013.
102. Balint B, Todorovic M, Tarabar O, Ostojic G. CLL associtaed severe AIHA treated by MMA.Lymphoma and Myeloma 2013; New York, 24-26.10.p 13.

103. Antic D, Jelacic J, Djurasinovic V, Vukovic V, Milic N, Todorovic M, Bila J, Andjelic B, Perunicic M, Jakovic Lj, Mihaljevic B. Is there adequate prognostic score for patients with primary gastric diffuse large B cell lymphoma? Lymphoma and Myeloma 2013; New York, 24-26.10.2013.p 17.
104. Mihaljević B, Antić D, Todorović M. Primary testicular lymphoma-single center experience. Lymphoma and Myeloma 2013; New York, 24-26.10.2013.p 24.
105. Todorovic M, Balint B, Andjelic B, Bila J, Stanisavljevic D, Vujic D, Kraguljac Kurtovic N, Sefer D, Jelacic J, Mihaljevic B. Therapeutic outcome of relapsed/ refractory Hodgkin lymphoma patients treated with high dose therapy and autologous stem cell transplant: a single center experience. Accepted for 40<sup>th</sup> EBMT Congress, Milan 30 mar-2 Apr 2014.
106. Balint B, Todorovic M, Vojvodic D, Ostojic G, Stamatovic D, Vucetic D, Elez M. Total CD34+ quantity and CD34 subtype ratio in Cobe-Spectra vs. Spectra-optia autologous stem cell harvests-a comparative research. Accepted for 40<sup>th</sup> EBMT Congress, Milan 30 mar-2 Apr 2014.
107. Andjelic B, Perunicic-Jovanovic M, Jaković Lj, Antic D, Todorovic M, Bila J, Sretenovic A, Djurasinovic V, Vukovic V, Jeličić J, Smiljanic M, Mihaljevic B. Hodgkin lymphoma patients with low number of FOXP3 lymphocytes in tumor tissue-risk profile and treatment outcome. 13th International Conference on malignant lymphoma 17-20 June 2015, Lugano, Switzerland. Hematol Oncol 2015;33(suppl 1):248.
108. Todorovic Balint M, Antic D, Zaric E, Milic N, Balint B, Kraguljac Kurtovic N, Jelacic J, Bila J, Mihaljevic B. CD5-positive chronic B-cell lymphoproliferative disorders: Diagnostic criteria and prognosis. 13th International Conference on malignant lymphoma 17-20 June 2015, Lugano, Switzerland. Hematol Oncol 2015;33(suppl 1):253.
109. Antic D, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelacic J, Nikolovski S, Mihaljevic B. Development of a prediction score for the identification lymphoma patients at risk for thromboembolism. 13th International Conference on malignant lymphoma 17-20 June 2015, Lugano, Switzerland. Hematol Oncol 2015;33(suppl 1):309.
110. Antić D, Milić N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Nikolovski S, Mihaljevic B. Development of a predictive score for the identification of lymphoma patients at risk for thromboembolism. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):20-21.
111. Todorovic Balint M, Sretenovic A, Kecman V, Antic D, Jeličić J, Bogdanovic A, Bila J, Andjelić B, Djurasinovic V, Vukovic V, Smiljanic M, Mihaljevic B. The occurrence of other malignancies in patients with chronic lymphocytic leukemia. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):423-424.
112. Andjelic B, Perunicic-Jovanovic M, Jaković Lj, Antic D, Todorovic M, Bila J, Sretenovic A, Djurasinovic V, Smiljanic M, Vukovic V, Jeličić J, Mihaljevic B. Hodgkin lymphoma patients with high number of macrophages in tumor tissue-risk profile and treatment outcome. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):456-457.
113. Jeličić J, Todorovic M, Andjelic B, Sretenovic A, Antić D, Bila J, Stanisavljevic D, Djurasinovic V, Vukovic V, Smiljanic M, Mihaljevic B. Does age adjusted Charlson comorbidity score strongly predict outcome of the patients with follicular lymphoma treated with immunochemotherapy? 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):462.
114. Jeličić J, Bila J, Vukovic V, Djurasinovic V, Andjelić B, Sretenovic A, Smiljanic M, Antić D, Todorovic M, Mihaljevic B. Clinical features, prognosis and treatment outcome of the extraosseous plasma cell neoplasia: plasmacytoma, multiple myeloma and primary plasma cell leukemia. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):520-521.
115. Jeličić J, Todorović M, Antić D, Bila J, Andjelic B, Stanisavljević D, Djurasinovic V, Sretenovic A., Vukovic V, Smiljanic M, Mihaljevic B. Is there a place for total tumor resection of primary Central nervous system lymphoma in patients with good performance status? 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):659-660.
116. Jeličić J, Todorović M, Antić D, Bila J, Andjelic B, Stanisavljević D, Djurasinovic V, Sretenovic A., Vukovic V, Smiljanic M, Petkovic I, Vrbic I, Mihaljevic B. The role of prognostic and comorbidity indexes in patients with diffuse large B cell lymphoma treated with immunochemotherapy. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):660-661.
117. Mihaljevic B, Smiljanic M, Jeftovic D, Ranin J, Salemovic D, Todorović M, Bila J, Andjelić B, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Antic D. Favorable prognostic parameters in treatment of Aids related lymphoma patients: ten years single centre experience. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):662. .
118. Vuković V, Antic D, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Jeličić J, Mihaljevic B. Cumulative illness rating scale (CIRS)- an independent prognostic parameter for chronic lymphocytic leukemia patients pretreatment stratification. 20th Congress of the European Hematology Association, Vienna, Austria, June 11-14 2015. Haematologica 2015;100 (Suppl 1):682.
119. Todorovic Balint M, Antic D, Zaric E, Milic N, Balint B, Kraguljac Kurtovic N, Jelacic J, Bila J, Mihaljevic B. CD 5 positive chronic lymphoproliferative disorders- diagnostic criteria and prognosis. Hematological Oncology 2015; 33 (1): xx [Abs 313].

120. Todorovic-Balint M, Antic D, Zaric E, Miljic N, Balint B, Kraguljac-Kurtovic N, et al. CD5 positive chronic lymphoproliferative disorders - diagnostic criteria and prognosis. *Hematol Oncol* 2015; 33 (1): [Abs 313].
121. Antic D, Milic N, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Nikolovski S, Mihaljevic B. Decoding risk for thromboembolic events in lymphoma patients. Thrombosis and hemostasis issues in cancer, Bergamo, Italy, April 8-10, 2016. *Thromb Res.* 2016;140(s1):S171
122. Antić D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Mihaljevic B. Decoding the risk of thromboembolic events in lymphoma patients. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 19-20.
123. Bila J, Sretenovic A, Jelcic J, Tosic N, Glumac I, Dencic Fekete M, Antic D, Todorovic Balint M, Markovic O, Puric M, Milojevic Z, Radojkovic M, Trajkovic G, Pavlovic S, Mihaljevic B. Is there a prognostic impact of the cereblon expression in Multiple myeloma? 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 101:259-260.
124. Sretenovic A, Bila J, Jelcic J, Dencic Fekete M, Djuasinovic V, Smiljanic M, Vukovic V, Antic D, Andjelic B, Todorovic M, Mihaljevic B. Prognostic significance of the revised international staging system in multiple myeloma. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 101:545-546.
125. Djurasinovic V, Djurdjevic P, Antic D, Andjelic B, Sretenovic A, Vukovic V, Bila J, Jelcic J, Todorovic-Balint M, Mihaljevic B. Prevalence of lymphoproliferative diseases in patients with autoimmune disorders. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 709.
126. Jelcic J, Todorovic Balint M, Antic D, Andjelic B, Markovic O, Petkovic I, Sretenovic A, Bila J, Vukovic V, Djurasinovic V, Smiljanic M, Pejic I, Mihaljevic B. Analysis of clinical parameters, absolute lymphocyte and absolute monocyte count in patients with diffuse large B cell lymphoma. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 706.
127. Vukovic V, Antic D, Cokic V, Buac M, Diklic M, Todorovic Balint M, Bila J, Andjelic B, Dencic Fekete M, Djurasinovic V, Sretenovic A, Jelcic J, Mihaljevic B. CD38 and interleukin 6 gene polymorphism in B-cell chronic lymphocytic leukemia- correlation with clinical and laboratory parameters. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 718.
128. Markovic O, Andjelic B, Tarabar O, Todorovic M, Filipovic B, Bila J, Antic D, Marisavljevic D, Mihaljevic B. Late relapse of Hodgkin lymphoma – is it different in clinical characteristics and outcome? 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 750
129. Jelcic J, Todorovic Balint M, Antic D, Andjelic B, Markovic O, Petkovic I, Sretenovic A, Bila J, Vukovic V, Djurasinovic V, Smiljanic M, Pejic I, Mihaljevic B. Absolute lymphocyte count as independent parameter may predict prognosis of follicular lymphoma patients. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 753
130. Andjelic B, Jelcic J, Todorovic M, Bila J, Antic D, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Mihaljevic B. Initial treatment response predicts the outcome of elderly follicular lymphoma patients treated with immunochemotherapy. 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12 2016. *Haematologica* 2016;101 (Suppl 1): 757.
131. Andjelic B, Jakovic Lj, Antic D, Todorovic M, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Smiljanic M, Mihaljevic B. ABVD as the treatment option in Hodgkin lymphoma with large mediastinal tumor. 10th International Symposium on Hodgkin lymphoma, Cologne, Germany, October 22-25 2016. *Haematologica* 2016;101 (Suppl 5): 25.
132. Andjelic B, Jakovic Lj, Antic D, Todorovic M, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Smiljanic M, Mihaljevic B. Advanced Hodgkin lymphoma – a risk stratification of ABVD treated females in generative age. 10th International Symposium on Hodgkin lymphoma, Cologne, Germany, October 22-25 2016. *Haematologica* 2016;101 (Suppl 5): 26.
133. Djurasinovic V, Andjelic B, Saric M, Ignjatovic S, Todorovic Balint M, Antic D, Vukovic V, Jelcic J, Sretenovic A, Mihaljevic B. Are we aware of nutritional status and vitamin D level in Hodgkin lymphoma patients? 10th International Symposium on Hodgkin lymphoma, Cologne, Germany, October 22-25 2016. *Haematologica* 2016;101 (Suppl 5): 72.
134. Todorovic Balint M, Jelcic J, Bila J, Balint B, Andjelic B, Antic D, et al. The role of lymphocyte recovery after high dose therapy and autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma and multiple myeloma. *Haematologica* 2016; 101(s1): p867
135. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jelcic J, Mihaljevic B. Thrombosis lymphoma score performance in female population. 7<sup>th</sup> International Symposium on Women's health issues in thrombosis and haemostasis, Barcelona, Spain, March 3-5, 2017. *Thrombosis research* 2017; 151(s1): 125.
136. Antić D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Mihaljevic B. Comparative analysis of predictive models for thromboembolic events in lymphoma patients. 13th International Conference on malignant lymphoma 14-17 June 2017, Lugano, Switzerland. *Hematol Oncol* 2017;35(suppl 2):416.

137. Smiljanic M, Balint Todorovic M, Antić D, Kraguljac Kurtovic N, Bila J, Andjelic B, Sretenovic A, Djurasinovic V, Vukovic V, Jeličić J, Mihaljevic B. Chronic lymphocytic leukemia involvement of central nervous system: a single centre experience. 13th International Conference on malignant lymphoma 14-17 June 2017, Lugano, Switzerland. Hematol Oncol 2017;35(suppl 2):386.
138. Balint Todorovic M, Jeličić J, Balint B, Bila J, Antić D, Vujic D, Kraguljac Kurtovic N, Sefer D, Andjelic B, Smiljanic M, Djurasinovic V, Sretenovic A, Vukovic V, Mihaljevic B. Achievement of complete remission after autologous stem cell transplantation is strongly correlated with improved survival of patients with hodgkin lymphoma. 13th International Conference on malignant lymphoma 14-17 June 2017, Lugano, Switzerland. Hematol Oncol 2017;35(suppl 2):323.
139. Antić D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Jeličić J, Mihaljevic B. Comparative analysis of predictive models for thromboembolic events in lymphoma patients. 22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 160.
140. Jeličić J, Antić D, Balint Todorovic M, Andjelic B, Markovic O, Petkovic I, Nikolic V, Bila J, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Sretenovic S, Mihaljevic B. High comorbidity index along with high NCCN-IPI strongly influence survival of diffuse large B cell lymphoma patients: Serbian lymphoma group experience. 22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 398.
141. Jelcic J, Antic D, Balint Todorovic M, Bila J, Andjelic B, Markovic O, Petkovic I, Nikolic V, Bila JJ, Djurasinovic V, Sretenovic A, Vukovic V, Smiljanic M, Mihaljevic B. Low albumin level correlates with poorer survival of patients with diffuse large b cell lymphoma: serbian lymphoma group experience .22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 688.
142. Vukovic V, Antic D, Karan Djurasinovic T, Milic N, Balint Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jelcic J, Dencic Fekete M, Perunicic Jovanovic M, Kraguljac Kurtovic N, Pavlovic S, Mihaljevic B. Comparative analysis of international prognostic index for chronic lymphocytic leukemia, progression-risk score and md anderson cancer center 2011 score: real world data from a single institution. 22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 719.
143. Vukovic V, Antic D, Milic N, Balint Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jelcic J, Perunicic Jovanovic M, Kraguljac Kurtovic N, Djurdjevic P, Cvetkovic Z, Zivanovic A, Mihaljevic B. Richter syndrome: Serbian lymphoma group experience. 22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 721.
144. Andjelic B, Antic D, Jakovic Lj, Todorovic M, Bila J, Djurasinovic V, Vukovic V, Sretenovic A, Jelcic J, Smiljanic M, Mihaljevic B. Advanced Hodgkin lymphoma patients without large tumormass – a new prognostic score identifies patients with favorable outcome. 22th Congress of the European Hematology Association, Madrid, Spain, June 22-25 2017. Haematologica 2017;102 (Suppl 2): 746.
145. Todorovic Balint M, Jelcic J, Bila J, Vujic D, Balint B, Kraguljac Kurtovic N, Sefer D, et al. CD34+ cell dose is an independent prognostic factor in patients with Hodgkin lymphoma and multiple myeloma who underwent autologous stem cell transplantation. Bone Marrow Transpl 2017; 52 : S463.
146. Todorovic Balint M, Jelcic J, Balint B, Bila J, Antic D, Vujic D, et al. Achievement of complete remission after autologous stem cell transplantation is strongly correlated with improved survival of patients with Hodgkin lymphoma. Book of abstracts of the 14-ICML, Lugano, 14-17 June, 2017. A355. p323.
147. Balint B, Stanojevic I, Todorovic M, Stamatovic D, Pavlovic M, Vojvodic D. The frequency of immature CD90+ subset in peripheral blood correlates narrowly and inversely with harvested total stem cell count in multiple myeloma patients. Book of abstracts of the Lymphoma and Myeloma 2017, October 26–28, 2017, New York, NY, P–006.

#### **Izvod u zborniku nacionalnog skupa**

1. Donfrid B. Nešić O, Todorović M, Turina M. Hiruško lečenje masivne plućne tromboembolije. II Kongres Angiologa Jugoslavije sa međunarodnim učešćem, Beograd 8–11 maj 1991, Abstract Book, p. 33.
2. Donfrid B, Šegović I, Galović B, Todorović M, Lukić T, Gnjatović O, Borković M. . Naša iskustva u lečenju flebotromboza donjih ekstremiteta II Kongres Angiologa Jugoslavije sa međunarodnim učešćem, Beograd 8–11 maj 1991, Abstrac Book, p. 109.
3. Nedeljkov–Jančić R, Donfrid M, Sretenović M, Mihaljević B, Petrović M. Alkalna fosfataza leukocita u sideropenijskim anamijama. Osnivački Kongres hematologa Jugoslavije, beograd 27–29. oktobar 1994. Bilt Hematol 1994; 3 (2): 30.
4. Petrović M, Donfrid M. Rezultati primene Neupogena (G–CSF) u lečenju bolesnika sa malignim limfomima. Osnivački Kongres hematologa Jugoslavije, Beograd 27–29. oktobar 1994. Bilt Hematol 1994; 3 (2): 41.
5. Donfrid M, Jančić–Nedeljkov R, Sretenović M, Mihaljević B, Janković S, Jovanović V, Petrović M. Rezultati lečenja nehodgkinskih limfoblastnih limfoma protokolom LALA–87. Osnivački Kongres hematologa Jugoslavije, Beograd 27–29. oktobar 1994. Bilt Hematol 1994; 3 (2): 51.
6. Milivojević G, Nedeljkov– Jančić R, Janković S, Sretenović M, Mihaljević B, Donfrid M, Jovanović V, Petrović M. Udruženost intraabdomenske lokalizacije M. Hodgkin i tuberkuloze – prikaz slučaja. Osnivački Kongres hematologa Jugoslavije, Beograd 27–29. oktobar 1994. Bilt Hematol 1994; 3 (2): 51.

7. Čemerikić–Martinović V, Stojšić J, Bogdanović A, Donfrid M, Suvajdžić N, Sretenović M, Milivojević G, Čolović. Spikule kostne srži: Morfološka i imunohistohemijska evaluacija. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 41.
8. Kraguljac N, Janković G, Marisavljević D, Radošević N, Donfrid M, Pantić M, Suvajdžić N, Miletić N, Bošković D, Čolović M. Akutna mijeloidna leukemija neobičnog imunološkog profila. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 42.
9. Suvajdžić N, Bogdanović A, Donfrid M, Pantić M, Kraguljac N, Novak A, Čolović M. Imunofenotip i citogenetske osobine bolesnika sa akutnom mijelofibrozmom. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 48.
10. Donfrid M, Janković G, Kraguljac N, Suvajdžić N, Čemerikić V, Bogdanović A, Petrović M, Čolović M. Klinički tok i imunofenotipske osobine bolesnika sa mantle–cell limfomom. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 48.
11. Suvajdžić N, Donfrid M, Marisavljević D, Milivojević G, Tomić D, Cvejić T, Radlović N, Čolović M. Prikaz genotipa i kliničkih osobina 14 bolesnika sa morbus Gaucher. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 56.
12. Petrović M, Mihaljević B, Janković S, nedeljkov–Jančić R, Sretenović M, Milivojević G, Donfrid M, Petrović Z, Jovanović V, Janković G. Rezultati lečenja bolesnika sa Hodgkinovim limfomom u periodu 1989–1996. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 49.
13. Donfrid M, Apostolski S, Mičić v, Dožić M, Čemerikić V, Čolović M. Monocitoidni B ćelijski limfom sa anti MAG ploneuropatijom. VIII Kongres hematologa Jugoslavije, Herceg–Novi, 30.09– 04.10.1998; Bilt Hematol 1998; 26: 82.
14. Čolović M, Bogdanović A, Donfrid M, Janković G, Suvajdžić N, Bogunović M. Rezultati primene standardne hemioterapije tipa “3+7” i ADE/MAE sa/bez postremiosine primene visokih doza Ara–C. XI Jugoslovenski hematološki dani, Novi Sad 21–23.09.2000. Bilt Hematol 2000; 28(1,2/3): 49.
15. Bogdanović A, Janković G, Donfrid M, Bogunović M, Suvajdžić N, Vidović A, Čolović M. Da li stari bolesnici sa akutnom mijeloidnom leukemijom imaju koristi od standardne indukcione terapije? XI Jugoslovenski hematološki dani, Novi Sad 21–23.09.2000. Bilt Hematol 2000; 28(1,2/3): 49.
16. Čolović M, Suvajdžić N, Janković G, Bogdanović A, Donfrid M, Bogunović M, Čemerikić V, Jovanović V, Nedeljković N. Analiza ishoda lečenja bolesnika sa hipoplastičnom akutnom mijeloidnom leukemijom. XI Jugoslovenski hematološki dani, Novi Sad 21.–23. 09. 2000. Bilt Hematol 2000; 28(1,2/3): 50.
17. Kraguljac N, Bogdanović A, Tomin D, Janković G, Donfrid M, Miletić N, Čolović M. Imunofenotipske karakteristike T– akutne limfoblastne leukemije odraslih. XI Jugoslovenski hematološki dani, Novi Sad 21–23.09.2000. Bilt Hematol 2000; 28(1,2/3): 53.
18. Donfrid M, Čemerikić V, Simić S, Bonači B, Čolović M. Intestinalni T– ćelijski limfom udružen sa eneteropatijom. XI Jugoslovenski hematološki dani, Novi Sad 21–23.09.2000. Bilt Hematol 2000; 28(1,2/3): 72.
19. Donfrid M, Čemerikić V, Jevtović Đ, Bogdanović A, Bila J, Čolović M. Promene u kostnoj srži kod pacijeneta sa AIDS–om. XI Jugoslovenski hematološki dani, Novi Sad 21.–23. 09. 2000. Bilt Hematol 2000; 28(2/3): 73.
20. Donfrid M, Čemerikić V, Simić S, Bonači B, Čolović M. Intestinalni T– ćelijski limfom udružen sa eneteropatijom. XI Jugoslovenski hematološki dani, Novi Sad 21.–23. 09. 2000. Bilt Hematol 2000; 28(1, 2/3): 75.
21. Marković O, Marisavljević D, Čemerikić V, Vidović A, Bakrač M, Peruničić M, Suvajdžić N, Čolović M. Proliferativna aktivnost mijelomskih ćelija merena antitelom Ki 67: biološki i klinički značaj. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32: 3.
22. Vidović A, Marković O, Bakrač M, Antić D, Tomin D, Janković G, Elezović I, Suvajdžić N, Petrović M, Mihaljević B, Čolović M, Bulajić N, Milić N, Bošković D. Lečenje akutnih febrilnih neutropenija u bolesnika sa malignim hemopatijama. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32: 13.
23. Marković O, Marisavljević D, Čemerikić V, Peruničić M, Vidović A, Bakrač M, Suvajdžić N, Čolović M. Biološki i klinički značaj ekspresije ciklina D1 kod bolesnika sa novootkrivenim multiplim mijelomom. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32(1/2): 19.
24. Čemerikić–Martinović V, Peruničić M, Suvajdžić N, Tomin D, Bakrač M, Bošković D. Non –Hodgkin limfomi u autoimunim bolestima. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32(1/2): 19.
25. Bakrač M, Tomin D, Elezović I, Petrović M, Čolović M, Bošković D. Prognostički značaj rane remisije u bolesnika sa akutnom limfoblastnom leukemijom. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32(1/2): 23.
26. Nedeljkov–Jančić R, Mihaljević B, Janković S, Bakrač M, Čemerikić V, Bošković D. Konsekutivna pojava HL kod bolesnika sa B–ćelijskim limfomom. XII hematološki dani, Niš 27–30 oktobar, 2004. Bilt Hematol 2004; 32(1/2): 23.
27. Todorović M, Todorović V, Čolović M, Tomin D, Petrović M, Elezović I, Bila J, Antić D, Bošković D. Angiogeneza u kostnoj srži kod bolesnika sa akutnom limfoblastnom leukemijom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 84.
28. Antić D, Tomin D, Čemerikić V, Peruničić M, Elezović I, Suvajdžić N, Bakrač M, Bila J, Mitrović M, Bošković D. Naša iskustva u dijagnostici i lečenju bolesnika sa granulocitnim sarkomom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 85.

29. Todorović M, Mihaljević b, petrović M, Bila J, Bogdanović A, Kraguljac N, Elezović I, Suvajdzic n, Bošković D. Kliničke karakteristike bolesnika sa uznapredovalim stadijumom mantle cell limfoma. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 86.
30. Janković S, Mihaljević B, Anđelić B, Milošević V, Todorović M, Mitrović M, Čolović M, Sretenović A, Jaković Lj, Peruničić M, Čemerikić V, Petrović M. Kombinacija rituksimaba i protokola HyperCVAD u lečenju Burkittovog limfoma. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 96.
31. Kraguljac n, Stanojević V, Bogdanović A, Dragović-Ivančević T, Gotić M, Janković S, Mihaljević B, Todorović M, Čolović M, Sretenović A, Bošković D. "Large granular lymphocyte" (LGL) leukemije-imunofenotipske karakteristike. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 103.
32. Bila J, Peruničić M, Elezović I, Suvajdzic N, Gotić M, Tomin D, Mihaljević B, Bakrač M, Vidović A, Antić D, čemerikić V, Bošković D. Prognostički značaj sistema tumor- domaćin u kostnoj srži bolesnika sa multiplim mijelomom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 110.
33. Marković O, Marisavljević D, Čemerikić V, Vidović A, Suvajdzic N, Bakrač M, Peruničić M, Čolović M. Ekspresija p53 proteina kod bolesnika sa multiplim mijelomom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 111.
34. Elezović I, Suvajdzic N, Miljić P, Sretenović M, Bila J, Bakrač M, Antić D, Mitrović M, Bošković D. Lečenje hemofilije sa inhibitorom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 113.
35. Suvajdzic N, Stanković B, Artiko V, Cvejić T, Bulat V, Bakrač M, Čolović M, Bošković D. Porast broja trombocita posle eradikacije Helicobacter pylori infekcije kod odraslih bolesnika sa hroničnom idiopatskom trombocitopenijskom purpustom. XI Kongres hematologa sa međunarodnim učešćem, Novi Sad septembar 2007, Bilt Hematol 2007; 35(3): 114.
36. Balint B, Ostojić G, Todorović M, Ljubenov M, Ignjatović Lj, Rafajlovski S. Imunoadsorpcijom posredovana selektivna izmena plazme – principi i terapijski efekat. Zbornik rezimea XXII seminara Anestezista, Reanimatora i Transfuzista Srbije sa međunarodnim učešćem; 13–17. maja 2009. Vrnjačka Banja. p. 83.
37. Todorović M, Balint B, Suvajdzic N, Marjanović G, Gotić M, Čolović M. Alogena transplantacija matične ćelije hematopoeze od nesrodnog HLA kompatibilnog davaoca u bolesnika sa malignim hemopatijama: prednosti i nedostaci. Zbornik rezimea XXII seminara Anestezista, Reanimatora i Transfuzista Srbije sa međunarodnim učešćem; 13–17. maja 2009. Vrnjačka Banja. p. 84
38. Balint B, Ostojić G, Todorović M, Trkuljić M, Rafajlovski S, Radojević M. The use of our simplified extracorporeal immunoadsorption system for ABO-incompatible kidney transplants. Zbornik rezimea XXII seminara Anestezista, Reanimatora i Transfuzista Srbije sa međunarodnim učešćem; 21–25. 04. 2010. Vrnjačka Banja. p. 111
39. Todorovic M, Balint B, Pavlovic M, Tosic T, Palibrk V, Veljkovic D, et al. G-CSF plus Dexametasone mobilized granulocyte support of neutropenic patient with invasive fungal sepsis following autologous stem cell transplantation. Bilten za Transfuziologiju 2010; 56: 150.
40. Balint B, Ostojić G, Todorović M, Trkuljić M, Rafajlovski S, Radojević M. The use of our simplified extracorporeal immunoadsorption system for ABO-incompatible kidney transplants. Zbornik rezimea XXIII seminara Anestezista, Reanimatora i Transfuzista Srbije sa međunarodnim učešćem; 13–17. april 2010. Vrnjačka Banja. Beograd: ART. p. 110
41. Đurđević P, Suvajdzic N, Todorović M, Peruničić M, Stojanović R, Novković A, Tomin D, Elezović I, Mihaljević B. Clinical characteristics of patients with lymphoproliferative neoplasmas in the setting of systemic autoimmune diseases. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.91.
42. Bila J, Vujić D, Veljković D, Antić D, Anđelić B, Todorović M, Šefer D, Kraguljac N, Elezović I, Tomin D, Gotić M, Mihaljević B. High dose treatment and autologous stem cell transplantation in patients with multiple myeloma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.94.
43. Anđelić B, Mihaljević B, Todorović M, Bila J, Jaković Lj, Peruničić M, Jovanović M. The impact of lymphoma associated macrophages on the outcome of follicular lymphoma patients. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.98.
44. Knežević V, Kraguljac Kurtović N, Dragović Ivančević T, Bogdanović A, Jovanović J, Tomin D, Suvajdzic Vuković N, Vidović A, Todorović M, Gotić M. Imunofenotipski profil B akutne limfoblastne leukemije. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.107.
45. Todorović M, Elezović I, Tomin D, Bila J, Todorović V, Peruničić M, Mihaljević B. Značaj ispitivanja angiogeneze u kostnoj srži bolesnika sa akutnom limfoblastnom leukemijom. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematološka sekcija SLD 2011. p.111.
46. Antić D, Agić D, Todorović M, Djunić I, Novaković V, Bogunović M, Đurđević P, Milošević I, Milošević R, Sretenović S, Popović S, Anđelković N, Mihaljević B. Rituximab u kombinaciji sa hemioterapijom u prvoj liniji

- terapije bolesnika sa heoničnom limfocitnom leukemijom RHLL1 iskustva Srpske limfomske grupe. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.137.
47. Novaković V, Bogunović M, Janković S, Antić D, Tomin D, Todorović M, Kraguljac N, Peruničić M, Bogdanović A, Mihaljević B, Gotić M. Efiksnost primene hemioterapijskog protokola fludarabin-ciklofosfamid kod bolesnika sa hroničnom limfocitnom leukemijom. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.143.
  48. Bila J, Bodrožić J, Smiljanić D, Leković D, Anđelić B, Antić D, Janković S, Milićević S, Todorović M, Vidović A, Bogdanović A, Gotić M, Tomin D, Elezović I, Mihaljević B. Multipli mijelom neizlečivi malignitet ili hronično stanje: rezultati dvadesetogodišnjeg praćenja u Klinici za hematologiju KCS. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.156.
  49. Bila J, Bodrožić J, Smiljanić M, Bogunović M, Anđelić B, Antić D, Janković S, Milićević S, Todorović M, Vidović A, Bogdanović A, Gotić m, Tomin D, Elezović I, Mihaljević B. Bortezomib u multipolm mijelomu: rezultati lečenja bolesnika u recidivu. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.156.
  50. Bila J, Smiljanić M, Bodrožić J, Janković S, Antić D, Anđelić B, Milićević S, Todorović M, Elezović I, Tomin D, Gotić M, Mihaljević B. The role of thalidomide as the maintenance therapz in elderlz patients with multiple myeloma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.157.
  51. Anđelić B, Mihaljević B, Antić D, Janković S, Jančić Nedeljkov R, Todorović M. Poređenje različitih modaliteta lečenja i analiza faktora rizika za loš ishod bolesnika sa novodijagnostikovanim folikularnim limfomom. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.161.
  52. Anđelić B, Mihaljević B, Antić D, Janković S, Todorović M. Immunochemotherapy vs chemotherapy and risk factor analzsis in first relapse of follicular lymphoma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.161.
  53. Antić D, Jevtović Đ, Smiljanić M, Todorović M, Bila J, Anđelić B, Janković S, Ranin J, Salemović D, Mihaljević D. Desetogodišnje iskustvo u lečenju limfoma udruženih sa HIV infekcijom u Kliničkom centru Srbije. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.162.
  54. Antić D, Peruničić Jovanović M, Todorović M, Bila J, Janković S, Anđelić B, Milićević S, Smiljanić M, Vuković V, Mihaljević B. Primarni kutani B krupnoćelijski limfom "leg type"-prikaz slučaja. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.162.
  55. Bogunović M, Agić D, Antić D, Todorović M, Đunić I, Novaković V, Milošević R, Anđelić B, Smiljanić M, Milošević I, Popović S, Gotić M, Mihaljević B. Late-onset of neutropenia following RFC as a primarz treatment of CLL. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.163.
  56. Mihaljević B, Todorović M, Anđelić B, Antić D, Peruničić Jovanović M. Gastric plasmablastic lymphoma in HIV –negative patient. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.166.
  57. Mihaljević B, Jovanović D, Anđelković N, Popović S, Vukićević T, Anđelić B, Popović L, Todorović M, Vlasisavljević N, Sretenović A, Đurđević P, Sretenović S, Janković S, Marković O, Marjanović G, Vrbić S, Hajder J, Živić D. Primena rituximaba u kombinaciji sa hemioterapijom kod bolesnika sa relps\_refraktarnim folikularnim NHL iskustva srpske limfomske grupe. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.166.
  58. Milošević R, Smiljanić M, Anđelić B, Bogdanović A, Todorović M, Mihaljević B, Petrović Z. Kćinički tok i prognoza bolesnika sa MALT limfomom orbite-studija jednog cetra. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.167.
  59. Milošević R, Todorović M, Krstić M, Babić D, Mihaljević B. Primarni NHL slezine analiza 26 bolesnika. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.168.
  60. Peruničić Jovanović M, Bogdanović A, Jaković Lj, Todorović M, Anđelić B, Terzić T, Gotić m, Mihaljević B. Immunophenotyping profile, main clinicopathological features and outcome in diffuse large B cell lymphoma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.171.
  61. Smiljanić M, Antić D, Todorović M, Bila j, Anđelić B, Janković S, Milićević S, Vuković V, Mihaljević B. Primarni ektranodalni difuzni B krupnoćelijski limfomi testisa. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.174.
  62. Smiljanić M, Antić D, Bila J, Todorović M, Anđelić B, Janković S, Mihaljević B. Prikaz slučaja bolesnice sa primarnim limfomom centralnog nervnog sistema i disfunkcijom hipotalamusa. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.175.

63. Sretenović S, Martinović Čemerikić V, Jovanović D, Anđelić N, Đurđević P, Necin Jovanović Ž, Stojanović V, Todorović M, Mihaljević B. Transformacija non Hodgkin limfoma marginalne zone u difuzni B krupnoćelijski limfom-klinički izazov i dilema-prikaz bolesnika. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p.176.
64. Todorović M, Balint B, Anđelić B, Bila J, Mihaljević B. Transfuzija mobilisanih granulocita u sklopu terapije invazivne gljivične infekcije nastale nakon autologne transplantacije matičnih ćelija: prikaz bolesnika. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 179.
65. Todorović M, Balint B, Anđelić B, Kraguljac Kurtović N, Jančić Nedeljko R, Mihaljević B. Outcome prediction of advanced mantle cell lymphoma by IPI/mantleIPI. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 180.
66. Todorović M, Anđelić B, Balint B, Radisavljević Z, Mihaljević B. Switching Bcl6 positive to negativity in relapsing diffuse large B-cell lymphoma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 180.
67. Todorović M, Vuković V, Ješić R, Anđelić B, Peruničić M, Mihaljević B. Posttransplant lymphoproliferative disease in hepatitis B positive patient with liver transplanted. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 181.
68. Virijević M, Todorović M, Anđelić B, Đunić I, Novakvić A, Vidović A, Suvajdžić Vuković N, Tomin D, Mihaljević B. Independent prognostic factors in patients with mucosa associated lymphoid tissue non Hodgkin lymphoma. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 182.
69. Antić D, Elezović I, Peruničić Jovanović M, Suvajdžić N, Todorović M, Bila J, Vidović A, Sretenović M, Đunić I, Mitrović M, Tomin D. Isolated myeloid sarcoma-single centre experience. Knjiga sažetaka 2. kongresa hematologa Srbije sa međunarodnim učešćem. 04–07.11.2011. Beograd. Beograd: Hematolološka sekcija SLD 2011. p. 197.
70. Balint B, Todorović-Balint M, Stamatović D, Ostojić G. Current cryopreservation strategy: controlled–rate vs. uncontrolled–rate freezing for blood and stem cells. Vrnjačka Banja 24–28. april 2013. Zbornik rezimea ART. p. 5–7.
71. Balint B, Ostojić G, Todorović-Balint M, Vavić N, Ljubenov M. Komparativna studija afereznih sistema Cobe–Specra vs. Specra–Optia – opšti pristupi i tretman hiperlipidemije. Vrnjačka Banja 24–27. april 2014. Zbornik rezimea ART. 1-2
72. Ostojić G, Raičević R, Stamatović D, Todorović-Balint M, Ljubenov M, Balint B. Plasma exchange–basic therapeutic approaches. Bilt Transfuziol 2014; 60 (1–2): 121A.
73. Balint B, Kanjuh V, Todorović-Balint M, Obradović S, Ostojic G, Rafajlovski S. From apheresis prevention to the cell therapy of threatening and manifested myocardial ischemic disorders. Zbornik radova i sažetaka IV kongresa Udruženja za aterosklerozu Srbije sa internacionalnim učešćem, SANU, Beograd, 20–23. 11. 2014. p. 53–54.
74. Balint B, Kanjuh V, Todorović-Balint M, Obradović S, Trifunović Z, Rafajlovski S, et al. Harvesting, ex vivo manipulation and clinical use of mononuclear and CD34<sup>+</sup> cells in the treatment of myocardial ischemia. Srce Krvni Sudovi 2015; 34(1): 2–3.
75. Smiljanić M, Vuković V, Jeličić J, Sretenović A, Anđelić B, Antić D, Bila J, Todorović M, Mihaljević B. Plazmocitom testis I fokalne osteolitične lezije u sklopu multiplog mijeloma. Prikaz slučaja. XV kongres uduženja internista Srbije, 04.-07-06.2015., Zlatibor, Zbornik sažetaka 2015: 55.
76. Andjelic B, Perunicic-Jovanovic M, Jaković Lj, Todorović M, Bila J, Antic D, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Jeličić J, Mihaljevic B. Netumorske ćelije i angiogeneza u tumorskom tkivu Hočkinovog limfoma – prognostički značaj na ishod lečenja. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 118.
77. Antic D, Jeličić J, Todorović M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Vukovic V, Mihaljevic B. Principi lečenja primarnog difuznog B krupnoćelijskog limfoma želuca. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 118.
78. Mihaljevic B, Vukovic V, Perunicic-Jovanovic M, Todorović M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jeličić J, Antic D. Rihterov sindrom – iskustvo jednog centra. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 119.
79. Sretenovic A, Bila J, Jeličić J, Djurasinovic V, Dencic Fekete M, Jovanovic J, Vukovic V, Smiljanic M, Andjelic B, Antic D, Todorović M, Mihaljevic B. Prognostički značaj revidiranog internacionalnog prognostičkog indeksa (R-ISS) kod bolesnika sa multiplim mijelomom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 121.
80. Jeličić J, Todorović M, Antic D, Bila J, Andjelic B, Stanisavljevic D, Vukovic V, Djurasinovic V, Sretenovic A, Smiljanic M, Petkovic I, Pejic I, Mihaljevic B. Prognostički značaj komorbiditeta kod bolesnika sa difuznim B krupnoćelijskim limfomom lečenih imunohemioterapijom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 121.
81. Antic D, Vukovic V, Milic N, Kraguljac Kurtovic N, Todorović M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jeličić J, Mihaljevic B. Leukemije zrelih T ćelija – principi dijagnostike i lečenja. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 125.
82. Smiljanic M, Milosevic R, Antic D, Andjelic B, Sretenovic A, Djurasinovic V, Jeličić J, Vukovic V, Bila J, Todorović M, Mihaljevic B. Rezultati u lečenju 34 pacijenta sa non Hodgkin limfomima orbite i okularnih adneksa – desetogodišnje iskustvo jednog centra. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 125-126.

83. Vukovic V, Antic D, Todorovic M, Bila J, Andjelic B, Djurasinovic V, Sretenovic A, Smiljanic M, Jeličić J, Mihaljevic B. Prediktivna vrednost komorbiditetnih indeksa kod bolesnika sa hroničnom limfocitnom leukemijom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 143.
84. Milosevic V, Bogunovic M, Antic D, Tomin D, Todorovic-Balint M, Kraguljac Kurtovic N, Perunicic Jovanovic M, Bogdanovic AD, Mihaljevic B. Efikasnost primene hemioterapijskog protokola fludarabin-ciklofosamid kod bolesnika sa hroničnom limfocitnom leukemijom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 147.
85. Andjelic B, Perunicic-Jovanovic M, Jakovic Lj, Todorovic M, Bila J, Antic D, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Smiljanic M, Mihaljevic B. Analiza faktora rizika kod obolelih od Hočkinovog limfoma sa malim brojem FOXP3 limfocita u tumorskom tkivu. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 148.
86. Sretenovic A, Andjelic B, Djurasinovic V, Smiljanic M, Vukovic V, Jeličić J, Antic D, Bila J, Todorovic M, Mihaljevic B. Primarni limfomi ženskog genitalnog trakta – iskustvo Klinike za hematologiju KCS. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 154.
87. Mihaljevic B. Smiljanic M, Antic D, Jeftovic Dj, Salemovic D, Perunicic M, Andjelic B, Djurasinovic V, Sretenovic A, Vukovic V, Jeličić J, Bila J, Todorovic M. Definisanje povoljnih prognostičkih parametara u lečenju limfoma udruženih sa HIV infekcijom: desetogodišnje iskustvo jednog centra. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 155.
88. Tošić N, Todorovic Balint M, Mihaljevic B, Jeličić J, Kostic J, Stanic B, Pejanovic N, Lucic B, Glumac I, Stojiljkovic M, Karan Djurasevic T, Perisic O, Rakocevic G, Popovic M, Raicevic S, Bila J, Antic D, Andjelic B, Pavlovic S. Primarni limfom difuznih B ćelija centralnog nervnog sistema: određivanje genetičkog profila metodom sekvenciranja nove generacije. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 159.
89. Djurasinovic V, Vukovic V, Antic D, Andjelic B, Bila J, Sretenovic A, Jeličić J, Todorovic M, Mihaljevic B. Nutritivni status bolesnika sa limfomima-ima li značaja. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 160.
90. Sretenovic A, Bila J, Jeličić J, Djurasinovic V, Vukovic V, Smiljanic M, Andjelic B, Antic D, Todorovic M, Mihaljevic B. Značaj Charlson komorbiditetnog indeksa i gerijatrijske skale sposobnosti obavljanja dnevnih aktivnosti u lečenju bolesnika sa multiplim mijelomom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 162.
91. Jeličić J, Bila J, Djurasinovic V, Vukovic V, Sretenovic A, Smiljanic M, Andjelic B, Antic D, Todorovic M, Mihaljevic B. Značaj hematopoetskog transplantacionog i karlson komorbiditetnog indeksa kod mlađih bolesnika sa multiplim mijelom. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 163.
92. Smiljanic M, Bila J, Vukovic V, Jeličić J, Sretenovic A, Djurasinovic V, Andjelic B, Antic D, Todorovic M, Mihaljevic B. Plazmocitom testisa kao prva manifestacija multiplog mijeloma. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 167.
93. Djurasinovic V, Bila J, Jeličić J, Vukovic V, Sretenovic A, Smiljanic M, Andjelic B, Antic D, Todorovic M, Mihaljevic B. Valdenstemova makroglobulinemija: prognostički indeksi, lečenje i tok bolesti. 3. kongres hematologa Srbije, Kragujevac, 12–15.11.2015. Hematolološka sekcija SLD 2015: 168.
94. Todorović Balint M, Djunić I, Bila J, Balint B, Vujić D, Braić I et al. Transfuzijska potpora tokom visokodozne terapije i autologne transplatacije matičnih ćelija hematopoeze. Bilt Transfuziol 2018; 63(1/2):P 82.

#### **Udžbenici, praktikumi (poglavlja)**

1. Bakrač M. Eritrocitopoeza, eritrocit i eritropoetin. Anemije, urednici B. Mihaljević i B. Stojmirović, izdavač CIBID, Univerzitet u Beogradu, Medicinski Fakultet, Libri Medicorum, 2007. (*udžbenik za posle diplomsku nastavu*), p 15-22.
2. Balint B, Kanjuh V, Ostojić M, Obradović S, Todorović M, Rafajlovski S. Matične ćelije – biologija i primena u regenerativnoj medicini kod bolesti srca. In: Ostojić M, Kanjuh V, Nedeljković S. Kardiologija. Zavod za udžbenike Beograd 2011. p 333-340.
3. Mihaljević B, Todorović M, Andjelić B: Folikularni limfom; poglavlje Hematološki maligniteti. Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 509-517.
4. Todorović M, Mihaljević M: Mantle ćelijski limfom; poglavlje Hematološki maligniteti Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 526-530.
5. Todorović M, Mihaljević B: Burkittov limfom, poglavlje Hematološki maligniteti. Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 530-534.
6. Todorović M, B. Andjelić B, Mihaljević B: Hočkinov limfom; poglavlje Hematološki maligniteti. Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 596-607.

7. Vujić D, Todorović M. Indikacije za transplantaciju matičnih ćelija hematopoeze, oblici transplantacije, kondicioniranje i rezultati Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 658-668.
8. Salemović D, Todorović M. Hematološke manifestacije u toku HIV infekcije. Hematološki maligniteti. Klinička hematologija, urednici D. Marisaveljević, B. Mihaljević, I. Elezović, S. Popović, N. Suvajdžić, D. Vujuć, D. Janjić, P. Milenković, M. Mostarica, G. Bogdanović. Zavod za udžbenike Beograd, 2012. P 1228-1235.
9. Todorović M, Jeremić K. Limfomi i trudnoća. Kancer, fertilitet i trudnoća, urednik Kesić V. Zavod za udžbenike Beograd 2016.

#### **Monografije, knjige (koautor)**

1. Balint B, Todorović M, Ostojić G, Urošević I. Hemobiologija i terapijska primena eritrocita – od dogmi do savremenih pristupa. Udruženje ART Srbije, 2007.
2. Balint B, Trkuljić M, Todorović M. Osnovini principi hemoterapije. Beograd: Čigoja štampa; 2010.
3. Marjanović S, Todorović M. Hemioterapijski priručnik. Beograd: Print Aleksandar; 2010.
4. Balint B, Todorović M, Jocić M, Stamatović D. Hemoterapijski pristup transplantaciji organa i ćelija. Beograd: Udruženje ART Srbije; 2011.

#### **Poglavlja u monografijama, knjigama**

1. Balint B, Todorović M. Od hematopoeze do kliničke primene hemoprodukata. In: Balint B, Trkuljić M, Todorović M. Osnovini principi hemoterapije. Beograd: Čigoja štampa; 2010. p. 39–183.
- 2.
3. Balint B, Todorović M. Matične ćelije – hemobiologija i terapijska primena. In: Balint B, Trkuljić M, Todorović M. Osnovini principi hemoterapije. Beograd: Čigoja štampa; 2010. p. 257–335.
4. Balint B, Obradović S, Todorović M, Pavlović M, Mihaljević B. Stem cell-based (auto)grafting: from innovative research toward clinical use in regenerative medicine. In: Alimoghaddam K, editor. Stem Cell Biology in Normal Life and Diseases. London: IntechOpen. 2013. p. 111–35.
5. Balint B, Pavlović M, Todorović M. Rapid cytoreduction by plateletapheresis in the treatment of thrombocytopenia. In: Kerrigan SW, editor. Platelets. London: IntechOpen 2020. DOI: 10.5772/intechopen.93158

#### **b) Rukovođenje ili angažovanje u nacionalnim ili međunarodnim naučnim ili stručnim organizacijama**

- U periodu od 2002. do 2006. godine bila je član istraživačkog projekta MNTR "Značaj određivanja bioloških markera u malignim bolestima krvi" M1916 (rukovodilac: Prof.dr Darinka Bošković)
- Od 2007-2011. istraživač u projektu MNTR pod nazivom: *Molekularno genetski markeri klonskog preobražaja matičnih ćelija hematopoeze*, br. 145061B (rukovodilac: Prof. dr Milica Čolović).
- Aktuelni istraživač projekta Retke bolesti MNTR III broj 410004, podprojekat 3,. Rukovodilac: naučni savetnik Sonja Pavlović

#### **c) Citiranost radova**

Ukupna citiranost svih radova dr Milena Todorović Balint je 653 (RG) i h index 13 (RG), bez autocitata.

#### **d) Organizovanje naučnih sastanaka i simpozijuma**

- "Transplantacija matičnih ćelija hematopoeze: od istorijata do savremenih terapijskih pristupa" Simpozijum sa međunarodnim učešćem, 25.novembar 2016. Beograd.
- "Prezentacije institucionalnih vodiča za bolesnika u program alogene transplantacije" Nacionalni kurs, 29.mart 2018. Beograd.
- „Challenges in stem cell transplantation“ Međunarodni seminar 4. maj 2018. Beograd.
- "Overview and treatment of hematopoietic stem cell transplant failures - challenges and perspectives", Međunarodni seminar 20.jun 2020.

#### **F. OCENA O REZULTATIMA NAUČNOG I ISTRAŽIVAČKOG RADA**

Dr Milena Todorović Balint je priložila **408** radova objavljena u celini ili u vidu abstrakta: 167 rad napisan u celini i 241 izvod na međunarodnim i nacionalnim skupovima. Pored ovih radova, autor je ili koautor u 17 poglavlja u knjigama ili monografijama, kao i koautor u 4 monografije.

U kategoriji JCR (vodećim naučnim časopisima međunarodnog značaja) je publikovala 69 radova, od toga je u 12 prvi autor, u 2 je nosilac, a u 55 je saradnik. Kumulativni IF za ove radove iznosi 123,232.

Objavila je 7 radova u časopisima indeksiranim u SCIENCE CITATION INDEX Expanded (SCIE), bez IF, a 8 radova u časopisima indeksiranim u MEDLINE-u.

U celini je objavila 67 rada u časopisima koji nisu indeksirani, u 18 je prvi autor, a u 49 je saradnik.

Još 14 radova u celini objavila je u zborniku nacionalnog skupa, u 4 kao prvi autor, u 1 kao jedini autor, u 9 kao saradnik. Dva rada u celini objavila je u zborniku međunarodnog skupa, u jednom kao prvi autor.

Dr Milena Todorović Balint je koautor knjige "Osnovini principi hemoterapije" Beograd, Čigoja štampa 2010, i u

istoj knjizi ima 2 poglavlja. Takođe je koautor u monografijama "Hemobiologija i terapijska primena eritrocita – od dogmi do savremenih pristupa" Beograd, udruženje ART Srbije, 2007, kao i "Hemoterapijski pristup transplantaciji organa i ćelija" Beograd, udruženje ART Srbije; 2011. Koautor je monografije "Hemoterapijski priručnik" Beograd, Print Aleksandar; 2010. Koautor je poglavlja u inostranoj monografiji "Stem Cells biology in normal life and diseases". London: IntechOpen. 2013. i poglavlja u monografiji. Platelets. London: IntechOpen 2020.

Autor je poglavlja u udžbeniku za posle diplomsku nastavu "Anemije", izdavač CIBID, Univerzitet u Beogradu, Medicinski Fakultet, Libri Medicorum, 2007, kao i autor i koautor u 6 poglavlja u udžbeniku "Klinička hematologija" Zavod za udžbenike Beograd, 2012, dok je koautor u 1 poglavlju udžbenika "Kardiologa", Zavod za udžbenike Beograd, 2011.

Veliki broj stručnih radova dr Todorović posvećen je analizi kliničko-laboratorijskih i molekularno-bioloških parametara kod bolesnika sa limfoproliferativnim bolestima, prevashodno limfomima, a u cilju adekvatnije stratifikacije bolesnika i planiranja terapije.

U okviru toga nalazi se rad koji se odnosi na molekularno genetički profil bolesnika primarnim limfomom CNS određen NGS tehnikom, gde je utvrđeno da TP53 i ATM geni učestvuju u molekularnoj patofiziologiji bolesti, a da geni PTEN i SMO mogu uticati na preživljavanje bez obzira na inicijalni tretman bolesti.

Veliki broj istraživačkih radova odnosi se na proučavanje mantl ćelijskog limfoma i prognoznih parametara koji su ispitivani u sklopu prognoznih indeksa, bitnih za bolje i potpunije definisanje bolesnika pri dijagnozi, a u cilju planiranja terapijskog pristupa.

Deo radova poentira poremećen proces angiogeneze u kostnoj srži bolesnika sa akutnom limfoblastnom leukemijom.

Značajan broj radova posvećen je ulozi transplantacije matičnih ćelija, kao vida lečenja visokorizičnih bolesnika sa malignim hemopatijama.

Dva rada produkt su saradnje sa stručnjacima iz Bethesde (NIH) koji obrađuju dijagnostiku i lečenje bolesnika sa sidromom: policitemija-paragangliom somatostatinom.

Deo publikovanih radova predstavlja kazuistiku u kojoj se prikazuju retke udruženosti različitih oboljenja kao što su: imunološka trombocitopenija i Wilsonova bolest, ili pak autoimuni poliglandularni sindrom tipa I i izolovana aplazija eritroidne loze, terapija bolesnice sa eritropoetin-sekretujućim paragangliomom, kao i sindromom COVID kod bolesnice sa agresivnom non Hodgkin limfomom.

## **G. OCENA O ANGAŽOVANJU U RAZVOJU NASTAVE I DRUGIH DELATNOSTI VISOKOŠKOLSKE USTANOVE**

U okviru nastavne delatnosti dr Milena Todorović Balint je bila vrlo angažovana sa kvalitetnim pedagoškim radom kako u osnovnoj tako i posle diplomskoj nastavi.

Kandidat u svom svakodnevnom radu daje značajan naučni, stručni i pedagoški doprinos aktivnim učešćem u u posle diplomskoj nastavi u okviru akademskih specijalističkih studija, kao i specijalističke nastave.

Šef je Katedre za posle diplomsku nastavu iz hematologije od 2015.godine. Od 2017.do 2015. bila je sekretar Katedre i od tada je aktivno učestvovala u izradi programa posle diplomске nastave. Koordinator je hematološke nastave na Katedri za opštu medicinu. Koordinator je modula "Od molekularne genetike do savremenih terapijskih modaliteta" na doktorskim studijama "Biologija tumora i slobodni radikali".

Član Veća za specijalističku nastavu Medicinskog Fakulteta u Beogradu. Dala je doprinos u pisanju udžbenika iz interne medicine za studente OAS.

## **IZBORNI USLOVI ZA IZBOR U ZVANJE REDOVNOG PROFESORA**

### **ZA STRUČNO-PROFESIONALNI DOPRINOS:**

#### ***Angažovanost u sprovođenju složenih dijagnostičkih, terapijskih i preventivnih procedura.***

Prof.dr Milena Todorović Balint je Načelnik Odeljenja za transplantaciju koštane srži sa ambulantom za transplantirane bolesnika na Klinici za hematologiju KCS i kao osoba koja rukovodi ovim odeljenjem sprovodi najkompleksnije medicinske procedure. U medicini uopšte, transplantacija je najkompleksnija i najskuplja procedura koja se koristi u lečenju rizičnih hematoloških bolesnika i pruža, kao takva kurativnu opciju. U svom radu, ona radi na primeni kondicionih pretransplantacionih protokola, suvereno vlada principima imunosupresivne terapije, kao i postransplantacionog praćenja bolesnika uz lečenje svih komplikacija. Na odeljenju je razvila algoritam praćenja infektološkog statusa, dijagnostiku molekularno genetičkog i imunohematološkog himerizma, uz osnivanje multidisciplinarnog tima za praćenje postransplantacionog toka.

#### ***Broj i složenost složenih, dijagnostičkih, terapijskih i preventivnih procedura koje je kandidat uveo, ili je učestvovao u njihovom izvođenju***

Uradila je preko 400 procedura autolognih transplantacija, 65 alogenih transplantacija od srodnog podudarnog i haploidentičnog donora, kao i od od HLA podudarnih nesrodnih donora iz međunarodnog registra. Prvu alogenu transplantaciju uradila je sa svojim timom u novoformiranom odeljenju matične klinike u decembru 2017.godine.

Procedura su sledeće:

1. Uvođenje infektološkog, molekularno genetičkog i imunohematološkog profila bolesnika pre transplantacije
2. Uvođenje protokola nedeljnog praćenja potencijalnih infektivnih komplikacija do d+100 nakon alogene transplantacije matičnih ćelija

3. Praćenje post-transplantacionog himerizma i prevencija bolesti kalema protiv domaćina
4. Uvođenje nesrodne alogene transplantacije, srodne HLA podudarne, kao i haploidentične transplantacije
5. Kontrola molekularnog relapsa bolesti primenom infuzije limfocita donora (DLI) kao vida apativne imunoterapije u kombinaciji sa biološkim lekovima

#### ***Kontinuirana medicinska edukacija u organizaciji Medicinskog fakulteta***

Organizovala je međunarodni Seminar „Challenges in stem cell transplantation“ u maju 2018. koji je dao KME bodove 14/7 (Svečana sala dekanata MFUB) uz promociju u viziting profesora MFUB Prof. Nicolausa Kroegera lidera u transplantaciji matičnih ćelija (Direktor Klinike za transplantaciju koštane srži, Hamburg, Eppendorf) i Predsednika Evropskog udruženja za transplantaciju (EBMT).

Predlaganje i usvajanje predloga ispred katedre hematologije za promociju prof.dr Nicolausa Koroegera (Eppendorf, Hamburg, Nemačka) za dodelu počasnog doktora nauka Univerziteta u Beogradu 2020 godine.

#### **ZA DOPRINOS AKADEMSKOJ I ŠIROJ ZAJEDNICI:**

##### ***Značajno strukovno, nacionalno ili međunarodno priznanje za naučnu ili stručnu delatnost***

- Četiri Univerzitetske nagrade za uspeh tokom školovanja
- Nagrada Legat „Dušan Blagojević“ za uspeh u toku studija

##### ***Predsedavanje nacionalnim ili međunarodnim strukovnim ili naučnim organizacijama***

Predsednik Udruženja za transplantaciju matičnih ćelija hematopoeze od 2016.godine.

##### ***Rukovođenje ili angažovanje u nacionalnim ili međunarodnim naučnim ili stručnim organizacijama***

Član je: Srpskog lekarskog društva, Evropskog udruženja za transplantaciju, Udruženja za transplantaciju matičnih ćelija hematopoeze, Udruženja transfuziologa Srbije

##### ***Rukovođenje ili angažovanje u nacionalnim ili međunarodnim institucijama od javnog značaja***

Načelnik Odeljenja za transplantaciju koštane srži Klinike za hematologiju KCS i zamenik direktora klinike za hematologiju KCS

Vođa tima za transplantaciju Klinike u Evropskom udruženju za transplantaciju koštane srži (PI CIC 373)

Član Republičke stručne komisije za hematologiju u Ministarstvu zdravlja RS

Član je Republičke stručne komisije za transplantaciju u Ministarstvu zdravlja RS

#### **ZA SARADNJU SA DRUGIM VISOKOŠKOLSKIM, NAUČNO-ISTRAŽIVAČKIM USTANOVAMA U ZEMLJI I INOSTRANSTVU - MOBILNOST:**

##### ***Učestvovanje na međunarodnim kursevima ili školama za užu naučnu oblast za koju se bira***

- ESO Postgraduate Athens Leukemia and Lymphoma Course (October, 1997, Voulagmeni, Greece, organiser: Prof Pangalis).
- ESO Postgraduate Athens Leukemia and Lymphoma Course (October, 1999, Voulagmeni, Greece, organiser: Prof Pangalis).
- Rome, Italy, San Camillo Forlanini maj 2007. i jul 2008. godine.
- Balkan School of Apheresis Procedures (GambroBCT) 17-21. July 2006,
- Lyfe (Lymphoma Forum of Excellence) 12.-13. novembar 2009. London St Bartholomew's Hospital
- Hamburg Eppendorf Hospital, Germany, Educational and practical Training in stem cell transplantation Oct 2017.
- 4th International cGvHD Symposium and TCWD Educational Meeting, Zagreb, Croatia Novembar 2018.
- Terumo BCT simpozijum “Unlocking the Potential of Blood Together for a Better Tomorrow” Portorož, novembar 2018.

##### ***Predavanja po pozivu na akreditovanim domaćim i međunarodnim skupovima***

1. Centar za kontinuiranu medicinsku edukaciju Medicinskog fakulteta, Univerzitet u Beogradu: Malokrvnost, dileme u dijagnostici i principi lečenja, sa predavanjem: Eritrocitopoeza održanim 4. 11. 2005 godine.
2. Škola kontinuirane medicinske edukacije Medicinskog fakulteta, Univerzitet u Beogradu za lekare opšte medicine: Malokrvnost, dileme u dijagnostici i principi lečenja, sa predavanjem Eritrocitopoeza održan 17.decembra 2005. godine.
3. Centar za kontinuiranu medicinsku edukaciju Medicinskog fakulteta, Univerzitet u Beogradu, predavač u programu: Izabrani lekar primarne zdravstvene zaštite, sa predavanjem: Hematološki poremećaji (anemije i maligniteti)-održala je 4 predavanja tokom 2007. godine.
4. XIII hematološki dani: predavač sa temom: Transplantacija matične ćelije hematopoeze od nesrodnog HLA kompatibilnog davaoca: prikaz saradnje sa bolnicom San Camillo Forlanini, održanom 26. novembra 2008, Kragujevac
5. XXII seminar Anestezista, Reanimatora i Transfuzista Srbije sa međunarodnim učešćem sa predavanjem: „Alogena transplantacija matične ćelije hematopoeze od nesrodnog HLA kompatibilnog davaoca u bolesnika sa malignim hemopatijama: prednosti i nedostaci“.13–17. maj 2009. Vrnjačka Banja.

6. V Congress of Internal Medicine for the South Eastern Europe, „Mantl ćelijski limfom dijagnostičke dileme i terapijski principi“ 6.-9. mart 2009, Beograd
7. Udruženje medikalnih onkologa Srbije (UMOS) Sastanak Best of ASCO International Serbia sa predavanjem koje se odnosi na novine u terapiji limfoma, a koji je održan 27.-28. Juna 2010, Beograd.
8. IV Kongres transfuziologa Srbije sa međunarodnim učešćem sa predavanjem: „Primena transfuzije granulocita dobijenih protokolom uz primenu G-CSF I Deksametazona kod bolesnika sa invazivnom gljivičnom sepsom nakon autologne transplantacije matičnih ćelija“ koji je održan 10.-12. novembra 2010. Beograd.
9. II Kongres hematologa Srbije i VI Balkanski dani, moderator i predavač na sesiji: Kontroverze u hematologiji sa temom o savremenom lečenju Hoćkinovog limfoma, održanim 4.-7. Novembra 2011. Godine, Beograd.
10. Stremljenja u medicini Medicinski fakultet univerzitet u Beogradu; simpozijum "Kontroverze u hematologiji" sa predavanjem; Limfomi sive zone održanim 4. decembra 2012. godine Beograd.
11. Stremljenja u medicini Medicinski fakultet univerzitet u Beogradu; simpozijum "Savremena hematologija" sa predavanjem; Savremeno lečenje Hoćkinovog limfoma. decembar 2014. godine Beograd.
12. Treatment of Hodgkin lymphoma in 10th National Congress of & 10th Balcan day of hematology Oct 2015 Sofia, Bulgaria
13. III Simpozijum o dijagnozi i terapiji gljivičnih oboljenja sa predavanjem: „Značaj primene transfuzije granulocita kod neutropeničnih bolesnika sa gljivičnom sepsom“ koji je održan 1.-2. marta 2012. Beograd.
14. Lečenje autolognom transplantacijom limfoma i mijeloma, V Kongres transfuziologa sa međunarodnim učešćem novembar 2014
15. Hematološke bolesti i trudnoća. Seminar “Kancer i humana reprodukcija” oktobar 2015. Beograd
16. Balcan day of hematology, The role of autologous transplantation in the treatment of high risk Hodgkin lymphoma, 23. oktobar 2015, Sofija, Bugarska.
17. "Transplantacija matičnih ćelija hematopoeze: od istorijata do savremenih terapijskih pristupa“ Simpozijum sa međunarodnim učešćem, Udruženje za transplantaciju matičnih ćelija hematopoeze, 25.novembar 2016. Beograd.
18. Cardiovascular complications of cancer therapy (pathophysiology), Practical aspects and comparative analysis of ACC/AHA and ESC guidelines In Serbia 2017 (PRACSIS 2017) mart 2017.
19. Akademija medicinskih nauka Srpskog lekarskog društva Simpozijum „Hemoterapija i hemobiologija“ predavanje „Alogene naspram autolognih transplantacija matičnih ćelija: terapijski učinak i potencijalne komplikacije“, 27.novembar 2018. Novi Sad
20. Stremljenja u medicini Medicinski fakultet univerzitet u Beogradu; simpozijum „Savremena hematologija-gde smo danas“, Savremena dostignuća u transplantaciji matičnih ćelija hematopoeze, 11.decembar 2018.

#### ***Učešće u međunarodnim projektima***

A Phase 2b Open-label, Randomized Two-arm Study Comparing High and Low Doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial **SGN35-005** „A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)”.

## ZAKLJUČNO MIŠLJENJE I PREDLOG KOMISIJE

Na konkurs za izbor dva nastavnika u zvanje redovnog profesora za užu naučnu oblast Interna medicina (hematologija) prijavila su se dva kandidata: **dr Ana Vidović i dr Milena Todorović Balint**, dosadašnji vanredni profesori na Katedri uže naučne oblasti Interna medicina.

Na osnovu priložene dokumentacije, pedagoške, stručne i istraživačke aktivnosti, ispunjenosti izbornih uslova za izbor u nastavnička zvanja i ličnog poznavanja prijavljenih kandidata, Komisija zaključuje da prof dr Ana Vidović i prof. dr Milena Todorović Balint ispunjavaju sve uslove predviđene Zakonom o visokom obrazovanju i Pravilnikom Medicinskog fakulteta za izbor u zvanje redovnog profesora.

Komisija ima zadovoljstvo da jednoglasno predloži Izbornom veću Medicinskog fakulteta u Beogradu da utvrdi predlog za izbor **dr ANE VIDOVIĆ i dr MILENE TODOROVIĆ BALINT** u zvanje **REDOVNOG PROFESORA** za užu naučnu oblast **INTERNA MEDICINA (hematologija)** na Medicinskom fakultetu Univerziteta u Beogradu.

U Beogradu, jul 2020. godine

### KOMISIJA:

1. **Prof. dr Biljana Mihaljević**, redovni profesor Univerziteta u Beogradu - Medicinskog fakulteta, predsedavajući
2. **Prof. dr Nada Suvajdžić Vuković**, redovni profesor Univerziteta u Beogradu - Medicinskog fakulteta, član
3. **Prof. dr Ivana Urošević**, redovni profesor Univerziteta u Novom Sadu - Medicinskog fakulteta, član